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SUMMARY
This thesis has investigated the effects of a number of environmental factors on sleep and explored 
the amelioration of such effects by pharmacological interventions. The presence of changes in sleep 
was measured by recordings of the electrical activity o f the brain (electroencephalogram, EEG), eye 
movements (electroocculogram, EOG) and muscle activity (electromyogram, EMG). The 
pharmacological interventions were not only tested for their efficacy in ameliorating sleep 
deprivation or sleep disturbance but also far any residual effects on performance.
The environmental factors studied were those that are likely to be encountered by occupational 
groups such as shiftworkers, aircrew and mountain guides. Any disturbance of sleep in these groups 
may lead to episodes of drowsiness and performance impairments when they are carrying out 
skilled tasks. It is therefore important to investigate safe treatments to ameliorate the sleep 
disturbances.
Shift work and jet lag do not have direct effects on sleep rather it is the requirement to sleep at times 
in the circadian cycle that are not conducive to sleep that causes problems. The morning sleep after 
the night shift is shorter than night sleep and adaptation of the circadian rhythm confers little benefit 
in those workers whose shifts rotate rapidly. Cumulative sleep deprivation and a low alertness at 
night lead to performance impairments. Early morning shifts also cause problems as workers find it 
difficult to retire early at a time of peak alertness. Jet lag leads to difficulties with sleep depending 
on the direction of travel. Westward travel causes similar problems to night work: difficulties in 
maintaining sleep. Eastward travel is associated with difficulties in falling asleep as the traveller 
attempts to sleep early in the circadian cycle.
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The drug investigated for the treatment of shift work and jet lag was melatonin. Melatonin has been 
advocated for the treatment of such conditions. The usefulness of melatonin depends on its ability to 
be effective at all times in the circadian cycle. A dose response study (0.5 to lOmg) on its effects on 
nocturnal and evening sleep was compared with a benzodiazepine (temazepam 20mg) which is 
often used by individuals coping with irregular patterns of work. Melatonin had little effect on 
nocturnal sleep. Hypnotic activity of melatonin (0.5 to 10 mg) in the evening was similar to 20 mg 
temazepam.
Sleep is disturbed in those who ascend to altitude with periodic breathing and many awakenings, 
this may lead to daytime drowsiness and impaired performance. Sleep disturbance at two altitudes, 
3500m, in the Italian Alps, and 5400m, in the Karakorum mountains in Pakistan, were studied. The 
effects of 20mg temazepam at the lower altitude and the effects of lOmg temazepam together with 
500mg acetazolamide daily were studied in two groups of climbers. In addition a dose response 
study of the effects of temazepam (10 to 30 mg) and diazepam lOmg on sleep at ‘altitude’ was 
carried out in a decompression chamber at a simulated altitude of 3810m.
Sleep during the alpine expedition was limited to reductions in sleep efficiency and increases in 
awake activity. Delays and reductions in rapid eye movement sleep were seen at the beginning of 
the stay at altitude. No overall benefit of temazepam was seen at this lower altitude although some 
benefit was seen in older subjects who had more disturbed sleep. No relationships between hypoxic 
ventilatory responses and behaviour at altitude were established.
In the Karakorum expedition sleep at around 5,400m was very disturbed in spite of prophylactic 
treatment with acetazolamide. Total sleep time was lower and sleep onset lengthened linearly 
during the six nights at 5,400m. Similar reductions in sleep efficiency and stage 4 sleep were also 
observed. The number of respiratory pauses greater than 5 seconds at 5,400 ranged from 700 per
night in one subject to less than 20 in another. There was no effect of temazepam on the number of 
these events. The beneficial effects of temazepam (lOmg) on sleep seen previously at around 4900m 
were not evident at this increased altitude.
The detailed analysis of the respiratory data in the decompression chamber study showed no 
evidence of respiratory depression with up to 30 mg temazepam. Although there was an increase in 
end tidal PCO2 with diazepam (lOmg). Both 20 and 30 mg temazepam improved sleep at the 
simulated altitude without any evidence of respiratory depression.
Two separate experiments were carried out; one of which investigated the effect of light, the other 
the effect of noise on sleep during the day after a reduced night of sleep at home. The levels of light 
were chosen based on 300 lux, which is roughly equivalent to moderate interior lighting. The 
brightest condition was 2400 lux, which is approximately equivalent to interior light levels on a 
sunny day. The conditions investigated were dark, 300, 600, 1200, and 2400 lux.
Prior to the second experiment, a pilot study was used to identify the noise level most likely to 
cause sleep disturbance. Based on this study, sounds at approximately 55dB(A) were presented to 
subjects via loudspeakers whilst they were in bed. To put this in perspective, noise levels of 35 
dB(A) are approximately equivalent to that heard in a library, 65dB(A) to office noise and 
125dB(A) to a jet aircraft taking off.
Eight different noise stimuli were used and were randomly presented, with a maximum of eight 
events per hour and a maximum duration of 10 seconds/event. Each subject performed the trial on 6 
occasions, corresponding to 6 different conditions. With the exception of a no-noise condition, the 
conditions varied according to the timing of the noise stimuli during the sleep period.
Light had only a small effect on the quality of daytime sleep. The main disturbance occurred when 
sleeping in the brightest condition (24001ux). Slow wave sleep (SWS), was reduced. In addition, 
total sleep time was reduced during the second 100-minute period, and individuals reported that
their sleep had been disturbed. Some changes were also seen at lower light levels: at 1200 lux more 
awakenings occurred compared with sleeping in the dark, and at 600 lux there was a reduction in 
total sleep time during the second 100-minute period.
Noise commencing at or soon after falling asleep reduced the amount of SWS by approximately 
50%. This reduction was associated both with the overall sleep period and with the first 100 minutes 
of sleep, which is roughly equivalent to the first sleep cycle. The time taken to enter SWS after 
sleep onset also increased when the noise began at lights out. There was no evidence that 
performance during the 4 hours after rising was affected by exposure to noise, and subjects did not 
report any differences in the quality of their sleep under the different noise conditions.
The final experiment studied the effect of a novel zaleplon on sleep in a noisy environment. The 
effectiveness and residual effects of zaleplon, 10 and 20mg, zopiclone 7.5 mg in promoting sleep 
after middle of the night administration were compared with placebo. The residual effects 4 hours 
after administration were also compared.
Zaleplon 10 and 20 mg reduced the time taken to return to sleep after awakening in the middle of 
the night and was free o f effects on psychomotor performance the next morning. The control drug, 
zopiclone, impaired performance in the morning.
In summary, the diverse environmental factors considered here are all associated with some degree 
of sleep disturbance and potentially impaired performance. Pharmacological interventions are useful 
in some instances.
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CHAPTER ONE
GENERAL INTRODUCTION
1.1 BACKGROUND
A number of environmental factors disturb sleep and in this introduction a review of these factors 
will highlight those areas where information is lacking and which are the subjects of the 
experimental part of this thesis. The environmental factors studied are altered circadian timing of 
sleep, light and noise. These factors were chosen to represent the factors most likely to disturb sleep 
in an occupational setting such as that experienced by aircrew. In addition, the effect of altitude on 
sleep was studied in the field and simulated in the laboratory. Exposure to altitude is experienced by 
a number of groups who go to altitude for occupational and recreational reasons. Hypoxia during 
sleep is also seen in patients suffering from conditions associated with sleep apnoea. Further, in 
aircrew who undertake long haul operations longer than 13 hours there is a requirement to sleep on 
board the aircraft in order to avoid excessive sleepiness. The aircraft are pressurised to between 5 
and 10,000 feet.
Before considering the effect of the environment on sleep a brief review of sleep and its function is 
given in order to put into context the significance of any sleep disturbance caused by the 
environment. This also makes clear the need for interventions that may ameliorate any sleep 
disturbance. A number of such interventions are reviewed in this introduction and some of the gaps 
identified are investigated in the experimental chapters.
1.2 SLEEP AND SLEEP STRUCTURE
Sleep is a behavioural state normally characterised in man (Kleitman and Doktorsky 1933) and 
many other animals (Zepelin 2000) by the adoption of the supine position. In man, certain sleeping 
positions have been associated with good and poor sleep (De Koninck et al. 1983). Using time lapse 
photography, subjective quality of sleep was related to sleeping position and it was reported that 
good sleepers adopted more contorted positions than poor sleepers. Subjects move many times 
during the night when asleep and changes in position of between 20 and 60 times each night have 
been reported (Johnson et al. 1930 Kleitman 1963). Sleep is easily reversible (Williams et al. 1964) 
although some subjects who are deeply asleep are more difficult to arouse and can easily fall back
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to sleep again if  they are left undisturbed, particularly babies and young children. In most cases 
sleep is associated with closed eyes and the onset o f eye rolling is often a sign of impending sleep 
(Rechtschaffen and Kales 1968). Humans spend around 7 to 8 out of 24 hours sleeping and around 
16 out of 24 hours awake. (Hyppa et al. 1991, Johnson and Spinweber 1983, Lugaresi et al. 1983) 
This 8-hour sleep period is in most cultures normally taken in one block during the night in young 
adults, although aged subjects may also nap during the day and their nocturnal sleep quality may be 
improved by restricting these naps (Friedman et al. 1991). The duration of normal sleep does vary 
from one individual to another and can be as little as 4 hours or as many as 10 hours and appears to 
be genetically determined (Karacan and Moore 1979). Sleep is a fundamental requirement for 
humans. The required amount of sleep for an individual is believed to be needed for the 
maintenance of physiological and psychological health. In general more sleep is taken at weekend 
and less sleep is taken during the working week (Breslau et al. 1997). Sleep is generally taken in a 
quiet and dark environment. If natural conditions are not quiet and dark most humans alter their 
environment to recreate these ideal conditions by the use of curtains, double glazing, masks and ear 
plugs (Li et al. 1998).
Sleep is interspersed with dreaming and the phenomenon of dreaming has interested scientists and 
philosophers since the time of Aristotle (Thorpy 1991). Sigmund Freud formed much of his 
considerable reputation on the basis of his theories on the interpretation of dreams (Freud 1900) and 
their link to the unconscious mind. However, it was the recording of brain electrical activity in the 
human (Berger 1930) which heralded the explosion in sleep research. Berger observed differences 
in the signals, or electroencephalograms as he termed them, when the subjects were awake or 
asleep. Blake and Kleitman (Blake and Gerard 1937 Blake et al. 1939) who described the human 
electroencephalogram during sleep further developed this work. A systematic and continuous 
recording of the EEG and EOG (electrooculogram) simultaneously in more than 30 subjects 
allowed the discovery of the electrical activity associated with rapid eye movement sleep 
(Aserinsky and Kleitman 1953). This led to the first description of the various sleep stages and the
first use of the term rapid eye movement (REM) sleep, they also described that these stages 
followed a systematic pattern over the night, alternating between REM and non- REM sleep 
(Dement and Kleitman 1957). Non-REM sleep encompasses all the other stages of sleep (stages 1, 
2, 3 and 4). Dement had also shown that similar sleep stages existed in animals, in particular in cats 
(Dement 1958).
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Figure 1 Sleep patterns in the Cat and the Rat
In Man the sleep wakefulness cycle is monophasic and there are only briefperiods o f  wakefulness 
during sleep. In cats and rats the sleep wakefulness cycle is polyphasic. Wakefulness and sleep 
alternate in a more rapid succession than in man. The cycle in the cat is around 30 minutes and in 
man it is around 90 minutes.
Jouvet’s group in Lyons extended the knowledge of sleep in cats. They observed that the periods of  
low voltage fast EEG activity and rapid eye movements are accompanied by total postural 
relaxation, which manifests itself by dropping the head. (Jouvet et al.1959). Jouvet and co-workers 
also showed that this postural relaxation was associated with electrical inactivity in the neck 
muscles during REM sleep. These research workers used three measures that are used today to
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define sleep: the electroencephalogram (EEG), the electro-oculogram (EOG) and the 
electromyogram (EMG). In 1969 a group of sleep researchers met to standardise the methodology 
for recording sleep and for determining the various sleep stages in man. This method, commonly 
called Rechtshaffen and Kales, is still used today although various other methods, mainly based on 
spectral analysis o f the EEG have also been advocated (Borbely et al. 1981 Acherman and Borbely 
1998). It has not only resulted in a manual for sleep scoring but also more recently its standards 
have been incorporated into a number of computer based sleep analysis programs (Rechtschaffen 
and Kales 1968).
1.2.1 Sleep recording and stages of sleep
The three measures (EEG, EOG, EMG) that areiised to define sleep are also recorded in a 
standardised way across sleep laboratories throughout the world.
Figure 2 Electrode positions used to record sleep
Electrode positions to record 3 channels o f electroencephalographic activity, two channels o f eye 
movement activity and electromyographic activity from the submental musculature. (Nicholson A.N  
Stone B.M 1983 RAF Institute o f Aviation Medicine)
The placement of electrodes on specific site is for two reasons. Firstly, to avoid discomfort during 
sleep they are placed away from the more prominent parts of the skull. Secondly, a standardised 
placement allows comparison between recordings from different laboratories, this is particularly
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important for measures of amplitude which vary according to the distance between electrodes. The 
electrodes are placed according to the 10-20 electrode placement system recommended by the 
International Federation of Societies for EEG and Clinical Electrophysiology. This International 
system was developed by Jasper (1958) and uses a series of measurements, which ensure that 
electrodes can be placed with accuracy in the same place from one day to another.
For the recording of sleep a simplified system is used with many fewer electrodes. The activity in 
the central area of the scalp can usually be used to identify the various characteristics o f the 
different sleep stages. In particular alpha rhythm, sleep spindles, K complexes, vertex sharp waves 
and the high amplitude slow waves which characterise slow wave sleep can all be identified from 
recordings from C3 and C4 positions. An occipital recording is also useful when alpha activity is 
low. Alpha (8-13Hz) activity is one of the standard frequency bands used to classify EEG activity. 
The full range of bands is as follows:
Less than 4 Hz: delta
4 to less than 8 Hz: theta
8 to 13 Hz inclusive: alpha
More than 13 Hz: beta
It is also important to ensure high quality recordings throughout the sleep period and electrode 
resistances are maintained at a low level with prior scalp preparation and the use o f electrode jelly 
to maintain electrical contact.
Recordings of eye movements during sleep (electro-occulograms) are used to detect the onset of 
sleep heralded by slow rolling eye movements and the presence of phasic bursts of rapid eye 
movements - the cardinal sign of REM sleep. There is a small potential difference between the front 
and the back of the eye, which allows measurement of eye movement from electrodes situated on
the skin around the eye. For the purposes of sleep recording, electrodes are placed on the outer 
comers (canthi) of the eye. One electrode is placed on the right outer canthus (ROC) and one on the 
left outer canthus (LOG) with one of these slightly above and the other slightly below the 
horizontal. These electrodes are referenced to the opposite mastoid process or earlobe.
In order to measure the atonia in the neck musculature during REM sleep the muscle activity from 
the chin is recorded. Two or three electrodes to measure this electromyogram are attached to the 
skin overlying the submental musculature. The electrodes are referenced to each other. The third 
electrode acts as a back up as these electrodes are easily detached. The requirement for high quality 
recordings is also important for EOG and EMG recordings.
For a standard sleep recording it is necessary to attach 12 electrodes although not all of the 
electrodes are recorded from at all times. (Carskadon 1982) A number of the electrodes are applied 
as back ups in case of failure. Before retiring to bed the impedance of the electrodes is checked. 
Impedances below 10,000 ohms will produce adequate recordings, although half that value is 
advisable for good quality recordings. The electrodes are then tied together in order that the subject 
does not tangle the electrodes during the recording. When the subjects’ electrodes are plugged in a 
standardised procedure is followed to ensure the integrity of the recording and to ensure that the 
subject is in the same state of mind before lights out. This involves asking the subject to blink five 
times, look right and left, grit their teeth and open and close their eyes. When the recordist has 
ensured that all the electrode resistances are low and the recording is satisfactory the subject is 
warned that the lights are about to be switched off and the sleep recording begins.
The electroencephalogram (EEG) measures brain activity during sleep, and information from the 
EEG together with that the EOG and EMG enables sleep to be categorised into a number of stages 
and to determine sleep onset and the number of arousals and awakenings throughout the night. The 
onset o f sleep under normal circumstances is through non-REM sleep. Indeed the abnormal entry 
through REM sleep in adults is a diagnostic sign of a sleep disorder -  narcolepsy. The definition of 
sleep onset is controversial and varies between different laboratories. Stage 1 or ‘drowsy’ sleep
usually occurs during the transition from waking to sleep. It is characterised by a change from the 
dominant alpha activity (8-13 cycles per second activity) of relaxed wakefulness with eyes closed to 
a relatively low voltage mixed frequency activity.
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Figure 3 Waking state - Stage IV
The waking state is characterised by alpha (8-12 Hz) and/or a low voltage mixed frequency activity. 
Some subjects have virtually a continuous alpha record, while others may show little or none. This 
stage is usually, but not necessarily, accompanied by a relatively high amplitude electromyogram 
together with blinks and eye movements. (Nicholson A.N Stone B.M 1983 RAF Institute o f Aviation 
Medicine)
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Figure 4 Awake to Stage 1 sleep.
When alpha activity together with low voltage activity amount to less than 50% o f the record and 
are replaced by relatively low voltage mixed frequency activity, the epoch is scored as stage 1. The 
relatively low voltage, mixed frequency electroencephalogram characteristic o f drowsy sleep has 
most activity in the 2-7 Hz range. The fast frequencies are o f lower voltage than the 2-7 Hz activity. 
Stage 1 sleep tends to occur in the transition from wakefulness to sleep, or after body movements. 
During nocturnal sleep it is usually of short duration — about 1 to 7 minutes. (Nicholson A.N Stone 
B.M 1983 RAF Institute o f Aviation Medicine)
The EEG activity with the highest amplitude during stage 1 sleep is theta activity (3 to 7 cycles per 
second). This EEG change usually follows the start o f slow rolling eye movements. In some 
subjects the onset of Stage 1 sleep coincides with the perceived onset o f sleep, in others subjects 
will report that they are awake during this activity.
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Figure 5 Stage 1 sleep.
In the latter part o f stage 1 7Hz activity o f high voltage (about 50-70 uV) may occur in irregularly 
spaced bursts, and vertex sharp waves may also appear. The amplitude o f  a vertex sharp wave is 
occasionally as high as 200 uV .(Nicholson A.N Stone B.M 1983 RAF Institute o f Aviation 
Medicine)
Absence of clearly defined K complexes and sleep spindles is essential to the definition of drowsy 
sleep. Traces of low voltage activity of 12-14 Hz may begin to appear as stage 2 sleep approaches, 
but a rhythmic burst of at least 0.5 seconds duration is necessary for the record to be scored as stage 
2 sleep. In stage 1 sleep, particularly after wakefulness, there are slow eye movements, each of 
several seconds duration, which are usually most prominent during the early part o f the stage. Rapid 
eye movements are absent, and the amplitude of the electromyogram is usually lower than during 
relaxed wakefulness. In some laboratories the beginning o f drowsy (stage 1) sleep is taken as sleep 
onset.
This first period of Stage 1 sleep lasts for about 1 to 7 minutes Subjects in stage 1 sleep may also be 
capable of carrying out a simple behavioural task such as tapping two switches alternatively at a 
steady pace (Carskadon and Dement, 1979). In view of the possibility that subjects are not 
‘subjectively’ asleep during stage 1 in my laboratory I await the presence o f the signs o f stage 2 
sleep before sleep onset is declared, Stage 2 sleep normally occupies up to 50% of the sleep period.
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The time from Tights out’ to reach the first episode of stage 2 is termed ‘sleep onset latency’. Stage 
2 sleep is characterised by the presence of K complexes or sleep spindles.
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Figure 6 Sleep onset (Stage 2 sleep)
Stage 2 sleep is indicated when spindles and K  complexes are present and when there is insufficient 
high amplitude, slow activity to indicate slow wave sleep. The first appearance o f  spindles and/or K  
complexes signals the onset o f sleep. A sleep spindle must last fo r at least 0.5 seconds and should 
consist o f at least 6 to 7 distinct waves o f 12-14 Hz. K  complexes are waveforms which have a well 
defined negative sharp wave followed immediately by a positive component. The total duration 
exceeds 0.5 sec and waves o f 12-14 Hz may or may not constitute a part o f  the complex. K  
complexes can occur as a response to sudden stimuli, but they also appear frequently in the absence 
o f any obvious stimulus.. (Nicholson A.N Stone B.M 1983 RAF Institute o f  Aviation Medicine)
This first period of stage 2 sleep lasts for about 10 to 25 minutes. As stage 2 sleep progresses there 
is an appearance of high amplitude (< 75 pv) and slow (1-2 cycles per second) activity. When this 
slow wave activity reaches 20% but less than 50% of the EEG activity the subject is in stage 3 
sleep.
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Figure 7 Stage 3 sleep
A record in which at least 20%, but not more than 50%, o f the epoch consists o f waves o f 2 Hz or 
slower (delta waves) with amplitudes greater than 75 uVfrompeak-to-peak (the difference between 
the most negative and positive points o f the wave) is scored as stage 3. Wave by wave 
measurements are only necessary fo r epochs with borderline amounts o f high amplitude, slow wave 
activity, i.e., around 20 and 50%. Sleep spindles may or may not be present in stage 3. (Nicholson 
A.N Stone B.M 1983 RAF Institute o f Aviation Medicine)
When the amount of slow waves equal or exceed 50% of the activity then stage 4 sleep is scored.
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Figure 8 Stage 4 sleep.
When more than 50% o f the epoch consists o f waves o f 2 Hz or slower with amplitudes greater 
than 75 uVfrom peak-to-peak the epoch is scored as stage 4 . Although only slightly more than half 
of an epoch may contain high amplitude slow waves, most stage 4 epochs have the appearance of 
being completely dominated by this activity. Intervals o f lower amplitude, faster activity rarely 
persist for more than a few  seconds in this stage, though they are more prominent in stage 3 sleep. 
Sleep spindles may or may not be present in stage. 4. (Nicholson A.N Stone B.M 1983 RAF Institute 
of Aviation Medicine)
Stage 3 sleep generally lasts for only a few minutes whereas the first period o f stage 4 sleep is 
around 20 to 40 minutes in duration. ‘Deep’ sleep (stages 3 and 4), otherwise known as slow wave 
sleep (SWS) or delta sleep, predominates in the early part o f the night and the amount of slow wave 
sleep is influenced by the length of prior wakefulness (Taub and Berger 1973). After about 70 to 90 
minutes of non-REM sleep the EEG changes to a lighter sleep stage, this is often precede by a few 
body movements, and the first period of REM sleep occurs.
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Figure 9 Transition between stage 2 and rapid eye movement (REM) sleep.
The sleep spindles and K  complexes in the first half o f the record are characteristic o f stage 2 sleep. 
At around the midpoint o f the record saw-tooth waves which herald eye movements appear, and at 
the same time electromyographic activity drops to the lowest level o f the recording session. 
(Nicholson A.N Stone B.M 1983 RAF Institute o f Aviation Medicine)
e y e  m ovements
This first episode of REM sleep is short and may last for as little as 1 to 5 minutes. The EEG during 
REM sleep is mixed frequency, low amplitude activity.
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Figure 10 Rapid eye movement sleep.
The appearance o f relatively low voltage, mixed frequency activity together with episodic rapid eye 
movements indicates rapid eye movement sleep The electroencephalogram has some resemblance to 
drowsy sleep, except that vertex sharp waves are not present. So-called “saw-tooth ” waves appear 
frequently, but not always, in vertex and frontal regions in conjunction with bursts o f rapid eye 
movement activity. Alpha activity may be more prominent than during drowsy sleep, although the 
frequency is generally 1 to 2 Hz slower than during wakefulness. As with stage 1, there are no sleep 
spindles or K  complexes. Rapid eye movement sleep should not be scored when electromyographic 
activity is elevated. During rapid eye movement sleep the amplitude o f  the electromyogram is not 
higher than the level during the preceding sleep stages. Indeed, it almost always reaches its lowest 
levels during this stage o f sleep. (Nicholson A.N Stone B.M 1983 RAF Institute o f Aviation 
Medicine)
During REM sleep the presence of eye movements and the absence o f muscle tone in the neck 
musculature allow it to be identified easily. The low voltage mixed frequency activity resembles 
that seen when subjects are awake or in drowsy sleep and it is for this reason that the French use the 
term sommeil paradoxale (Paradoxical sleep) for REM sleep (Jouvet and Delorme 1965). The 
paradox is the sleeping body with the awake like electrical activity o f the brain, in particular the 
presence of beta activity in the EEG which is usually found only during wakefulness. Episodes of 
rapid eye movement sleep (REM) occur at intervals, and are associated with dreaming. REM sleep
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seems to be associated with the consolidation of memory and may be linked with mood. This topic 
is discussed in more detail later in this chapter.
A typical night’s sleep pattern in a young adult is illustrated in Figure 11. The normal sequence of 
sleep stages during the night is awake, stage 1, stage 2, stage 3, stage 4, stage 3 and then stage 2. At 
this point the first period of REM sleep occurs. It is followed by stages 2, 3, 4, 3 and 2 and a further 
REM episode. Sleep cycles recur throughout the night, with each cycle lasting around 90 minutes. 
As the night proceeds, the content of the sleep cycle alters, with less SWS and more REM sleep in 
the latter cycles.
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Figure 11 Typical nocturnal pattern of sleep in a healthy young adult
A typical sleep onset latency o f around 10 minutes is shown. The sleep period time is around 7.5 
hours and sleep is interrupted by only a few  awakenings. The beginning o f the night is 
predominated by an episode o f stage four sleep o f around 1 hour. The first short REM period 
appears after about 90 minutes after sleep onset. Later periods o f REM sleep are more prolonged. 
(Nicholson A.N Stone B.M 1983 RAF Institute o f Aviation Medicine)
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1.2.2 Definitions
In order to compare studies carried out in different laboratories a number of definitions to examine 
different parts of the sleep cycle have been developed.
Sleep onset latency is the time elapsed from lights out until the onset of stage 2 sleep. Some 
laboratories score sleep onset from the onset of stage one sleep.
Total sleep time is the total duration of all the various sleep stages from sleep onset.
Sleep period time is the time elapsed from sleep onset until the final awakening. Other measures 
include the duration and percentages o f the sleep stages and awakenings as well as the latencies to 
the first period of REM sleep.
1.2.3 Age and sleep
Total sleep time and the amount of the various sleep stages alter with age. Total sleep time is 
longest in infancy but stabilises at between 7 and 8 hours at around 20 years.
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Figure 12 Total sleep time changes with age.
Total sleep time (TST) is longest in infancy and appears to stabilise around 7 h at about 20 years. It 
remains constant during adulthood and changes very little throughout old age. Males 3-5 year olds 
have a longer TST than females o f the same ages whereas between 40-59 years males have shorter 
TSTs than females. (Nicholson A.N Stone B.M 1983 RAF Institute o f Aviation Medicine)
If there are no medical conditions which disturb sleep or any incidence of sleep disorders there are 
no age related changes in total sleep time. There are, however, changes in sleep efficiency with age. 
Elderly patients in good health without sleep pathology have sleep efficiencies between 80 and 85% 
(McCall et al. 1992 Hirshkowitz et al. 1992; Redline et al. 1998 Hoch et al. 1994) which is lower 
than the efficiencies o f around 90% seen in healthy young adults. There may also be gender 
differences with the sleep of older women being superior to that of older men. (Rediehs et al. 1990).
27
Awake activity 
(percentage)
males
0 10 20 30 40 50 60 70 60
age (years)
Figure 13 Changes in awakenings with age
The number o f awakenings increase with age, although the proportion o f time spent awake during 
night time sleep changes very little during the first five decades for women and the first four 
decades fo r men. During these ages it remains below 2% of sleep period time fo r  both sexes, but 
after this it increases rapidly, and is variable between subjects. (Nicholson A.N Stone B.M 1983 
RAF Institute o f Aviation Medicine)
However, the number o f arousals may be more than that suggested by an analysis of 30 second 
epochs, as an awake episode of just less than 30 seconds spread evenly across two epochs would not 
be scored as wakefulness. This is relevant to the analysis of sleep in the aged. Arousals of short 
duration may be frequent, and these may be due to paroxysmal leg movements or respiratory 
pauses.
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However, it is in slow wave (stages 3 & 4) sleep that the greatest age related changes in sleep are 
observed (14). The age at which the loss in slow wave sleep begins is a subject o f some 
controversy. There are a number of studies suggesting that the decline begins around the age of 20 
years (Feinberg 1974 Williams et al. 1974). Similar results to those seen in visually scored records 
have been reported with automated EEG analysis and both the delta amplitude in young adults 
(Feinberg et al. 1978) have shown negative relationships with age in subjects in their 20’s. In young 
adults about 20% of the night is spent in slow wave sleep, this drops to around 5 to 10% in elderly 
subjects (Feinberg et al. 1967 Williams et al. 1974). There are still changes after 70 years as 
reductions in slow wave sleep delta activity has also been reported between 70 and 80 years of age 
(Reynolds et al. 1991).
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Figure 14 Rapid eye movement and slow wave sleep changes with age
Rapid eye movement sleep has the longest duration in infancy and in childhood. There is a fa ll in 
the percentage o f the sleep period time (SPT) spent in this stage from around 30% in 3 to 5 year 
olds to around 25% where it remains until another slight fa ll in the oldest group studied. In 40-49 
year olds, the percentage o f REM sleep is greater in females than in males. Slow wave sleep 
percentage rises as the percentage of REM sleep falls reaching its peak level before 20 years o f  
age. It then falls to levels o f only around 5% at 65 years. (Nicholson A.N Stone B.M 1983 RAF 
Institute o f Aviation Medicine)
The percentage of SPT spent in stage 3 sleep remains between 2 and 8% throughout life in subjects 
who continue to show this stage in later years. However after 49 years fewer subjects have any 
stage 3, although more women than men show it in later years.
Between 3 and 19 years about 16-20% of the SPT is spent in stage 4 sleep. This level falls and this 
decline continues throughout life, but is more pronounced in men than in women. In the 70-80 year
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old group no men showed any stage 4 but some stage 4 was still seen in 50% of the women. 
However, changes may be due to a reduction in amplitude rather than to a decrease in the incidence 
of slow wave activity.
Because o f the change in amplitude Webb and Dreblow (1982) suggested that sleep stage scoring of 
slow wave sleep should abolish amplitude criteria and only score on frequency. However this has 
not been generally adopted and it is complicated by the preservation o f slow wave sleep in older 
women (Reynolds et al. 1986). The position of slow wave sleep is further complicated by a report 
(Dijk et al. 1989) that the gender difference is also seen in younger subjects and may relate to 
factors such as skull thickness.
Whether there are changes in REM sleep with age is a matter o f some controversy (Feinberg et al. 
1967 Hayashi and Endo 1982, Prinz 1977). Benca and co workers (1992) reported the results of a 
meta-analysis and observed that although there was some evidence o f a reduction in overall REM 
duration that the first REM period lengthens with age. The declines in the amount o f REM sleep 
with age are at the most fairly minor and may amount to around 3% of the total sleep time (Redline 
et al. 1998). Some of the differences between studies may be related to the different sleep durations 
studied.
These changes in sleep with age may be related to a different requirement for sleep in older 
subjects, or it may be related to maturational processes of declining cortical metabolic rate, 
increasing dendritic pruning and decreased synaptic activity in the cortex (Feinberg et al. 1990). It 
also may represent a manifestation of the ageing process.
There may be some link between disturbed sleep and alterations in melatonin levels. Haimov et al. 
(1994) reported that elderly individuals with normal melatonin levels did not show the sleep 
problems o f those whose levels showed age related changes. Studies o f genetics may also help us 
understand why the ageing process in sleep is seen much earlier in some subjects than in others.
31
Age is an important selection criterion when selecting subjects for experimental studies and trials of 
new compounds. It is firstly important to select the age group for the intended use o f a compound 
and also to avoid the increased variability associated with a wide age range.
The age related changes with age may also complicate the environmental influences on sleep, which 
are considered in this thesis. Older subjects with lighter sleep may be more susceptible to the 
disturbing effects of the environment.
1.3 SLEEP DEPRIVATION
Sleep is essential to daytime function and sleep deprivation leads to impairments in daytime 
performance. Two centuries ago a study of sleep deprivation in man was published (Patrick and 
Gilbert 1896). They studied performance during 90 hours of wakefulness and as well as showing 
decreases in reaction time, motor speed and memory they reported that the subjects found it 
impossible at times to stay awake. They also reported a circadian rhythm in performance and the 
deeper sleep following the end of the deprivation period.
Apart from experiments to study the consequences of sleep loss, the causes sleep deprivation and 
sleep reduction can be considered as sociological/behavioural, pharmacological, medical (sleep 
disorders and pain) and environmental. Since the work o f Patrick and Gilbert there have been 
numerous studies on the physiological and psychological effects of total and partial sleep 
deprivation. The most obvious effect of acute sleep deprivation is sleepiness. Subjects who are sleep 
deprived can be easily identified, as they show behavioural manifestations o f their sleep loss. These 
signs include frequent yawning, slurring of speech and difficulty maintaining focused vision.
(Kollar et al. 1968). Symptoms are more severe as the sleep deprivation is extended. These 
behavioural changes are accompanied by characteristic EEG changes. The alpha rhythm that 
characterises the alert, relaxed, eyes closed EEG gradually decreases. After 24 h without sleep only 
10 seconds of alpha activity was produced, and this fell to around 1 to 3 seconds after 120 h of sleep 
deprivation (Rodin et al. 1962). These changes in the EEG are accompanied by performance
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decrements. The severity of the decrements is related to the characteristics o f the task administered, 
as well as with the individual’s susceptibility to sleep loss. The most sensitive tasks are boring and 
repetitive (Wilkinson 1992) and a relationship between the lack o f stimulation associated with a 
task and the time to observe decrements after sleep deprivation has been reported by Kjellberg 
(1977). Motivation and financial reward, however, can overcome the effects on the most boring of 
tasks (Home and Pettitt 1985). These results have led to complacency about the relevance of sleep 
deprivation to all but the most routine tasks. However, Harrison and Home (1998) reported 
impairments in short and novel language tasks which are focused in the prefrontal area of the brain. 
Further, it is the frontal region of the brain that shows the most decreases in glucose uptake with 
sleep deprivation (Thomas et al. 1993). In a review of the impact of sleep deprivation on decision 
making (Harrison and Home 2000) the theory (Broadbent 1953) that sleep deprivation causes 
cognitive slowing which can be overcome with extra time and increased motivation is questioned. 
The lapse hypothesis which suggests that errors become more frequent as sleep deprivation 
lengthens is also countered by the observation that decrements can occur in the first five minutes of 
testing in some decision making tasks involving the prefrontal cortex. Furthermore, the task was not 
time bound and incentives were available for good performance. These results concur with studies 
on the performance of hospital doctors where poorer performance involving decision making after 
sleep deprivation was observed (Goldman et al. 1972, Nelson et al. 1995). In particular innovative 
thinking, verbal fluency and focused planning were impaired.
Most of these studies have involved total sleep deprivation or very curtailed sleep. There are also a 
number of reports on the effects of acute and chronic partial sleep deprivation. Perhaps the study 
that showed the importance of obtaining sufficient sleep most clearly was that carried out by 
Wilkinson (Wilkinson et al. 1966). Decreases in vigilance performance were observed in subjects 
who had less than three hours sleep for one night. In those whose sleep was restricted to five hours 
on two consecutive nights, vigilance performance was also impaired. Later studies have shown 
impairments with sleep restricted to six hours (Rosenthal et al. 1993). It does not appear that the
deleterious effects of sleep deprivation can be overcome with familiarity. In a recent study 
(Williamson et al. 2001) long haul truck drivers whose job involved long and irregular hours of 
work did not cope better with sleep deprivation than those who normally worked from nine to five. 
As well as the effects on performance of sleep restriction or deprivation there are a number of 
reports of autonomic, biochemical and immune function changes. Even after prolonged sleep loss 
autonomic changes are minor and even effects on exercise performance are minimal. For example, 
after 64 hours of sleep loss, heart rate, respiratory exchange ratio and blood lactate were not altered 
although a 7% decrease in maximal oxygen uptake was observed (Plyley et al. 1987). There are also 
small reductions in body temperature during sleep deprivation (Patrick and Gilbert 1896). The 
circadian rhythm of body temperature has also been reported to increase, decrease or be unchanged 
by sleep loss (Home 1978). Apart from changes in the normal rhythms o f hormones whose 
excretion is related to sleep patterns such as growth hormone and prolactin (Beck 1981) and 
increased thyroid activity related to the increased energy requirements of continuous wakefulness 
(Gary et al. 1996), there are very few biochemical changes associated with sleep loss. There are a 
number of studies which have reported changes in immune function after sleep deprivation (Binges 
et al. 1994 Moldofsky et al. 1989). Changes reported include decreases in natural killer cell activity 
or in the numbers of natural killer cells.
The major consequence of both total and partial sleep deprivation is impaired performance and 
therefore any intervention or environmental factor which impairs sleep is likely to be associated 
with reductions in efficiency, lapses in performance both in monotonous tasks and those requiring 
complex decision making abilities. It is, therefore, important to understand the severity o f the sleep 
disturbance resulting from environmental factors and also to use interventions to ameliorate these 
effects.
There are many external stressors that lead to impairments in sleep and it is the purpose o f this 
thesis to explore some of them. As well as age-related impairments in sleep, many o f those who 
have reduced sleep duration or reduced sleep quality are suffering from a sleep disorder. Indeed,
sleep disorders increase with age. Disorders include sleep apnoea, narcolepsy and restless legs 
syndrome, these will not be considered in this thesis, nor will chronic insomnia or insomnia caused 
by psychological problems however temporary be included. The stressors studied are those that lead 
to temporary loss of sleep quality or quantity. These include circadian rhythm disturbance such as 
that associated with jet lag and shift work, altitude, noise, and light. The effects o f external 
temperature changes are not included as the direct effects of body temperature on sleep complicate 
these.
Although laboratory studies allow us to quantify the consequences o f sleep loss under controlled 
conditions, daytime sleepiness is a serious problem in our society and at times it can lead to 
accidents at work and on the roads. Links between sleepiness and life-threatening events have been 
made in several studies. The greatest number o f traffic accidents occur during the early morning 
hours, when sleepiness is at its highest levels and because most people are asleep at this time, traffic 
volume is at its lowest (Mackie and Miller 1978 Mitler et al. 1988). Driving on a motorway falls 
into the category of a monotonous well-learnt task, although the consequences o f falling asleep 
would appear to offer sufficient motivation to stay alert. Sadly, the duration of the task at times 
leads to loss of alertness and the inevitable accident.
1.4 SLEEP FUNCTION
In order to understand the consequences of sleep deprivation, sleep reduction or sleep disturbance 
some understanding of the functions of sleep are necessary. There are a number of hypotheses for 
why we sleep although none of them provide a comprehensive story. New theories of sleep function 
are developed each year.
1.4.1 Sleep as an adaptive response
35
In this theory it is hypothesised that the purpose of sleep is a way of adapting to the environment 
(Meddis 1977) and promoting survival. Thus for man the avoidance o f danger at night when food 
hunting or gathering would not be possible, also results in energy conservation and these combine 
to promote survival. Indeed, the benefits provided by sleep depend on the animal, for some energy 
conservation is of prime importance, for others protection from predators may be paramount.
The duration and depth of sleep periods in vertebrates can be predicted to a large extent by the 
relative importance of these two factors. Cats sleep for 12.5 hours, giraffes for 4.5 hours. The Indus 
dolphin sleeps for seven hours a day in short naps of 4-60 seconds as it most always swim to 
survive the strong river currents (Pilleri 1979).
However, the conclusion that one of the purposes of sleep is for energy conservation is 
questionable. The difference between the energy used during quiet rest and during sleep is minimal 
and has been estimated to be around 15 calories an hour (Zepelin 2000). Thus 8 hours of 
uninterrupted sleep would save around 120 calories, hardly a sufficient saving for such a 
complicated process.
The fact that natural selection has not resulted in the elimination of sleep suggests at least that in all 
mammals and birds some amount of sleep is necessary. There is no evidence that in man where 
predator avoidance and energy conservation are no longer necessary and where artificial light 
promotes a 24-hour society that sleep durations have shortened or that sleep is less important which 
suggests that there are some other functions for sleep.
1.4.2 Sleep as a restorative process
Restorative theories argue that sleep is a used to recover or restore physiological or psychological 
functions, which were expended during the waking period. The existing evidence argues for a 
particular role for sleep in brain restitution and rather less for body restitution. A number of 
experiments on the effect of sleep deprivation on physical performance have shown few effects
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other than those associated with perception of effort. Oxygen uptake, heart rate response and 
measures of stress such as cortical or epinephrine levels are unaltered by sleep deprivation. In his 
review Home (1978) summarises the results o f around 50 of these studies and concludes that sleep 
deprivation does not alter physiological measures of stress such as cortisol or epinephrine levels, 
although recent studies of air stewardesses have shown increased cortisol levels during recovery 
from jet-lag (Cho 2001). Furthermore, exercise performance is little altered by sleep deprivation 
(Plyley et al. 1987). Chronic sleep deprivation has been linked to lowered immune responses in 
animals (Everson 1993) and there are reports of similar effects in humans (Boyum et al. 1996). The 
effects of exercise on subsequent sleep has shown conflicting results depending on whether the 
exercise was sufficient to raise brain temperature when increased slow wave sleep is observed 
(Home and Staff 1983). Slow wave sleep was also increased following warming o f heads and faces 
with a hairdryer. On the other hand Ryback and Lewis (1971) found no changes in slow wave sleep 
associated with six weeks bed rest, if exercise played a role in SWS reductions would have been 
expected.
These studies suggest therefore that the effects of physical activity may be mimicking the effects of 
brain activity since cerebral activity also raises brain temperature. This suggestion is supported by a 
study by Kattler et al. (1994) who stimulated the hand with a vibrator, which activated the 
contralateral somatosensory cortex. On the following night this part o f the brain exhibited more 
slow wave activity during sleep.
In subsequent chapters the environmental factors studied will sometimes have specific effect on 
REM or slow wave sleep and it is therefore necessary to consider the function o f these different 
stages.
There are a plethora of studies of selective REM deprivation particularly in animals and these have 
resulted in at least nine theories of the function of REM sleep. (Hobson and McCarley 1977 Sterne 
and Morgane 1974 Pearlman 1982 Berger 1969) are the authors of some o f these theories. Jouvet
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(1975) suggested that REM sleep has evolved to reprogram innate behaviours to preserve them in 
species that rely strongly on learning. This theory explains the lack o f REM sleep in reptiles and 
paucity in birds which both rely on instinctive behaviours. However, such a theory would predict 
that mammals with the most learning ability would have the most REM sleep. This is not the case 
however. It is the role of REM sleep in memory consolidation, and the sorting of memory traces 
that has received the most attention. Animal studies have reported more REM sleep associated with 
memory acquisition and reduction in memory performance following REM deprivation. However, 
the studies of REM deprivation in animals are associated with considerable stress and the results 
have not been as spectacular in humans. A number of studies showed no effect of REM sleep 
deprivation on a number of memory tasks (Tilley and Empson 1978 McGrath and Cohen 1978). 
However recent studies have shown improvements in perceptual learning in humans related to REM 
sleep (Kami et al. 1994).
Slow wave sleep becomes more and more difficult to deprive with time. When subjects are 
continuously awoken from stage 4 sleep they make increasing efforts to go back into this stage of 
sleep (Agnew et al. 1964 Agnew et al. 1967). In a comparison between the effects o f stage 4 and 
REM sleep deprivation Agnew and co-workers (1967) observed that between five and seven times 
as many arousals were necessary to deprive subjects o f stage 4 sleep compared with REM sleep. 
This would support the theory that slow wave sleep is the stage most involved in brain restitution, 
During slow wave sleep cerebral metabolic rate and cerebral blood flow decline to around 75% of 
waking levels. Indeed, regional cerebral blood flow (rCBF) during slow wave sleep is lowest in the 
prefrontal cortex, orbitofrontal areas, anterior cingulate gyri, insula, and thalamus (Braun and 
Balkin 1997) similar results have been observed with regional cerebral metabolic rate (rCMR). 
(Buschbaum et al. 1989). Therefore those regions o f the brain which show the greatest activation 
when awake are among those which show the greatest reduction in activity during non-REM sleep. 
It could be predicted from these different theories for the function of slow wave and REM sleep that 
selective deprivation of one or the other type of sleep would add insight into their function and
relative importance. However after either REM or SWS deprivation for as many as seven nights 
there were no decrements in performance during the following day in either of two studies (Agnew 
et al. 1967, Johnson et al. 1974). Recovery from total sleep deprivation occurred at the same rate 
whatever the type of sleep contained in the recovery sleep
1.4.3 The effect of sleep loss on subsequent sleep
The longer an individual is awake, the greater the requirement for SWS, so that, if  sleep is taken 
earlier than usual, the amount o f SWS is reduced, whereas, if  sleep is delayed, the amount of SWS 
is increased. The requirement for SWS increases according to a simple exponential function, known 
as the ‘S process’ (Borbely 1982). The S process reaches a peak at the start of a sleep period, when 
the propensity for SWS is highest, and its lowest value is at the end of sleep, when the propensity 
for SWS is low. Sleep intensity is thus reflected by the extent o f slow wave activity (Blake and 
Gerard 1937) and the responsiveness to stimuli are reduced as slow wave increases (Williams et al 
1964). The S process therefore represents the requirement for SWS. It also appears to be directly 
related to the build up of fatigue and, as such, it forms an important component o f sleep and 
alertness models that are considered later.
After a period of sleep loss, there is a requirement to recover both SWS and REM sleep. Generally, 
SWS is recovered first, at the expense of REM sleep, which may be recouped later in the night or on 
the following night (Kales et al. 1970).
1.4.4 Models of sleep regulation
Three processes regulate sleep. The homeostatic process associated with the build up of the 
requirement for slow-wave sleep during wakefulness or process S, the circadian process - process C 
which is essentially independent of prior sleep history and the ultradian process which is present 
during sleep and represents the alternation between NREM and REM sleep.
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These processes have been combined into a number of models, which can predict the duration of 
sleep from the amount of sleep debt and the circadian phase o f sleep onset. In general one or two of 
these processes has described these models. The model of Borbely (1982) elaborated and quantified 
in man processes which were first proposed to account for sleep regulation in the rat (Borbely, 
1980). In this model Process S varied between an upper and a lower threshold, a single circadian 
process controls these thresholds. The model has been developed and improved over the years to 
take into account phenomena that were not explained by the original model (Dijk et al. 1987 
Acherman et al. 1990). The model has been further developed by the addition of a third component 
W (wakeup process) to be able to predict sleepiness and alertness (Âkerstedt et al. 1990). Other 
models (Kronauer et al. 1982 have been based on two circadian oscillators or on the cyclical 
alternation (reciprocal interaction model) o f NREM and REM sleep (McCarley et al. 1986). 
Massaquoi S et al. (1992) has combined all the processes into one model and Acherman et al. 1992 
have linked the models of a number of modellers into a combined model. The SCN controls the 
circadian aspect of sleep propensity (Cohen et al. 1991, Edgar et al. 1993). It is phase locked to the 
circadian rhythm of melatonin secretion and core body temperature. The homeostatic component of 
sleep propensity is not under the influence of the SCN but is influenced by sleep deprivation. 
(Mistlberger et al. 1983) since in SCN lesioned animals this process in unaffected.
Models of alertness have also been developed from similar processes and the CHS alertness model 
has been used in a tool to maximise the alertness of aircrew by appropriate scheduling (Spencer 
1999). Similar models of alertness have been produced to aid in the assessment o f shiftwork 
systems.
The alertness model combines the circadian rhythm in alertness and the alertness related to time 
since sleep
40
— I 1 1 1 1 1 1 1 1 1 1 1
0 2 4 6 8 10 12 14 16 18 20 22 24 
Time of day (h)
Al
ert
ne
ss
0 2 4 6 8 10 12 14
Time since sleep (h)
Figure 15 Components of the alertness model
On the left is the circadian rhythm. When we are entrained to our normal environment, the peak o f  
alertness on our body clock tends to be in the late afternoon around 5 or 6 o ’clock. The lowest 
levels o f alertness tend to occur about 12 hours earlier, around 5 or 6 in the morning. The 
component related to sleep is shown on the right hand side. After a normal night’s sleep, there is 
usually a short initial period when alertness is low, the so-called sleep inertia effect, then alertness 
reaches a peak after 2 or 3 hours. Then it reduces exponentially, and does not recover until another 
sleep or a nap is taken (Spencer, 1999)
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Figure 16 Components o f the model during a normal day
During a normal day the individual components are shown on the left. With a wake up time o f 8am 
the two components combine to maintain levels o f alertness during the day. (Spencer, 1999)
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Figure 17 Components of the model at night
The pattern for a duty period overnight is very different. The figure assumes a wake up time o f 8pm. 
Both components are on a downward curve during the night and when they are combined, alertness 
falls away quickly. The position o f a night worker is even worse than the graphs represent. They are 
much more likely to have woken in the morning and alertness levels will be even lower. It is 
estimated that if  no sleep has been taken since the previous night and duty extends to 7am alertness 
and performance are at least as low as with a blood-alcohol concentration o f .08%. another 
assumption is that the individual is acclimatised to local time. For aircrew on log-haul operations 
this will often not be the case. (Spencer, 1999).
1.5 SLEEP IN ADVERSE ENVIRONMENTS
In modem life sleep deprivation or disturbance is an inevitable consequence of a number of work 
and leisure activities. Many of these related to the environment and in the next chapters some of 
these environmental factors will be examined in detail. Disturbed sleep in man arising from external 
or environmental factors can be viewed as a direct effect on sleep e.g. hypoxia, noise, light, 
electromagnetic fields and stress. Or it can be considered an indirect effect arising from the 
dissociation of the inherent rest/activity cycle from the requirement to sleep as in jet lag and 
shiftwork. Furthermore the consequences of such deprivation may be related to the specific changes 
in sleep produced. Sleep disturbance can manifest itself in many ways. Sleep length can be reduced 
and the durations and percentages of the various sleep stages can be altered. Sleep length can be 
shortened by an increase in the time before sleep onset occurs, early awakenings or by awakenings 
during the sleep period. There can be short multiple arousals that may lead to a lightening of sleep, 
or there may be one or two long arousals leading to reductions in sleep length.
In this thesis I will be exploring both types o f stimuli and their effects on sleep. In order to 
understand the indirect affects of the environment on sleep it is necessary to understand the role of 
the natural circadian rhythm of an individual on sleep and alertness.
1.5.1 Circadian rhythm and circadian rhythm of sleep
All physiological and psychological processes are rhythmic and follow a pattern regulated by the 
circadian clock. Some examples are given in Figure 15.
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Figure 18 Examples of circadian rhythms
Circadian rhythms o f body temperature, plasma cortisol, somatotrophin concentrations and renal 
potassium excretions under normal conditions o f light and with a normal sleep wake cycle are 
shown.
1.5.1.1 Circadian Terms
A number of terms and definitions are used to describe circadian rhythms. The period of the rhythm 
is the time to complete one cycle (24 hours for synchronised rhythms) this is sometimes termed tau. 
The point during the rhythm at which the maximum is expected to occur is known as the 
acrophase. For example the time of day when body temperature is at it’s highest. Since the 
acrophase is located on a time scale, a phase reference is usually given. The magnitude of the 
variation of the rhythm is known as the amplitude.
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1.5.1.2 Circadian mechanisms
Circadian rhythms are internally generated from the central pacemaker, the suprachiasmatic nucleus 
(SCN), in the hypothalamus. Moore and Eichler (1972) ablated the suprachiasmatic nuclei in rats 
and showed loss of rhythmic activity of the adrenal gland and Stephan and Zucker (1972) reported 
that similar lesions led to loss of behavioural circadian rhythms.
The SCN are a pair of ovoid shaped nuclei situated ventrolateral to the base of the third ventricle in 
the anterior hypothalamus, dorsal to the caudal border of the optic chiasma. (Rusak and Zucker 
1979) A number of in vitro studies have clearly shown that cultured hypothalamic SCN slices are 
able to generate stable oscillations in neuronal firing rate close to 24h. These oscillations were in 
phase with the biological clock of the donor animal. (Gillette et al. 1995) This group of neurones is 
responsible for generating the rhythmic temporal information that controls so many physiological 
and psychological processes. It is the influence on sleep that is of relevance to studies of jet lag and 
shiftwork. It is the circadian clock that is responsible for the pattern of fatigue and alertness with 
peak alertness in the evening and peak fatigue in the early morning hours. Lesioning the SCN in 
squirrel monkeys eliminates the normal circadian rhythm in sleep and wakefulness, brain 
temperature and drinking, the amount of total sleep time was also increased (Edgar et al. 1993). If 
the SCN is electrically stimulated this is followed by a phase shift in rodents. (Rusak and Groos 
1982). The neurones in the SCN also fire independently in a circadian pattern when they are 
separated from the rest of the brain. (Welsh et al. 1995). The phase length o f this pattern is around 
25 hours. The difference between the 25-hour firing rhythm and the 24-hour light dark cycle is 
corrected by inputs into the SCN, which alter the rate o f firing. These inputs act as zeitgebers or 
time givers. There are three major inputs: The retinal input via the retinohypothalamic tract (RET), 
the intergeniculate leaflet, via the RET and a serotonin releasing input from the raphe nuclei of the 
midbrain (Richardson and Tate 2000), light which influences by the first of these two inputs. In the 
isolated SCN the peak firing rate occurs around midday, and SCN slices show periods of sensitivity
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to Cyclic AMP, neuropeptide Y, serotonin, melatonin, cyclic GMP, and glutamate. There are two 
periods of sensitivity to melatonin- at dusk and at dawn. (Gillette et al. 1993)
Most circadian rhythms also have an exogenous component due to a direct interaction with the 
environment. For example sleep lowers body temperature and exercise raises body temperature. 
Therefore the rhythm which we observe measure or experience is the sum of the endogenous and 
exogenous influences. The exogenous influences are referred to as masking. The problems of jet lag 
are considered to be due to the endogenous component of the rhythm.
The natural circadian rhythms of man are synchronised to the environmental and social cues of the 
environment. Cues, ‘timegivers’ or zeitgebers maintains this synchronisation. The intrinsic tau or 
phase of the circadian pacemaker is considered to be around 24.2-24,3h. Daily phase adjustments 
are made to counteract the tendency of this pacemaker to delay and to keep human rhythms 
entrained to the 24h day.
The light -  dark cycle is now considered to be the strongest cue for the maintenance of circadian 
rhythms (Wever et al. 1983 Czeisler 1995 Lockley et al. 1997). The effects of light are related to the 
intensity, duration and timing of the light stimuli. Until recently, the human circadian pacemaker 
was thought to be less sensitive to light compared with other mammals (Klante et al. 1995) Phase 
shift and phase resetting experiments used high light levels in excess of 12001ux. (Deacon and 
Arendt 1996 Kennaway et al. 1987 Hashimoto et al. 1996) Now however it has been shown that 
normal room light (around 180 lux) will produce half the shift seen with levels of around 10,000 lux 
(Boivin et al. 1994 and 1996). On the other hand such low levels are unable to maintain the 
synchronisation of human circadian rhythms in isolated subjects in dim light. Levels of 1000 lux 
maintain entrainment, under 200 lux light rhythms showed evidence of free running.
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1.5.2 Shift work
The availability of artificial light, the expense o f machinery that is only used during the day, the 
requirement for 24-hour cover in medicine, transport and safety critical situations has led to an 
increase in shift work. Workers are required to sleep at a time out of phase with the circadian 
rhythm of sleep and alertness. It has been estimated that around 25% of workers in the European 
Community work at night.
Some people cope well with shift work others find it so difficult that they find alternative 
employment. Health problems involving disturbed sleep, gastrointestinal disorders, and 
neurological, cardiovascular and psychiatric problems may all be associated with shift work, and 
Colquhoun and co-authors (1996) review these problems.
The greatest need for sleep is experienced between 2400 and 0600; environmental clues normally 
encourage this. The quantity and quality of sleep are strongly dependent on the circadian phase and 
sleep taken during the day will be shorter and less recuperative than sleep taken at night. Although 
environmental factors during the day serve to accentuate this difference, even in rooms isolated 
from environmental factors sleep is less efficient during the day (Walsh et al.1981). It has been 
estimated that by the end of a week of night duty, the equivalent of at least one night’s sleep may 
have been lost (Knauth P. et al 1980). While the duration o f slow wave sleep is unchanged 
following the night shift, stage 2 and REM sleep are reduced. Sleep disturbance associated with 
sleep is well documented (Âkerstedt et al. 1991 Tors vail et al. 1989 Dahlgreen 1981 Anderson et al. 
1984) Sleep is also reduced in workers who are on-call overnight (Âkerstedt et al. 1990). These 
reductions in sleep following a night shift may be compensated for by the adoption of napping 
behaviour. This can involve taking a nap preceding the start of the shift or napping during work. 
(Matsumoto et al. 1982)
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Figure 19 Sleep of a shift worker
Sleep o f a shift worker in the morning following a night shift and at night preceding a day shift. The 
sleep during the day is shorter and the first REM period in the morning is earlier and prolonged. 
(Anderson H. et al. 1984)
Given that night workers are required to work at the lowest point in their circadian performance 
rhythm, strategies that can curtail the amount of sleep deprivation could be very beneficial. Night 
shift workers usually retire to bed almost as soon as they arrive home with little time given to the 
‘wind-down’ required after a busy day/night at work.
Early morning shifts also lead to reduced sleep times. (Kecklund et al. 1987) Because of the 
circadian peak in alertness it is difficult to retire to bed early before an early shift. Lavie (1986) has 
described this time as the forbidden zone for sleep. The age related decline in sleep quality and 
quantity are exacerbated by shift work (Matsumoto et al. 1987 Tepas et al. 1993 Foret et al. 1981), 
although older workers find it easier to tolerate early morning shifts.
There is evidence that shift workers are more likely to be involved in accidents than non-shift 
workers, particularly if they have a long drive to and from work. (Gabarino et al. 2002).
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These reductions in sleep lead to the inevitable increase in sleepiness associated in particular with 
the night shift (Âkerstedt 1995). A number of questionnaire studies o f shift-workers have measured 
the incidence of sleepiness at work, this sleepiness is sometimes associated with nodding off during 
the night shift. (Âkerstedt et al. 1985 Kogi et al. 1975). These studies of subjective sleepiness have 
been followed by measurement of brain electrical activity during work to determine whether EEG 
signs of sleepiness are also present. (Kecklund et al. 1993 Torsvall et al. 1987) In the study by 
Tors vail 36% of train drivers were reported to have fallen asleep when driving. This sleepiness 
while carrying out safety critical tasks is of great concern and accidents related to sleepiness are 
estimated to be high (Leger 1994 Webb 1995).
Given the adverse effects of sleep loss on alertness combined with the need to work at the circadian 
trough of alertness, one approach is to preserve sleep as much as possible. This can be approached 
in two ways : first by the application of sleep promotion techniques and by attention to the 
circumstances which surround sleep ; and second by the use of hypnotic substances and these 
techniques are considered in detail later in this chapter.
1.5.3 Jet lag
The problems of jet lag are considered to be due to the endogenous component of the circadian 
rhythm.
The natural circadian rhythms of man are synchronised to the environmental and social cues of the 
environment. Cues, ‘timegivers’ or zetigebers maintains this synchronisation. The intrinsic tau or 
phase of the circadian pacemaker is considered to be around 24.2-24,3h. Daily phase adjustments 
are made to counteract the tendency of this pacemaker to delay and to keep human rhythms 
entrained to the 24h day. After transmeridian travel the synchronisers in the environment are no 
longer in synchrony with the circadian rhythm of the individual. It is the inability o f the rhythms of 
the individual to adapt rapidly to a sudden shift of these external synchronisers that causes a short­
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term dysynchronisation or mismatch between the body and the environment. Light is considered to 
be the stronger synchroniser of circadian rhythms to the 24 hour day (Czeisler 1995).
1.5.3.1 Symptoms
After transmeridian flight this mismatch leads to a series o f symptoms which in some individuals 
lead to a subjective loss of well-being and to objective disturbance in sleep and performance. This 
syndrome, known as jet-lag, is characterised by sleep disturbances, reduced daytime alertness and 
performance, gastrointestinal symptoms, loss of appetite, distortion o f time and distance, loss of 
physical strength and a requirement to urinate during the night, and a general feeling o f malaise.
The organisation of the menstrual cycle in females may also be disturbed (Voge VM. 1996). Meals 
eaten out of phase with the internal clock may give rise to inappropriate pancreatic and metabolic 
responses, some of which may be long term risk factors for heart disease (Hampton SM. et al.
1996). These symptoms are obviously undesirable for service personnel who are involved in 
intensive and sustained operations. Even if subjective symptoms are not present the rhythms of an 
individual may require several days to adapt to the new time zone. The jet lag phenomena was first 
described in detail by Strughold (1952) and comprehensively reviewed by Klein and Wegmann 
(1979).
The internal circadian clock adapts slowly to abrupt changes of time cues. The rate of adaptation 
has been reported to follow a number of models. Rates of one hour per day without 
countermeasures, or quicker adaptation during the first days have all been quoted. However, since 
the adaptation is highly dependent on the individual, to the direction of flight, to the number of time 
zones crossed, to exposure to environmental cues any simplistic formula is inappropriate. The 
direction of the time zone change is particularly important. In general adaptation after eastbound 
travel is much slower than after westbound flight. Gander et al. (1989) showed that it took several 
days for the acrophase of the temperature rhythm to come within one standard error of complete 
resynchronisation after a 9h westward transition, and that the adaptation in an eastward direction 
took even longer. This differing rate of adaptation related to direction o f travel is shown in Table 1
(after Klein and Wegmann 1979.). This table also shows the differing rates of adaptation of various 
physiological and psychological variables. The average rates of adaptation do not take into account 
the swifter adaptation immediately after travel.
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VARIABLE WESTBOUND EASTBOUND
Body temperature 60 39
Reaction time 150 74
Heart rate 90 60
Urinary 17-OHCS 47 32
Table 1 Shift rates after transmeridian flight in minutes per day.
In addition to differing speed of adaptation depending on direction of travel, it is also relatively 
common for travellers to adapt in the ‘wrong’ direction, such as delaying 16h instead of advancing 
8h. (Gundel and Wegmann 1989).
Around one third of travellers do not experience jet lag. But for those who do it is particularly 
associated with disturbance in sleep patterns.
1.5.3.2 Sleep patterns
In studies in the United Kingdom the sleep and circadian rhythms of following both westward and 
eastward flight have been studied in volunteer subjects and in aircrew. In a joint study with the 
Henry Ford Hospital in Detroit the adaptation to a 5h shift in both directions was studied (Nicholson 
et al. 1986).
Healthy male volunteers were studied for two days before, for 8 days in Detroit, and after the return 
flight to London on an overnight flight they were studied for a further 5 nights and 4 days. Sleep 
was recorded by electroencephalography and sleepiness during the day was assessed by the multiple 
sleep latency test. Sleep with placebo after westward and eastward flights were compared with sleep 
during the control period. On the first night after the westward flight subjects fell asleep more
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quickly, but there was more awake activity and drowsy sleep during the second part of the night. 
(Fig20)
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Figure 20 Sleep after a five-hour westward flight
On the first night after the flight sleep onset was rapid but the second half o f the night was 
disturbed. (Nicholson et al. 1986)
The fast sleep onset reflects the requirement to sleep at a time equivalent to a late bedtime in the 
home time zone. The disturbed sleep in the second part of the night relates to the requirement to 
stay asleep around the equivalent of lunchtime in the home time zone. The late bedtime leads to a 
slight sleep deprivation that increases slow wave sleep and reduces the amount of Rapid Eye 
movement (REM) sleep. (Taub and Berger 1973 Webb and Agnew 1971). During the second and 
third nights after westward flights the ratio o f REM to non-REM sleep was raised. This is due to the 
natural circadian rhythm in REM sleep that peaks towards the end of the normal sleep period. 
(Nicholson et al. 1984). This change in ratio was not seen on the first night because slow-wave 
sleep was increased. By the fourth night a normal sleep pattern was established, and together with
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the realignment of the rising phase of daytime alertness, which was seen at the same time, indicated 
that sleep had adapted to the new time zone.
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Figure 21 Sleep after five-hour eastward flight
On the first night sleep after an overnight flight sleep was not disturbed. On subsequent nights sleep 
onset was delayed and this was still apparent on the fifth night. (Nicholson et al. 1986).
After eastward fight the subjects slept better than before the flight. The eastward flight was 
overnight and this caused a delay o f 19h in the first rest period, therefore on this first night the 
subjects were sleep deprived and slept quite well. The ratio of REM to non-REM sleep was also 
reduced. On the second night the subjects took longer to fall asleep reflecting the requirement to fall 
asleep at equivalent to 1830 in the time zone to which they were adapted. This difficulty in falling
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asleep persisted for the rest of the study. As well as difficulties in falling asleep, subjects also had 
reduced slow-wave sleep on the fourth night. On the fifth night which was the final recording night, 
total sleep time and sleep efficiency were reduced. The relatively slow adaptation after eastward 
flight may be related to the natural period of the circadian rhythm that is slightly longer than 24 
hours. This study of a relatively small time zone change confirmed that adaptation to eastward 
travel is slower than adaptation to westward travel. By the end of five days back in the home time 
zone sleep and daytime alertness were not fully adapted after eastward flight and this slower 
adaptation is proportionately worse after a greater time-zone difference.
Gundel and Wegmann (1987) also demonstrated the longer adaptation after a 9h eastward 
transition, as well as large differences in the pattern of adaptation, with 3 out of 12 individuals 
experiencing a phase delay rather than a phase advance. Aircrew flying the polar route between 
London and Tokyo (Spencer et al. 1991) exhibited similar complex patterns o f adaptation, with 
large individual differences.
In an attempt to predict the pattern of adaptation of aircrew and other travellers to rapid time-zone 
transitions, Gundel and Spencer (1992) developed a model based on the van der Pol equation. This 
equation has formed the basis for models of the human circadian system (Kronauer 1984), and has 
been used to represent the effects o f light on the circadian pacemaker (Kronauer 1990). The model 
of Gundel and Spencer is based on the forced van der Pol equation.
The same authors have recently (1999) fitted the output from the model to body temperature data 
recorded before and immediately after a lOh eastward transition between London and Sydney. This 
lOh eastward time-zone change was chosen because simulations suggested that the pattern of 
adaptation would be most sensitive to changes in the parameter values making up the model. The 
fitting procedure also allowed for masking effects.
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Figure 22 Estimated circadian phases after eastward travel
Circadian phases estimated from simulations using the estimated model parameters. Most o f the 
twelve subjects respond to the 10-hour shift by a delay o f the circadian time, the other one by an 
advance. Day 1 is the first day in the new time zone (Gundel A. Spencer M. 1999)
Only the temperature recordings during sleep and the rest periods were used for the estimation of 
circadian rhythmicity.
The adaptation of the 12 subjects to the 10-hour eastward transition is illustrated in Figure 22. This 
figure displays the estimates o f acrophase on consecutive days after the flight, based on the 
estimated values of the individual sets o f parameter values. Eleven subjects adapted by delaying his 
circadian clock, while only one adapted by advancing it. Those who delayed had adapted to within 
one hour of the new time zone after 8 days, whereas the one who advanced was adapted to within 
one hour after 6 days. During the time when the circadian acrophases were changing rapidly, the 
amplitudes of the rhythms were reduced to between 2% and 52% of the entrained values
The consequences of individual differences were also examined. Adaptation times were in a range 
between 1 and 11 days. However, weaker zeitgebers will generally lead to much longer adaptation 
times, and it has already been stressed that the zeitgebers in this study are likely to have been
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stronger than those that would normally be experienced, for example by aircrew on layover or 
military personnel on deployment. Since the prediction of adaptation times is dependent on the 
choice of the external force, estimates may need to be more conservative in real life situations when 
light exposure cannot be measured. This study emphasised the enormous individual differences in 
adaptation of the circadian, to long eastward time zone transitions. Similar proportions of phase 
delay resynchronisations after westward flight have been reported by Gundel et al. 1987. Aircrew 
who fly long haul routes show similar adaptations and also take naps preceding flights to enhance 
alertness.
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Figure 23 Sleep of a commercial pilot after a westward flight
Sleep o f a pilot operating a schedule between Europe and the West Coast o f  the USA. The overnight 
flight was preceded by a nap in 11 out o f 12 pilots studied. (Nicholson et al. 1986)
Performance rhythms also adaptation to a new time zone is also direction sensitive. Like 
physiological measures performance adapts more slowly after eastward flight and greater 
decrements in performance are observed after eastward travel. (Klein et al. 1970) The rate of 
adaptation also appears to be influenced by the complexity of the task. The more complex tasks are 
more sensitive to time zone crossings. The light-dark cycle is the principal time cue for resetting
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human circadian rhythms. And the judicious avoidance of light at particular times may be useful. 
For example, when travelling east over more than four or five time zones and arriving in the early 
morning, subjects will experience light, which opposes their adaptation. The use of blinds on the 
plane and eye masks on arrival may avoid this opposing light.
1.5.3.3 Long term health effects
It has been generally accepted that the main problem of the jet lag syndrome is the associated sleep 
disturbance. This sleep disturbance exacerbates the lowered performance associated with operating 
at the circadian low. Research has been focused on improving sleep by pharmacological and other 
means. Countermeasures to jet lag will be considered later. Apart from the sleep disturbance and the 
associated fatigue it was generally believed that jet lag is a mild inconvenience. However, in a 
recent study Cho (2001) has suggested that long term repeated time zone changes impair 
physiological and psychological health and induce stress. Cortisol levels in cabin crew after 
repeated exposure to transmeridian travel were higher than those exposed to short distance flights. 
(Cho et al. 2000) these higher cortisol levels were associated with cognitive deficits. It has been 
suggested that high cortisol levels lead to hippocampal atrophy and reduction in hippocampus 
dependent learning and memory (Porter and Landfield 1998 Lupien et a l l 998). In the study by Cho 
(2001) the long-term effect of repeated jet lag on the volume of the temporal lobe and 
hippocampus-dependent memory performance were tested in air stewardesses.
The temporal lobe was measured by MRI scan. The right temporal lobe was reported to be smaller 
in the group who had less than a five-day interval between outward transmeridian flights. These 
differences were reported to be unrelated to short-term sleep deprivation. The authors suggested that 
a longer recovery period may have eliminated the damage.
Rapid travel across time zones leads like shiftwork to a miss-match or lack of synchrony between 
internal rhythm generating systems and the local time cues (Klein and Wegman 1979, Arendt and 
Marks 1982). The adaptation to these time cues is slow (approximately 1 hour per day) although
there are individual differences, and the initial shift appears to be longer than the final stages of 
adaptation.
Around one third of travellers do not experience jet lag. The decrements in performance and 
alertness that are seen after transmeridian flight can be attributed at least in part to reductions in the 
quantity and quality of sleep which occurs as a result of the need to sleep at an inappropriate 
circadian phase. A recent study of cabin crew (Cho 2001) has reported reductions in temporal lobe 
volume, deficits in spatial learning and memory and prolonged elevation of cortisol levels. The 
author suggests that prolonged cortisol elevations were responsible for these changes. It is not clear 
whether the sleep disruption associated with jet lags may have played a part in elevating cortisol 
levels and in view of this uncertainty the preservation of sleep following time-zone travel is an 
important area of research. This is particularly important for aircrews who are subjected to jet-lag 
on a very regular basis. Hypnotic agents have been shown to improve sleep following jet-lag (Stone 
et al. 1997 Redfem 1992) although the same problems as for shiftwork (tolerance and dependency) 
are also important for jet-lag.
Following north-south travel there are no similar problems.
The circadian clock can adapt by as little as one hour per day without countermeasures. However, 
around one third of travellers do not suffer from jet lag. In particular, sleep disturbance is 
experienced by around 78% of subjects on the first flight after a transmeridian flight whereas after 3 
nights only around 30% of subjects had disturbed sleep. In another study 40% of subjects reported 
subjective weakness on the first night associated with the long period without sleep
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1.5.4 Altitude
Sleeping at altitude is a requirement for increasing numbers of people and includes many where the 
consequence of disturbed sleep and susequently impaired performance can have serious 
consequences. Business travellers to South America , Winter Sportsmen in Colorado as well as 
mountaineers in the Himalayan and Karakorum mountains are all examples of those for whom 
interrupted sleep could be a problem. Aircrew sleeping on board aircraft who are expected to 
resume work soon after the end of the sleep period could also have problems. Disturbed sleep at 
altitude is a common feature of acute mountain sickness. Indeed, it is well known (Reite et al. 1975) 
that climbers on ascent may sleep poorly, and this problem may persist even during a long stay at 
high altitude. This sleep disturbance is generally considered to be part o f a wider group of 
symptoms experienced at altitude known as acute mountain sickness. These other symptoms include 
headaches, nausea, vomiting and loss of appetite, decreased mental acuity and can lead in some 
individuals to more serious mountain sickness. The different forms of altitude illness are now 
considered to be a continuous spectrum in which one or another may manifest itself and one form 
may lead to another. Table 2 shows the various forms of such illnesses and the treatments 
recommended by Houston ( 1987).
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ILLNESS
Acute mountain 
sickness
High altitude pulmonary 
oedema
High altitude cerebral 
oedema
SYMPTOMS
Headache,nausea & 
or vomiting, sleep 
disturbance, excessive 
fatigue
Severe shortness of breath, 
cough (often with sputum), 
exhaustion.
Coma and death if not 
treated
Severe headache, ataxia, 
hallucinations, confusion
TREATMENT
Symptomatic therapy 
(in general condition is 
self-limiting) 
Acetazolamide or 
dexamethazone
Descent, oxygen, 
pressure bag 
Acetazolamide or 
dexamethazone
Descend immediately or 
when safe to do so 
Dexamethazone
Table 2 Symptoms and treatment of altitude illnesses
Individuals may awaken from sleep with a sensation of suffocation, when they take a deep breath 
and return to sleep. There may be marked hypoxaemia and breathing patterns during sleep may be
disturbed, with arousals from sleep associated with these events (Sutton et al 1979 Weil, et a l l 978). 
Periodic breathing is found in most sojourners at altitude and the apneic period may last for as long 
as 10-15 seconds. It is no means clear however that the periodic breathing causes the sleep 
disturbance. Increased awakenings can occur in the absence of periodic breathing and oxygen 
administration can abolish the periodic breathing but the awakenings remain (Reite et al. 1975 
Goldenburg et al. 1992 Normand et al. 1990). It has reported previously that insomnia is significant 
during sojourns around 4000m (Nicholson et al. 1988) and at this altitude a low dose of an hypnotic 
may be beneficial. In particular the amount of slow wave sleep is reduced, although any effect on 
REM sleep is inconsistent. Although a number of studies have investigated cognitive performance 
during expeditions to altitude. (Cahoon 1972 Greene 1957 Hormbein et al. 1989 Tune 1964) and 
reported deficits in a range of cognitive and other mental performance. It is not possible to link 
these effects to the sleep disturbance experienced at altitude, because o f the effects o f hypoxia per 
se and its deleterious effects on performance. However, with many more people sleeping at 
somewhat lower altitudes after rapid ascents, it is uncertain whether hypnotics would be equally 
useful in these circumstances. The altitude of many skiing resorts is over 2700m and an ascent from 
sea level to such altitudes can be associated with disturbed sleep for 2 or 3 nights. The difficulty 
falling asleep, frequent awakenings and morning fatigue may lead to errors on the ski slopes on the 
next day. In the study described later, the extent of sleep disturbance at lower altitudes is studied. In 
addition the usefulness of a hypnotic drug is also assessed at higher doses than previously tested at 
altitude.
In view of the difficulties in carrying out such studies the field study at altitude assesses only one 
drug at a single dose in a between group comparison design. In order to understand the effects of 
hypnotics on sleep and breathing at altitude a further study using a within group design was carried 
out at a simulated altitude in a decompression chamber. In this study three doses o f one drug were 
compared with another drug with hypnotic properties.
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There are enormous differences (Nicholson et al. 1988) between individual in their sleep patterns 
during sojourns at altitude and relationships between periodic breathing and hypoxic ventilatory 
response (HVR) has been suggested (White et al. 1987)
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Figure 24 Sleep at altitude
Hypnogmms o f a climber sleeping at 15000ft with and without a hypnotic drug (Nicholson et al.
7933)
Tibetans have several physiological advantages over lowlanders at altitude and one o f these is 
reported to be a higher level of hypoxic ventilatory responsiveness (Moore et al. 1998 Milledge
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1987). For this reason the HVR was measured in subjects before they left for the altitude 
environment. The relationship between periodic breathing and other altitude syndromes is also 
unclear. The relationship between scores on an environment symptoms questionnaire (Sampson et 
al., 1980) and HVR was also examined. In a further study at higher altitude the usefulness of the 
hypnotic drug (temazepam) in combination with acetazolamide was tested.
Acetazolamide acts by balancing the respiratory alkalosis of acute altitude exposure by lowering 
blood pH by inhibiting carbonic anhydrase and increasing bicarbonate excretion (Cain and Dunn 
1966). As well as ameliorating the sleep disturbance associated with altitude (Sutton et al. 1979 
Nicholson and Stone 1986) it also reduces the other symptoms o f AMS (Cain and Dunn 1966). 
Previous studies have not measured the incidence of sleep disturbance at the lower altitudes that are 
frequently encountered by trekkers, skiers and walkers as well as by climbers. Further, is any such 
disturbance ameliorated by treatment with a hypnotic drug.
All of the previous studies of the use of hypnotics at altitude have of necessity involved between 
group comparisons of one dose of a hypnotic drug with placebo. Furthermore the ability to record 
detailed respiratory data is reduced in the field and therefore it is still unclear whether there is any 
exacerbation of respiratory symptoms by the hypnotic drug treatment.
It is also unclear whether in the presence of Acetazolamide, hypnotics confer any advantage when 
used at even higher altitudes than studied previously.
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1.5.5 Light
During an overnight return flight from the Seychelles, the subjective alertness of aircrew was much 
lower than expected (Samel et al. 1997). Prior to the flight, crews had slept for around 6.0 hours. 
This sleep was taken during the day and one of the factors responsible for the low alertness levels 
may have been a reduction in sleep quality.
Aircrew often nap during the day in anticipation of long overnight duties and at times when they 
may not be tired. Daytime sleep is known to be light and fragmented (Knauth et al. 1980 Âkerstedt
1988). When individuals are deprived of sleep they may be able to initiate daytime sleep relatively 
easily but they are likely to have difficulties maintaining sleep (Âkerstedt et al. 1981).
Intrusion of other factors such as noise, light and high ambient temperatures may add to the 
likelihood of disturbed daytime sleep. Indeed, light may have affected the sleep of aircrew 
attempting to sleep during daytime layovers in places such as the Seychelles. Light and these other 
influences are recognised by the International Classification of Sleep Disorders (American Sleep 
Disorders Association, 1980 as a cause of Environmental Sleep Disorders. An Environmental Sleep 
Disorder is a sleep disturbance due to an environmental factor that results in a complaint o f either 
insomnia or excessive sleepiness.
Light plays an important role in influencing the SCN to adjust the phase o f the circadian rhythm 
under conditions of jet lag or some shift work. Duffy et al. (1996) showed that light was the most 
important factor in terms of phase shifting, overriding the influences o f sleep timing and social 
factors such effects of light will have indirect effects on sleep under certain circumstances.
In the only published study of the direct effects of light on sleep (Giedke and Spohn 1994), minor 
effects on the latency to slow wave sleep were detected in both young and older subjects. The study 
investigated night-time sleep and used light levels between 300 and 400 lux. Although there have 
been a number of studies investigating the effect of prior light exposure on subsequent daytime 
sleep in man, I have been unable to find any information on the effects o f bright light exposure
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during daytime sleep. Room light (300 lux) impairs diurnal sleep in the albino rat (Tobler et al. 
1995) and although rats normally sleep during the day, in their normal habitat they would be 
expected to avoid light during the sleep period. Humans avoid light during sleep by the use of 
curtains, blinds and eye masks. This is believed to be particularly important for those individuals 
who sleep during the day and in latitudes where light is present during the night hours. Although 
there have been a number of studies investigating the effect of prior light exposure on subsequent 
daytime sleep in man, there is no information on the effects of bright light exposure during daytime 
sleep.
Bright light of between 1500 and 5000 lux causes an acute increase in night-time core body 
temperature o f around 0.3°. (Badia et al. 1991 Bunnel et al. 1992 Myers et al. 1993). Light does not 
however alter daytime values (Murphy et al. 1991 French et al. 1990)
In shiftworkers and in aircrew there may be a requirement to sleep during the day and it is possible 
that some of the problems sleeping during the day may be worsened by poor curtains and/or bright 
outside light levels.
Direct effects on alertness may explain disturbing effects of light on sleep. Badia et al. (1991) 
compared four conditions: alternating 90 minute blocks of bright (5,000 lux) and dim (50 lux) at 
night during a sustained wakefulness protocol, a similar condition during the day and constant 
bright or dim light at night. Sleepiness under dim light was more than when the light levels were 
raised to 5,0001ux. The differences between the two conditions increased as the night progressed. 
Improvements in performance and alerting effects in an EEG measure o f alertness were also 
observed with bright light. Exposure to similar levels of light during the day was ineffective at 
improving alertness or performance. In a later study the same group (Wright et al. 1997) reported 
that a combination of caffeine (200mg) overcame the circadian drop in performance seen at night 
for most tasks measured. Campbell and Dawson (1990) reported that subjects exposed to lOOOlux 
during a simulated night shift maintained higher levels of alertness. Cognitive performance was also
improved although simple reaction time was unaffected. Daurat et al. (1993) suggested that the 
latter part of the night is the best time for using the alerting effect of bright light.
Previous studies have therefore studied the effects of 300 and 400 lux on sleep at night and the 
effect o f up to 5,000 lux on alertness. 300 lux is equivalent to moderate interior lighting. On a sunny 
day with the curtains open (or absent) levels of light could reach 2400 lux and there is no 
information on the effects of such levels on those who need to sleep during the day due to their 
occupation.
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1.5.6 Noise
There is evidence from both subjective and objective studies that sleep is disturbed by noise 
(Ohrstrom et ah 1988 Ohrstrom 1997). In particular, difficulty in falling asleep is considered an 
important aspect of noise-induced sleep disturbance. The sleep of aircrew is likely to be disturbed 
by exposure to intermittent rather than continuous noise (Thiessen and Lapointe 1983 Abel 1990).
The top" five factors causing sleep disturbance when aircrew attempt to sleep on the aircraft in the
bunks provided for long flights are given below. (Pascoe et al. 1994) :
• Random noise (91.7% at least sometimes, 19.2% always or almost always)
• Turbulence (86.2% at least sometimes, 5.9% always or almost always)
• Not tired (85.5% at least sometimes, 4.2 % always or almost always)
• Thoughts on mind (84.8% at least sometimes, 11.2% always or almost always)
• Too hot (68.9% at least sometimes, 2.1% always or almost)
The most disturbing factor is random noise that disturbed the sleep of more than 90% of the aircrew 
surveyed. 63% of aircrew were also sometimes disturbed by the constant background noise of the 
aeroplane. 64% of 291 pilots surveyed took various measures to improve the quality of their sleep 
these included:
• 82% who used ear plugs
• 16% who used eye shades
• 2% used ‘other methods’ such as personal bedding.
In a similar survey carried out by NASA random noise was also the factor considered to be the most 
disturbing in US aircrew (Rosekind et al. 2000).
There is reported to be no habituation to noise during 14 nights of exposure (Ohrstrom et al. 1988). 
If habituation exists it is only seen in experiments in which the experimental subjects were asked to
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press a button as soon as they were awoken by a noise (Collins and lanpietro 1972 Lukas et al. 
1975). In these studies no habituation was seen when the subject was not asked to signal their 
awakening.
Many of the studies on the effects of noise on sleep have concentrated on two main areas, firstly the 
effect o f traffic noise and secondly the effect of aircraft noise likely to be experienced by 
populations around airports. For high-density continuous traffic noise the critical limit for sleep 
disturbance appears to be 40dB(A) indoors (Griefahn 1986). For intermittent noise, the upper limit 
has been suggested to be between 45 and 68dB(A) (Griefahn 1990).
To put this in perspective, noise levels of 35 dB(A) are approximately equivalent to that heard in a 
library, 65dB(A) to office noise and 125dB(A) to a jet aircraft taking off.
This wide range in sensitivity is related to the fact that the maximum sound level and the number of 
noise events are not the only variables that determine whether awakening occurs. Individual 
susceptibility to noise may also influence awakenings (Robertson et al. 1999).
Peak noise levels of 45dB(A) have been shown to increase the time taken to fall asleep. However, 
the number of events and the difference between background and peak level seem to be more 
important than the peak level itself. When noise-sensitive individuals were exposed to 4 noise 
events per hour at a maximum noise level of 45dB(A) there was a reduction in sleep quality and, 
when this was increased to 8 events per hour, sleep onset was delayed (Griefahn 1986).
Griefahn reviewed the effects of noise on sleep (1991), and divided these effects into primary 
effects and after effects. The primary effects are the changes in the EEG such as sleep stage 
changes, awakenings and arousals as well as body movements and autonomic responses. The after 
effects include mood alterations and changes in performance observed when the subjects are awake. 
Other factors, which influence the likelihood of sleep disturbance due to noise, include age and the 
part of the night where the noise occurs. With increasing age, the probability o f awakening in 
response to noise becomes greater (Griefahn et al. 1976 Lukas and Krypter 1969 Lukas et al. 1971, 
Lukas and Dobbs 1972).
Subjects are more sensitive to the effects of noise in the second part of the night (Keefe et al. 1971 
Lukas et al. 1971). This could be due to circadian rhythm or to the sleep obtained in the first half of 
the night that contains more slow wave sleep. Further, the homeostatic control of sleep reduces the 
requirement for sleep in the second half of the night.
Research on the area of noise and sleep has concentrated on disturbance at night caused by factors 
which may be a hazard for populations living close to airports or near to busy roads. The 
shiftworker or the airline pilot is required to sleep during the day. Although it is known that sleep is 
impaired due to the circadian rhythm in sleep propensity, it is not clear whether the noises likely to 
be experienced by aircrew while sleeping in hotel rooms during the day will disturb sleep further.
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1.6 PHARMACOLOGICAL AND OTHER INTERVENTIONS
1.6.1 Strategies to treat shift-work and jet-lag
Both jet lag and shiftwork lead to deficits in performance caused by the requirement to operate at 
the circadian trough for performance, as well as the inevitable sleep loss associated with the need to 
sleep at times which are not conducive to sleep. For this reason a number o f interventions for jet-lag 
and shiftwork have been tested.
Given the adverse effects of sleep loss on alertness, one approach to optimising performance in 
situations involving shiftwork or transmeridian flights is to preserve sleep as much as possible. This 
can be approached in two ways: firstly, by the application o f sleep-promoting techniques and by 
attention to the circumstances surrounding sleep and, secondly, by the use o f hypnotic substances.
1.6.1.1 Techniques to promote sleep
Although this thesis has studied pharmacological interventions to ameliorate environmental sleep 
disturbance, it is important to put these into context. Among the techniques or strategies that may be 
applied to promote sleep are those which aim to ensure that the sleeping environment is optimal. 
While it is true that shiftworkers sleep badly even in sound- and light-proofed laboratories (Monk 
1994), sleep will be more disturbed if the bedroom environment is noisy and light. The effects of 
these environmental factors on sleep are dealt with later in this chapter. A number o f relaxation 
techniques to induce sleep in insomniacs have been claimed to be successful (Nicassio and Bootzin 
1974). Hawkins (1980) has reviewed the various methods in the context of disturbed sleep in airline 
pilots. Similarly, after transmeridian flight, it is important to ensure that extraneous noise and light 
are kept to a minimum to alleviate problems related to staying asleep in the morning or to falling 
asleep at night. If the sleeping environment is not ideal, ear plugs and eye shades can be used to 
screen unwanted external stimuli. These strategies are frequently used by airline pilots sleeping in 
hotel accommodation or when they have to obtain rest in the bunk facilities on board the aircraft
itself on long range flights' Aromatherapy products have also been promoted for the treatment of jet 
lag and sleep disturbance. Essential oils, selected for their alerting or sleep-inducing properties, are 
added to the bath at appropriate times of the day. At least two international airlines give these 
products to their passengers, although objective evidence of their effectiveness is unavailable. 
Caffeine and alcohol are known to have detrimental effects on sleep (Nicholson and Stone 1980 
Stone 1980), though alcohol may initially promote sleep onset. Avoidance o f caffeine close to 
bedtime and of excessive alcohol intake are measures which will serve to improve the sleep of 
shiftworkers and intercontinental travellers. The influence of dietary constituents has also been 
considered, and it has been suggested that a ‘jet-lag diet’ will speed adaptation of sleep and other 
rhythms (Ehret 1983) This diet proposes that an evening meal rich in carbohydrates will provide a 
source of tryptophan for serotonin synthesis to assist sleep, and that protein-rich meals in the 
morning will provide tyrosine to enhance catecholamine levels and increase alertness during the 
day. However, a review of this field of research concludes that there is no evidence to support this 
idea (Leathwood 1989)'Administration of tryptophan has been reported to increase total sleep time 
on the first night after transmeridian travel westwards (Spinweber 1987), though its effects on sleep 
are considered to be limited (Nicholson et al. 1994).
Changes in the timing of rest periods and naps during shiftwork or after a time zone change can lead 
to improvements in sleep. However, it is necessary to balance the changeover times o f shifts since 
sleep duration is reduced if the morning shift starts early or if the night shift finishes late (Knauth 
1993). During transmeridian travel, if  it is not possible to sleep during an overnight eastward flight, 
restricting sleep on arrival can aid sleep on the first night and, possibly, speed the rate o f adaptation. 
If passengers are able to sleep on board the aircraft, then sleep coinciding with bedtime in the 
destination time zone will avoid the desire for a sleep on arrival, and is likely to lead to better 
quality nocturnal sleep. Conversely, sleeping at a time coinciding with night-time in the home time 
zone may lead to disturbed sleep at the destination and, possibly, delayed adaptation.
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Finally, sleeping position is also important, and particularly relevant to long-haul air travel. On 
board aircraft, passengers are required to adopt a posture that may make sleeping difficult. Near­
horizontal sleeping facilities are preferable, but they are presently limited to first class cabins where 
a premium is charged for the increased space required. Assessment of sleep quality in aircraft seats 
has shown that the greater the back angle from the vertical, the more likely it is that the passenger 
will obtain reasonable sleep. Adequate sleep is likely as long as the back angle is around 40 degrees 
(Nicholson and Stone 1987). Over the last few years, airlines have begun to improve the seats, 
particularly for business and first class passengers. The sleeping facilities available for first class 
passengers are extremely comfortable, though other factors such as the unconstrained availability of 
meals may disturb those trying to sleep.
Apart from the sleep hygiene techniques (avoiding caffeine, alcohol etc.), most of the techniqes 
reviwed here are rather weak.
1.6.1.2 Hypnotic drugs and sleep promoting substances
The second approach to preserving sleep involves the use of drugs, and there have been numerous 
studies on the effects of hypnotic drugs (Buysse 1991). The largest class o f hypnotics, the 
benzodiazepines, is known to speed sleep onset, reduce awakenings and increase total sleep time in 
normal sleepers and in those suffering from transient and chronic insomnia. In addition, they may 
modify sleep architecture by delaying the appearance o f REM sleep, reducing slow wave sleep and 
enhancing sleep spindles (Gaillard 1994 Borbely and Achermann 1991 Borbely et al. 1991). The 
imidazopyridine, zolpidem, and the cyclopyrrolone, zopiclone, have similar effects on the EEG as 
benzodiazepines (Brunner et al. 1991 Guieu et al. 1996). Zolpidem, however, may increase slow 
wave sleep, at least in young individuals (Guieu et al. 1996 Nicholson and Pascoe 1983) and there is 
one report of a moderate increase in slow wave sleep with zopiclone (Nicholson and Stone 1983).
A hypnotic should, ideally, accelerate sleep onset and sustain sleep for a useful period of time. It 
may also be desirable to preserve slow wave sleep, although the overriding factor when considering
the potential use of a hypnotic by shiftworkers or during and/or after transmeridian flights is the 
drug’s duration of action (Nicholson 1994). Active metabolites may also prolong the duration of 
action of a particular drug. Clearly, the benefits associated with improved sleep may well be masked 
if the hypnotic chosen leads to unwanted side-effects on alertness after the sleep period. A hypnotic 
which has a mean elimination half-life of around 5h, such as brotizolam and zopiclone, or less (for 
example, midazolam, triazolam, zolpidem), and is without active metabolites, is likely to be free of 
residual effects and without accumulation if taken daily. Table 3 shows the elimination half lives of 
a number of hypnotic drugs. In Figures 25 and 26 the immediate and residual effects of some of 
these drugs on performance are shown. Suitable hypnotics also include temazepam that, although it 
has a half-life of around 8h, has a relatively short duration of action due to the decrease in plasma 
levels as the drug is distributed from the central to the peripheral compartment. Drugs with 
appropriate pharmacokinetic profiles have been evaluated in simulated and field studies of 
shiftwork and jet lag. In such situations, hypnotics are likely to be effective due to their sleep 
promoting properties (Donaldson and Kennaway 1991) rather than via an effect on shifting 
circadian rhythms, as suggested by early studies in animals (Redfem 1992).
After a transmeridian flight, hypnotics with a duration of action o f around 3 to 5h may be useful to 
sustain sleep during the adaptation phase without having adverse effects on performance (Nicholson 
et al. 1986 Nicholson et al. 1990 Donaldson and Kennaway 1991). For example, temazepam taken 
during eastward and westward flights across 11 time zones at the time corresponding to bedtime in 
the destination time zone and for four days after arrival improved subjectively assessed sleep 
without affecting performance during the day (Donaldson and Kennaway 1991). In another study, 
brotizolam reduced wakefulness and increased stage 2 sleep on the first two nights after a 5h 
westward time zone change and the drug was also effective in reducing wakefulness and stage 1 
sleep for five nights after the eastward journey (Nicholson et al. 1990). Improvements in sleep 
continuity with brotizolam were accompanied by a reduction in REM sleep on those nights when an
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increase was observed with placebo. This effect may not be desirable when there is a greater 
requirement for REM sleep, for example, several days after an eastward flight (Spencer et al. 1996). 
The effects of a hypnotic may depend on the extent o f sleep disturbance which, in turn, depends on 
factors such as the direction of travel, number o f time zones crossed and the age o f the individual. 
For example, the short-acting hypnotic, midazolam, taken for four nights after a 7h time zone 
change has been shown to improve sleep, though only after the eastward flight on the first and third 
night when sleep with placebo was poor (Lavie 1990). Similarly, on the first night after an eastward 
flight when sleep after placebo was better than control due to considerable sleep loss, it was not 
possible to show a further improvement in sleep with brotizolam (Nicholson et al. 1990).
As well as using hypnotic drugs on arrival in a new time zone, passengers may consider using 
medication on the flight itself to assist sleep timed to coincide with the nocturnal rest period at their 
destination. Certainly, in an unfavourable environment simulating troop transportation, the ultra- 
rapidly eliminated hypnotics, triazolam and zolpidem, with half-lives o f between 1.5h and 2h, had 
comparable sleep-promoting properties (Balkin et al. 1992). However, a field study suggested that 
triazolam may be ineffective on board an aircraft if  there is no control over factors such as the 
timing of meals or the cabin lighting (Penetar et al. 1989). Indeed, to sustain sleep during a long 
flight, a hypnotic with a half-life o f around 5h may be more appropriate.
In a laboratory study of sleep in airline seats, though midazolam and brotizolam improved sleep, 
midazolam further suppressed REM sleep, below levels which were already reduced by sleeping in 
the seat (Nicholson 1986). An additional consideration if taking a high dose o f an ultra-rapidly 
eliminated hypnotic is the possibility that high plasma levels may impair performance in an 
emergency situation (Balkin et al. 1992) or on arrival at the destination (Penetar et al. 1989). There 
could also be rebound effects on sleep parameters during the next rest period.
Hypnotics may also be used by shiftworkers, and a review (Walsh et al. 1995) concluded that
hypnotics reliably improve daytime sleep by increasing sleep efficiency and duration. Interestingly,
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the efficacy of hypnotics for nocturnal sleep may not always predict their effectiveness for daytime 
sleep (Nicholson and Stone 1979). With this in mind, evaluation of new compounds should include 
assessment of sleep promoting properties at different times of the day. Such studies would also take 
account of the different sleep problems experienced by shiftworkers in relation to their different 
schedules. As far as the night shiftworker is concerned, sleep onset is not likely to be as much of a 
problem as sustaining sleep during the day, whereas those working an early morning shift who 
choose to retire to bed in the early evening may have difficulty falling asleep.
To date, the majority of studies on hypnotics and shiftwork have been laboratory-based simulations. 
In these situations the effects of cumulative sleep loss may be underestimated when using subjects 
who are not shiftworkers, particularly if they are young adults who are normally good sleepers. In 
addition, sleep is more likely to be sustained when environmental conditions are controlled. For 
example, triazolam was more effective in sustaining daytime sleep in middle-aged shiftworkers who 
slept in the laboratory (Walsh et al. 1984) than in middle-aged individuals who slept at home 
(Walsh et al. 1991).
Studies suggest that the less restful sleep of the middle-aged is more likely to be improved by 
hypnotics than the sleep of young adults (Nicholson and Pascoe 1988 Walsh et al. 1988). Older shift 
workers have reported greater use of sleeping pills than their younger colleagues (Foret et al. 1981 
Niedhammer et al. 1995)'Furthermore, it is possible that middle-aged individuals may derive 
greater benefit from the sleep enhancing effects o f hypnotics in terms o f improved alertness 
overnight (Walsh et al. 1988) than young adults. Indeed, for young subjects who are good sleepers 
there may be no difference in overnight performance following a drug-assisted or natural evening 
sleep (Nicholson et al. 1985).
Another factor to consider is the potential effects of withdrawal o f medication, and age-related 
differences in the effect of hypnotics may also lead to different effects upon their discontinuation. 
Withdrawal of triazolam after four days usage for daytime sleep resulted in a greater reduction in 
sleep efficiency in middle-aged individuals than young adults (Walsh et al. 1988), though the
rebound effects in this study may have been related to the high dose used (0.5mg). Indeed, this dose 
of triazolam has been shown to impair performance following daytime sleep (Walsh et al. 1984), 
overnight sleep (Nicholson and Stone 1980), and both sleep on board aircraft (Penetar et al. 1989), 
and in conditions simulating those on board aircraft (Balkin et al. 1992). A lower dose of triazolam 
(0.25mg) has been shown to improve subjectively assessed sleep without having residual sequelae 
in military shiftworkers with disturbed sleep (Puca et al. 1996). However, other studies suggest that 
low doses of hypnotics may not be effective in some middle-aged individuals (Walsh et al. 1991, 
Nicholson et al. 1982).
It is important to balance the requirement to improve sleep with the need to avoid residual effects. 
Zolpidem has a pharmacokinetic profile similar to triazolam (Nicholson 1994) and, though it would 
appear to be free of residual effects improvements in daytime sleep were only observed at relatively 
high doses (20-3 Omg) in young adults and were accompanied by a reduction in REM sleep 
(Nicholson and Pascoe 1988). While zolpidem may be more effective in poor sleepers, it is possible 
that hypnotics which are short acting rather than ultra short acting may be more suited to sustaining 
daytime sleep. For example, temazepam has been used successfully in doses of 10-20mg by military 
aircrew to assist sleep at unusual times of the day during intensive operations when the interval 
between drug ingestion and commencement of duty may be as short as 6h (Baird et al. 1983, 
Nicholson et al. 1985). Similarly, temazepam improved daytime sleep and increased alertness 
during a simulated night shift (Porcu et al. 1996 Bellatrecia et al. 1998) and had no residual effects 
when used by military shiftworkers (Moon and Hindmarch 1983). Zopiclone may be an equally 
effective hypnotic as it improved sleep when bedtime was advanced by 4h (Trachsel et al. 1990) 
and when advanced or delayed by 6h (Kamo et al. 1993). One laboratory study reported decrements 
in performance on one task some 9h after drug ingestion (Nicholson and Stone 1983), though there 
were no residual effects when used by military shiftworkers (Moon et al. 1990).
As well as prescription medications, there are also over-the-counter preparations, which may 
alleviate sleep disturbance, including centrally acting antihistamines. While these drugs may assist
sleep onset, if modulation of monoaminergic activity is among their pharmacological properties, 
reduced wakefulness may be accompanied by suppression of REM sleep (Nicholson et al. 1985). 
Discontinuation of the medication could increase the pressure for REM sleep and may delay the 
return of a normal sleep pattern. In addition, if  the drug has a prolonged duration of action, it may 
cause residual effects.
The choice of hypnotic will depend upon the desired duration o f action. The lowest effective dose 
should be used and the concomitant use of alcohol should be avoided or restricted. However, 
hypnotics will not be appropriate for those suffering from illnesses, such as sleep apnoea, which 
may be exacerbated by the medication.
Advice on the use of hypnotics requires further clarification, particularly for those individuals with 
poor sleep whom frequently undertake night shiftwork or regularly cross time zones. The potential 
users should be aware of the general recommendation that hypnotics should only be taken 
occasionally. For example, this could involve using a suitable hypnotic on alternate days at the start 
of a period of night work, so that a sleep deficit does not accumulate. Dissemination of current 
knowledge and guidelines on promoting sleep to occupational physicians, shiftworkers and 
transmeridian travellers should be encouraged. At the present time, however, there is little 
information on the pattern of hypnotic usage and efficacy in shiftworkers over time. Further 
research in this area, including feedback from users, would allow better definition of the most 
suitable treatments.
The key pharmacokinetic parameters of a range of hypnotic drugs are given in Table 3
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Key Pharmacokinetic Parameters
T herapeutic A gen t t m a x ( h ) ty2 (h)
Flurazepam 0.5-6 47-100*
Diazepam 0.5-2 20-80*
Temazepam 1-3 10-20
Oxazepam 2-3 4-20
Brotizolam 0.8-1.2 3-8
Zopiclone 1.0 3.5-6.5
Zolpidem 1.5 1.1-3.3
Zaleplon 1.0 0.9-1.1
* active metabolite
Table 3 Mean elimination half-lives of a number of hypnotic drugs
The mean elimination half-lives o f brotizolam and zolpidem are around 5 h or less. Temazepam is a 
suitable hypnotic, which, although it has a longer half life, has a relatively short duration o f action 
due to the decrease in plasma levels as the drug is distributed from the central to the peripheral 
compartment. Zopiclone (3 .7 5 -7 .5  mg) is also rapidly absorbed, but the activity o f the 
recommended dose range extends beyond 6 h. .The limited duration o f action o f temazepam, 
brotizolam and zolpidem has been shown in laboratory studies where a lack o f residual effects on 
performance 6 h after ingestion has been established. Figures 25 & 26 show the immediate and 
residual effects o f a range o f hypnotic drugs on tracking performance.
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6.1.3 Melatonin
The alternative approach to the use of hypnotics is in situations where a disturbance of sleep is due 
to circadian rhythm disturbance when the naturally occurring hormone melatonin, may be 
appropriate, although hypnotic drugs with suitable profiles may also be useful as discussed earlier. 
Melatonin, the ‘darkness hormone’ produced by the pineal gland, signals the length of the dark 
phase in animals (Arendt et al. 1987 Arendt. 1994). It is almost exclusively synthesised during the 
hours of darkness. As well as the pineal gland melatonin has been found in the retina, gut (Vivien- 
Roels et al. 1981) There is much interest concerning the activity of melatonin and how melatonin 
may be used to alleviate disturbances of circadian rhythmicity and insomnia. Experimental work on 
the possible adjustment o f the circadian clock by melatonin is complicated by its sedative activity. 
This latter effect may improve sleep, thus alleviating the symptoms of circadian desynchrony, and 
even normalising the sleep-wake cycle. Whether melatonin can induce a phase shift of circadian 
rhythms is an issue much debated (Arendt et al 1997 Lewy and Sack 1997 Sack and Lewy 1997)). It 
may elicit a relatively weak phase shifting effect, but Cziésler (1997) has emphasised that this may
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be insufficient to induce a reliable entrainment. Any such effect with melatonin needs to be 
established by physiological parameters other than sleep and wakefulness.
Although sedative activity of melatonin has been demonstrated, its usefulness as a hypnotic is not 
clear. Indeed, Roth and Richardson (1997) have emphasised that the majority o f studies have 
evaluated only a single dose, or a limited dose range, and that there is a need for unambiguous 
information on its activity related to dose and to time of administration. Further, dose response data 
using electroencephalography are essential to an adequate understanding of its activity. Daytime 
ingestion of melatonin would appear to lead to reductions in sleep latencies (Dollins et al. 1994 
Nave et al. 1996 Reid et al. 1996 Hughes and Badia 1997). However, studies on its activity around 
the normal time of sleep have failed to establish a useful clinical effect, except possibly in elderly 
insomniacs (Monti et al. 1999 Hughes et al. 1998 Dawson et al. 1998).
The usefulness of a hypnotic in the management of sleep disturbance associated with shift work or 
with world wide travel would be dependent on it being effective at all times of the circadian cycle.
It is in this context that a dose response study on the activity of melatonin when given in the early 
and late evening in healthy volunteers was carried out. In chapter three the activity o f melatonin 
was studied on nocturnal sleep (23:00-07:30) and on evening sleep (18:00-24:00), using 
electroencephalography, and was compared with that of a benzodiazepine (temazepam 20 mg) 
which is often used by individuals coping with irregular patterns of rest in critical situations.
1.6.2 Strategies to treat other environmental sleep disturbances
In the studies on the insomnia associated with stays at high altitude conventional benzodiazepine 
hypnotics have been tested (Nicholson et al. 1988) as agents to ameliorate the sleep disturbance 
associated with such sojourns. However these drugs are only suitable if  at least six hours intervenes 
between ingestion and the requirement to be alert. In the case o f altitude it is important that 
mountaineers are able to take correct decisions about routes of ascent and equipment to be used. In 
most cases mountaineers retire early and therefore there is no requirement for an ultra short acting
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hypnotic. When noise disturbs sleep in the middle o f the night and the disturbed sleeper attempts to 
return to sleep in a noisy environment or if intrusive thoughts prevent sleep none of the 
conventional hypnotics such as temazepam are suitable as their use would be associated with 
impaired performance. Even the non benzodiazepine hypnotics zopiclone and zolpidem would be 
unsuitable for middle of the night administration as they would be likely to produce residual effects 
on performance in the morning.
For the treatment of middle of the night insomnia caused by an intrinsic condition in the individual 
or by environmental factors such as noise it is necessary to move to the most rapidly eliminated 
hypnotic recently introduced into clinical practice, zaleplon (Sonata6®)., a pyrazolopyrimidine 
compound that binds selectively to the y-aminobutyric acid (GABA)a receptor complex (Beer B et 
al 1994 Dâmgen et al. 1999). It is rapidly absorbed, with peak plasma concentrations at around Ih, 
and rapidly eliminated with a plasma elimination half-life o f approximately Ih (Beer et al; 1994 
Hurst et al. 1999). Zaleplon therefore has a rapid onset o f action and a rapid elimination half life 
and this profile is unlike any other hypnotic drug in the market today. The structure of zaleplon is 
unrelated to barbiturates, benzodiazepines and other hypnotic drugs. It also possesses agonist 
properties and it lacks many of the side effects commonly associated with other hypnotic drugs due 
to its short duration of action.
It has been shown to have useful hypnotic effects in patients with insomnia (Walsh et al. 1998 
2000a 2000b 2000c Ancoli-Israel et al. 1999 Elle R. et al. 1999). These effects included reduction 
in sleep onset latency and this was not associated with rebound insomnia on withdrawal or with any 
other withdrawal symptoms. In addition there was no tolerance during therapy reported In this way 
zaleplon can be used as a treatment for those patients with sleep onset insomnia (Walsh et al. 2000) 
or indeed for those with situational insomnia which manifests itself with problems falling asleep. 
Thus zaleplon may prove to be an extremely useful drug in the treatment of insomnia associated 
with circadian rhythm disturbance such as jet lag (Stone et al. 2001). Its rapid onset and swift
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duration of action (Beer et al. 1997) would suggest its use to aid sleep onset after eastward travel, 
where it is necessary to fall asleep at a time when the circadian rhythm is at its alert phase. It could 
also be taken for the sleep maintenance problems experienced after westward flight. In these 
circumstances it would be ingested in the middle of the night when it is common to wake up around 
midday in the home time zone. In shiftworkers who are required to retire to bed earlier in order to 
anticipate an early start. It may also be useful. However, many other short acting hypnotics may be 
useful in these circumstances although the lack of rebound insomnia, which occurs with some other 
hypnotics may make it more suitable in those who carry out skilled work. Rebound insomnia is the 
phenomena seen on withdrawal from hypnotic drugs when sleep may be worse than before the 
hypnotics were started, with zaleplon The unique property o f zaleplon is its ability to promote sleep 
in the middle of the night without any residual effects on performance on the following morning 
because of its ultra-short action. (Vermeeren et al. 1998 Danjou et al. 1999 Walsh et al. 2000a 
Hindmarch et al. 2001 Stone et al. 2002). 
extrinsic factors.
1.6.3 Other Drugs
Alcohol is often considered to be a sleep promoting substance. However, although it may initially 
promote sleep onset it also has detrimental effects on sleep (Stone 1980). In particular, alcohol leads 
to sleep disturbance in the latter part of the night. The amino acid tryptophan has been reported to 
increase total sleep time on the first night after westward transmeridian travel (Spinweber 1987). Its 
effects on sleep, however, are generally considered to be unpredictable and limited (Nicholson et al. 
1979).
A number of other drugs used to treat a range of medical conditions also possess sleep-inducing 
properties. The effects of HI antihistamines on sleepiness and performance have been widely 
studied. The first generation antihistamines are lipophilic, cross the blood-brain barrier with ease 
and have poor receptor selectivity. Sedation is a major side effect o f these drugs (Nicholson et al.
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1985) and the second generation drugs which do not have these problems have largely replaced 
their use in the treatment of allergy. In particular diphenhydramine is particularly sedating and for 
this reason is the main ingredient in many over-the counter sleeping aids. Promethazine is another 
sedating anthistamine (Risberg et al. 1975), which is included in cold and influenza remedies, which 
are taken at night. The sedating properties are also used when it is included as an active control in 
studies of the sedating and performance effects o f a range of drugs. The use of these drugs in 
insomnia caused by environmental factors has not been studied systematically. However, it is 
possible that individuals who can buy them easily in their local pharmacist may use them.
Many antidepressant drugs improve sleep. However, this sedation is accompanied by alteration of 
the sleep cycle such as suppression of REM sleep and performance deficits. Therefore, these drugs 
are considered unsuitable for use as a sleep-inducer in those carrying out skilled work. Lithium, a 
major tranquilliser, improves nocturnal sleep but is also associated with cognitive deficits and is 
unsuitable for skilled workers.
1.6.4 Drugs and respiration
In the use of hypnotics to treat altitude induced insomnia , the potential effects o f these drugs on 
respiration is very important. It has been reported that benzodiazepines reduce hypoxic ventilatory 
responses (Lakshminarayan et al. 1976 ) diazepam was given intra muscularly (lOmg) to normal 
subjects and ventilatory control, hypoxic and hypercapnie responses were studied. Although there 
were no changes in resting minute ventilation or resting end-tidal C02 tension, hypoxic ventilatory 
responses were depressed 15 (60% of control) and 30 min (53% of control) after administration of 
diazepam. After 70 to 130 minutes after drug administration the changes in hypoxic ventilatory 
responses were no longer evident and they were therefore considered to be possibly hazardous in 
those whose breathing was disordered during sleep. However recently these drugs have been tested 
in the elderly and in patients with sleep apnoea and there was no evidence o f increases o f sleep
disordered breathing in either group. Camacho et al. 1995 Hoijer et al 1994 ). Temazepam has been 
used in patients with heart failure and there was no change in oxygenation during sleep or in the 
extent of periodic breathing (Biberdorf DJ et al. 1993).
Further in an earlier study in the Himalayas showed that in subjects using acetazolamide or those 
using placebo, temazepam improved sleep without any apparent ventilatory depression. In Chapter 
four the usefulness of hypnotic drugs in the treatment of altitude induced insomnia is studied further 
in the field and in a decompression chamber.
1.7 SUMMARY AND RATIONALE FOR FURTHER STUDIES
To summarise the sleep disturbances caused by shift work and jet lag are well documented and are 
of sufficient magnitude to warrant intervention. Shift workers in particular are more likely to be 
involved in road accidents than non shift workers. The repetitive use o f conventional hypnotic drugs 
is unlikely to be acceptable to most shift workers and business travellers. The most suitable 
treatment may be melatonin, although further studies on its effectiveness at various times in the 
circadian cycle are required and this is the subject of Chapter three.
The use o f hypnotics at altitudes of many ski resorts has not been studied systmatically. The 
severity o f any sleep diturbance is also unknown In Chapter four the usefulness of a hypnotic at 
lower altitudes than previously studied is tested .The previous study at around 4000m showed that 
sleep disturbance was significant and that a low dose of temazepam was beneficial. The severity of 
the insomnia associated with higher altitudes was uncertain. Futhermore the use of acetazolamide 
may avoid problems with insomnia .A study of combined Temazepam and Acetazolamide treatment 
at 5400m was therefore studied. All the field studies involve between subject comparisons and a 
limited number of respiratory measures. The conditions at sea level in the field differed from the 
baseline measures. In the field conditions often became more severe as the ascent progressed. For 
example temperature dropped as a direct consequence of the ascent. In order to control conditions
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more a study in a decompression chamber where it was possible to carry out a dose response study 
in a within subject design.
The effect of environmental factors light and noise are less clear. In particular there is very little 
information on the disturbance caused by light levels tyhat may be experienced by aircrew 
attempting to sleep during the day. Similarly the effect of the intermittent noise that may disturb the 
sleep of aircrew has not been studied and these environmental factors are the subject of Chapter 
five. The two stimuli were administered separately in order to determine the relative importance of 
light and noise for sleep disturbance.
Finally, in Chapter six, the newer hypnotic, zaleplon, was investigated for its usefulness in the 
treatment of noise induced insomnia. Zaleplon is targeted at patients who are unable to fall asleep 
easily. This drug with its short duration of action may also be suitable for the treatment o f a number 
of environmental sleep disturbances.
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CHAPTER TWO
METHODS AND MATERIALS
A number of techniques have been used throughout this thesis and in this chapter details of the 
common experimental methods used are given. The experimental chapters give further details of 
methods used.
2.1 EXPERIMENTAL DESIGN
In all experiments the subjects were healthy volunteers and details o f their age ranges are given in 
the individual chapters. All the experiments were carried out double-blind. All experiments were 
subject to ethical approval by an Independent Ethics Committee. The Ethics commitee requires a 
power calculation as part of the submission. Data from similar studies was used to make this 
calculation. Subjects were subjected to a number of controls. Firstly they were required to retire at 
an agreed time on the nighr preceding the experiment. Restrictions on alcohol and caffeine intake 
were imposed.
In both field and laboratory studies the recording of sleep patterns used identical methodology as far 
as the placement of electrodes was concerned. In some cases where it was expected that subjects 
may be particularly restless extra electrodes were used as back up. In the laboratory the subjects 
slept in single light-proofed, sound-attenuated and temperature controlled (18±2°C) rooms. For the 
field studies of altitude portable recorders (Oxford Instruments) were used. In the laboratory data 
was recorded on either Grass or Nihon Kohdon pen recorders or Emblas and details o f these are 
given in the individual chapters.
In all the laboratory studies between subject designs with treatments arranged according to a latin 
square were used. In the altitude studies carried out in the field a between subject design was used.
2.2 SLEEP RECORDING
2.2.1 Electroencephalography
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An adaptation night preceded each experiment to familiarise the subjects with the recording 
procedures, and to ensure that their sleep patterns were normal. The subjects were assessed for the 
presence of sleep disorders by the use of electrodes to monitor respiration and leg movements from 
the anterior tibialis muscles. These records were then scored for the presence of sleep disorders, 
Any subject with such a disorder were excluded from the experiment. Although it is only strictly 
necessary to record from one pair of EEG electrode placements in order to analyse sleep according 
to Rechschaffen and Kales (1968), it is often easier to determine the presence or absence of alpha 
activity from the occipital region and therefore an occipital channel is included. Silver-silver 
chloride electrodes were used to record electroencephalograph (EEG) activity from the O1-A2 and 
C4 -A1 positions, together with bilateral electro-oculograms (EOG) and the submental 
electromyogram (EMG), on a Grass, Nicolet Biomedical Ultrasom (digital EEG) system, Nihon- 
Koden 4300 series EEG machines or Emblas. The electrodes are attached with collodion and EOG 
electrodes are attached with adhesive circles. They were then filled with electrode jelly to improve 
electrical contact. Resistances were maintained below lOKohms. Two analysts scored the records 
(10mm/s) manually from paper records or from the screen, independently, into 30s epochs 
according to the criteria of Rechtschaffen and Kales (1968). Any differences were then resolved. 
Various measures were derived from the data for subsequent statistical analysis. These measures 
include the latency to and duration of the individual sleep stages and the incidence and duration of 
any arousals.
2.2.2 Subjective assessments
Subjective assessments o f sleep were completed 15 min after rising. The extremes o f the 100 mm 
scales were: I slept, very poorly (0) - very well (100); Now I feel, very sleepy (0) - wide awake 
(100); I fell asleep, never (0) - immediately (100); After I fell asleep, I slept, very badly (0) - very 
well (100). Subjects also estimated the time to sleep onset and the sleep duration. The Stanford 
Sleepiness Scale (14) was completed prior to and after each sleep period in some o f the studies.
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2.3 PERFORMANCE
In the experiments on the effect of melatonin, and on zaleplon on noise induced insomnia, a number 
of performance tests were used. Subjects were well trained on all performance tasks and were 
observed during the tasks by means of closed circuit television. In the experiment on nocturnal 
sleep, tests were presented at 23:00 (0.5h before drug ingestion) and at 08:00 (8.5h after drug 
ingestion) in the following order: digit symbol substitution (DSS), letter memory recall, picture 
memory recall. During each session, mood and wellbeing were assessed using a series of twelve 
100-mm visual analogue scales (15). In the experiment on early evening sleep, DSS only was 
measured at 00:30, i.e. 6.5h after drug ingestion.
2.3.1 Digit symbol substitution
Subjects were presented with one of a series of 30 sheets with 200 randomised digits (0-9) arranged 
in 10 rows on each side of the sheet (16). In the space below each digit they were required to insert 
the appropriate symbol indicated by a code at the top of the page. Subjects were given 2 min per 
side to complete as many substitutions as possible.
2.3.2 Letter memory recall
A set containing 6 letters was presented on a monitor (17). Subjects were given a maximum of 15s 
to memorise the set. Then, a series of randomly generated letters was displayed individually on the 
screen and subjects used the appropriate button to respond positively if  the letter was contained in 
the memory set or negatively if it was not. The task lasted 2 min and was self- paced with a 
maximum time allowed of 5s per response. Response data and reaction times were recorded.
2.3.3 Picture memory recall
During the pre-sleep test session, subjects were given 1 min to examine a set o f 12 photographs of 
miscellaneous, unrelated objects (18). Nine hours later, subjects were given 45 s to recall and write 
down as many objects as possible. There were 8 different sets o f photographs and the order of 
presentation o f the sets was based upon a Latin Square design.
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2.4 MELATONIN ONSET
The subjects remained in constant dim light (<8 lux) in an isolation unit from 17:00 to 03:00 and 
produced saliva samples at half hourly intervals. Salivary melatonin levels were determined by 
radioimmunoassay (English et al. 1993) and the dim light melatonin onset was calculated as the 
time at which melatonin levels reached twice the limit of detection of the assay (1.3 pg/ml).
2.5 STATISTICAL ANALYSIS
This varied between the studies and is described in the individual chapters. In general analysis of 
variance (ANOVA) was used as an initial approach. Mutifactorial ANOVA was used. The 
assumptions of ANOVA (homogeneity of variance, normality and additivity) were studied by 
investigating transformations of the raw measures using the method of maximum likelihood. If the 
data were not distributed normally, an appropriate transformation was used . If the F ratio was 
significant, a number of planned comparisons were made. The planned comparisons were made 
using either Dunnet’s procedure or Bonferroni’s test which adjust for multiple comparisons with a 
control. Dunnef s assumes independence of the data. Bonferroni is more rigorous and was used 
when the data was assumed not to be independent.
2.6 HYPOXIC VENTILATORY RESPONSE
The method of Rebuck and Campbell (1974) was used to assess the ventilatory response to hypoxia. 
The subjects rebreathed from a small bag, starting with a gas mixture containing slightly above the 
normal inspiratory P02 which then fell as a result of the subject’s oxygen consumption. The Pco2 
was held steady by a ‘scrubber circuit’. The subjects rebreathed from a 5-litre bag that contained 
initially a mixture of 25% oxygen in nitrogen. Rebreathing created progressive hypoxia whilst end 
tidal PC02 was held constant at “mixed venous” level by a variable CO2 scrubbing circuit. The 
subject continued rebreathing until end-tidal P 0 2 fell to 35mmHg. Each subject carried out this
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procedure twice, with a thirty minute period between each test. The first test was used to familiarise 
the subjects with the experimental procedure and to minimise ventilatory effects related to anxiety. 
Oxygen saturation was measured continuously by ear oximetry (Hewlett Packard) and regression 
lines of ventilation on oxygen saturation were fitted by the least squares method.
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CHAPTER THREE
SHIFTWORK, JET-LAG AND MELATONIN
3.1 INTRODUCTION
There are some individuals who dislike the idea of taking conventional hypnotic drugs and the idea 
of taking the naturally occurring darkness hormone, melatonin, is more appealing.
There is much interest concerning the activity of melatonin and how melatonin may be used to 
alleviate disturbances of circadian rhythmicity and insomnia. Experimental work on the possible 
adjustment of the circadian clock by melatonin is complicated by its sedative activity. This latter 
effect may improve sleep, thus alleviating the symptomatology o f circadian desynchrony, and even 
normalising the sleep-wake cycle. Whether melatonin can induce a phase shift o f circadian rhythms 
is an issue much debated (Arendt et al. 1997 Lewy and Sack 1997 Sack and Lewy 1997). It may 
elicit a relatively weak phase shifting effect, but Cziesler (1997) has emphasised that this may be 
insufficient to induce a reliable entrainment. Any such effect with melatonin needs to be established 
by physiological parameters other than sleep and wakefulness.
Although sedative activity of melatonin has been demonstrated, its usefulness as a hypnotic is not 
clear. Indeed, Roth et al.(1997) have emphasised that the majority of studies have evaluated only a 
single dose, or a limited dose range, and that there is a need for unambiguous information on its 
activity related to dose and to time of administration. Further, dose response data using 
electroencephalography is essential to an adequate understanding of its activity. Daytime ingestion 
of melatonin would appear to lead to reductions in sleep latencies (Dollins et al. 1994 Nave et al. 
1996 Reid et al. 1996 Hughes et al. 1997). However, studies on its activity around the normal time 
of sleep have failed to establish a useful clinical effect, except possibly in elderly insomniacs 
(Monti et al. 1999 Hughes et al 1998 Dawson et al. 1998).
However, the usefulness of a hypnotic in the management of sleep disturbance associated with shift 
work or with world wide travel is dependent on it being effective at all times o f the circadian cycle. 
It is in this context a dose response study on the activity, o f melatonin when given in the early and
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late evening in healthy volunteers was undertaken. The activity o f melatonin was studied on 
nocturnal sleep (23:00-07:30) and on evening sleep (18:00-24:00), using electroencephalography, 
and was compared with that of a benzodiazepine (temazepam 20 mg) which is often used by 
individuals coping with irregular patterns of rest in critical situations.
3.2 METHODS
3.2.1 Subjects
The subjects were healthy male volunteers free of the use of medication. They gave informed 
consent to take part in the experiment that was approved by the local Ethics Committee. The 
experiment on nocturnal sleep took place between January and March, and the experiment on early 
evening sleep took place between November and December. In the nocturnal experiment the 
subjects were eight males aged 20 to 30 (mean 23.4) years weighing between 63 and 100 (mean 77) 
kg, and in the evening experiment the subjects were six males aged 21 to 31 (mean 26.5) years 
weighing between 69 and 89 (mean 77.3) kg. One subject participated in both experiments.
3.2.2 Experimental design
During the evening preceding the day of each experiment the subjects retired at their normal 
bedtime and consumed no more than two units of alcohol. Adherence to this restriction was checked 
with a Breathalyser. In the experiment on nocturnal sleep, caffeinated beverages were avoided from 
midday, and in the experiment on early evening sleep, subjects abstained from caffeine throughout 
the day. The order of drug ingestion in both experiments was based upon a Latin Square design. 
Medication was identical in appearance and the experiments were double-blind. Both designs were 
subjected to a power calculation that gave the minimum subject numbers.
3.2.2.1 Experiment I, nocturnal sleep
Each subject reported to the laboratory on eight occasions, at intervals o f at least one week, and 
ingested at 23:30, on separate occasions, melatonin (0.1, 0.5, 1.0, 5.0 and 10 mg), 20 mg
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temazepam (active control) and, on two occasions, placebo. An identical performance test session 
of 8 min duration was carried out before and after each sleep period (23:30-07:30).
3.2.2.2 Experiment II, early evening sleep
Each subject reported to the laboratory on six occasions, at intervals o f at least one week, and 
ingested at 18:00, on separate occasions, melatonin (0.5, 1.0, 5.0 and 10 mg), 20 mg temazepam 
(active control) and one placebo. A performance test session of 4 min duration was carried out after 
each sleep period (18:00-00:00).
3.2.3 Sleep and body temperature
3.2.3.1 Electroencephalography
The subjects slept in single light-proofed, sound-attenuated and temperature controlled (18±2°C) 
rooms. An adaptation night preceded the experiment to familiarise the subjects with the recording 
procedures, and to ensure that their sleep patterns were normal. Silver-silver chloride electrodes 
were used to record electroencephalograph (EEG) activity from the O1-A2 and C4 -A1 positions, 
together with bilateral electro-oculograms (EOG) and the submental eletromyogram (EMG), on a 
Nicolet Biomedical Ultrasom (digital EEG) system via three Nihon-Koden 4300 series EEG 
machines. Two analysts scored the records (10mm/s) manually from the screen, independently, into 
30s epochs according to the criteria of Rechtschaffen and Kales (1968). Any differences were then 
resolved. Various measures were derived from the data for subsequent statistical analysis.
3.2.3.2 Subjective assessments
Subjective assessments of sleep were completed 15 min after rising. The extremes o f the 100 mm 
scales were: I slept, very poorly (0) - very well (100); Now I  feel, very sleepy (0) - wide awake 
(100); I fell asleep, never (0) - immediately (100); After I fell asleep, I  slept, very badly (0) - very 
well (100). Subjects also estimated the time to sleep onset and the sleep duration. The Stanford 
Sleepiness Scale (14) was completed prior to and after each sleep period.
3.2.3.3 Body temperature
Core body temperature was recorded at 1 min intervals during sleep periods using a rectal 
thermistor connected to a portable data logger (Grant Instruments Ltd).
3.2.4 Performance
Subjects were well trained on all performance tasks and were observed during the tasks by means of 
closed circuit television. In the experiment on nocturnal sleep, tests were presented at 23:00 (0.5h 
before drug ingestion) and at 08:00 (8.5h after drug ingestion) in the following order: digit symbol 
substitution (DSS), letter memory recall, picture memory recall. During each session, mood and 
well-being were assessed using a series of twelve 100 mm visual analogue scales (15). In the 
experiment on early evening sleep, DSS only was measured at 00:30, i.e. 6.5h after drug ingestion.
3.2.5 Melatonin onset
Endogenous dim light melatonin onsets (DLMO) were determined on completion of the nocturnal 
sleep experiment. Immediately after providing each saliva sample, subjects were required to rate 
their fatigue level against 10 separate criteria on the Modified Samn-Perelli (MSP) checklist (Samn 
et al. 1982). From these ratings, a score in the range 0 (extremely fatigued) to 20 (extremely alert) 
was calculated.
3.2.6 Statistical analysis
Sleep, performance, subjective assessments and temperature data were analysed by analysis of 
variance (ANOVA) using a one factor model (drug) against subjects. The assumptions of ANOVA 
were studied by considering transformations of the raw measures using the maximum likelihood 
method of Box and Cox (1964). Each measure was examined for a possible order effect and, if  
significant, the order of drug ingestion was taken as a linear covariate. Differences between placebo, 
the active control (temazepam) and all doses of melatonin were examined using Dunnett’s
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procedure, which adjusts for multiple comparisons with a control so that the overall error rate 
remained at 5% (Dunnett 1964). A further comparison was made using the method of Dunnett 
between placebo, the active control and the mean o f the melatonin doses. The data from one subject 
in the first experiment were excluded from the analysis because his mean placebo sleep onset 
exceeded 2h. In the second experiment logarithmic transformations were used for wakefulness and 
stage 4 sleep (total duration, percentage and duration in the first, second and third 100 min of sleep), 
stage 3 sleep in the third 100 min of sleep, latency to stage 3 and rapid eye movement (REM) sleep. 
Square root transformations were used for REM sleep in the first, second and third 100 min of 
sleep, stage 3 sleep in the first and second 100 min o f sleep, slow wave sleep (stages 3 plus 4) in the 
first, second and third 100 min of sleep. Means of raw sleep data are given in the tables of results, 
though this may occasionally lead to apparent inconsistencies with the results of the analysis using 
the transformed data.
An equation of the form: temperature = a + b * exp (c * time) was fitted to each subject’s 
temperature data recorded during nocturnal sleep for each drug, and the values of a, b and c were 
estimated using a least squares fit. These three coefficients were analysed by ANOVA using a one 
factor model (drug) against subjects. A similar method was used for the temperature data recorded 
during early evening sleep, and the two coefficients (slope and intercept) were analysed by 
ANOVA. The temperature data from both experiments, recorded at minute intervals, was meaned 
over 30 min intervals from lights out and analysed by ANOVA.
3.3 RESULTS
3.3.1 Nocturnal sleep
3.3.1.1 Objective measures
The main effects of drugs upon various sleep measures are given in Tables 4 and 5. One dose of 
melatonin (5 mg) reduced the duration of stage 3 in the first 100 min of sleep (p<0.05), though 
analysis of mean values for melatonin failed to reveal any change with melatonin compared with
placebo in any sleep measure. Temazepam increased stage 2 sleep (duration and percentage in the 
first 6h and over the whole night; p<0.01). It also increased the duration in the first 100 min periods 
of sleep (from 59.1 min after placebo to 74.6 min after temazepam; p<0.05) and third 100 min 
(from 53.8 min after placebo to 68.3 min after temazepam; p<0.01). The latency to rapid eye 
movement (REM) sleep was also increased (p<0.05) compared with placebo. With temazepam there 
was a reduction in total and percentage of stages 0 and 1 combined, both in the first 6h of sleep and 
over the whole night (compared with placebo and the mean of the melatonin doses pO.Ol).
3.3.1.2 Subjective measures
No difference was found between drug treatments in subjective assessments of sleep onset, sleep 
duration, sleep quality, alertness or mood. One subject reported vivid dreams and many awakenings 
with 0.5 mg melatonin, and sleep disturbance with early morning awakening with 1 mg melatonin. 
Another subject reported feeling “foggy” after 1 mg melatonin.
3.3.1.3 Temperature and performance
Body temperature during nocturnal sleep with 0.1 mg melatonin (36.18°C, p<0.05) was lower than 
placebo (36.43 °C) 6.5 to 7h after lights out, but no other changes in body temperature with 
melatonin, either related to dose or time, were detected. With temazepam, body temperature during 
nocturnal sleep was reduced 4.5 to 5h (36.12 °C, p<0.05), 5 to 5.5h (36.11 °C, pO.Ol) 5.5 to 6h 
(36.14°C, pO.Ol), 6 to 6.5h (36.18°C, p<0.05) after lights out, compared with placebo (36.35, 
36.38, 36.43, 36.43 °C, respectively). There were no changes in performance after the nocturnal and 
early evening sleep periods with melatonin or temazepam. The changes in temperature are shown in 
figure 1 in the appended paper (Stone et al. 2000).
3.3.1.4 Melatonin onset
The endogenous dim light melatonin onset of all eight subjects occurred between 20:40 and 23:15. 
The mean time of melatonin onset was 22:02. Mild fatigue was reported on the Sam-Perelli fatigue 
checklist from 21:30h.
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3.3.2 Early evening sleep
3.3.2.1 Objective measures
Effects of drugs upon various sleep measures are given in Tables 6 and 7.
Melatonin increased total sleep time, sleep efficiency, the total duration o f stage 2 sleep (pO.OOl, 
all doses), the duration of stage 2 sleep in the second (0.5 mg, pO.Ol; 1 mg, p<0.05; 10 mg, 
pO.OOl) and third (0.5, 5 and 10 mg, pO.OOl; 1 mg, p<0.05) 100 min interval of sleep. It also 
increased the percentage of stage 2 sleep (two lower doses, pO.Ol; 5 mg, p<0.05; 10 mg pO.OOl). 
Melatonin increased the number o f REM periods (0.5 mg, pO.05; 1 to 10 mg, pO.OOl), the 
duration of REM sleep in the third 100 min interval of sleep (1 mg, pO .05), increased the number 
of stage shifts (0.5 mg, pO.05; 10 mg, pO.Ol). The percentage of wakefulness was also reduced 
(pO.05, all doses). Melatonin (5 mg) increased the duration of stage 3 sleep (16.3 min) in the 
second 100 min interval of sleep, compared with placebo (4.7 min; pO .05), and increased the total 
duration of stage 1 sleep and the duration of stage 1 sleep in the second 100 min interval of sleep 
(p<0.05). Melatonin (10 mg) increased wakefulness in the first 100 min interval o f sleep, compared 
with temazepam (pO.Ol).
Temazepam (20 mg) increased total sleep time and sleep efficiency (pO.OOl). It also increased the 
number of stage shifts (p<0.05), reduced wakefulness (total duration, pO .05 and percentage, 
pO.OOl), increased stage 2 sleep (total duration, percentage, and duration in the third 100 min of 
sleep, pO.OOl) and increased the duration of slow wave sleep (pO.05).
3.3.2.2 Subjective measures
Melatonin, improved subjective sleep quality (0.5 to 5 mg doses, pO.OOl; 10 mg, pO.Ol) and 
reduced alertness following sleep (0.5 and 5 mg doses, pO.Ol; 1 and 10 mg doses, pO.05). The 
two lower doses of melatonin also increased the subjects’ perceived requirement for sleep after the 
sleep period (0.5 mg, pO.05; 1 mg, pO.Ol). Temazepam (20 mg) reduced sleep onset latency 
(pO.05), improved sleep quality (pO.OOl), and reduced alertness following sleep (pO.OOl).
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Subjects reported that sleep quality was better after temazepam than melatonin (p<0.05 compared 
with 0.5, 1, 5 mg; pO.Ol compared with 10 mg melatonin).
3.3.2.3 Temperature and Performance
No effects were observed with melatonin or temazepam on body temperature during early evening 
sleep, and there were no changes in performance after the sleep period with either drug. Temazepam 
(20 mg) reduced core body temperature during nocturnal sleep from 4.5 to 6.5h after ingestion, 
compared with placebo (p<0.05).
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Measure Placebo Temazepam Melatonin Mean of 
melatonin
20mg O.lmg 0.5mg Img 5mg lOmg doses
Total sleep time (min) 440.6 447.0 446.9 447.2 450.0 446.3 446.4 447.4
Sleep efficiency 
index+ 0.92 0.93 0.93 0.92 0.93 0.93 0.93 0.93
Sleep onset latency 
(min) 16.5 19.9 14.4 15.8 13.9 19.4 13.8 15.5
REM/non-REM ratio 0.37 0.31 0.32 0.34 0.38 0.33 0.38 0.35
Latency (min) to slow 
wave sleep 
Latency (min) to 
REM sleep
18.8
84.6
17.1
129.4"
20.4
91.5
85.4
75.4
19.1
89.9
21.9
109.7
32.2
95.6
35.8
92.4
Number of REM 
periods 
Number of 
awakenings 
Number of stage 
shifts
4.7
17.8
119.6
4.1
16.1
113.6
4.6
16.9
126.6
4.7
17.7
110.3
4.7
18.6
120.6
3.9
15.9
118.3
4.6
15.1
121.3
4.5
16.8
119.4
Awake + Stage 1 
(min) 51.5 38.8b 53.3 52.3 51.9 47.6 54.4 51.9e
Stage 2 (min) 254.0 293.8b 263.7 271.2 259.6 271.4 258.5 264.9
Stages 3 + 4  (min) 34.7 22.7 38.8 29.1 31.0 30.5 28.7 31.6
REM (min) 117.1 104.9 108.4 112.1 123.3 109.7 122.6 115.2
Awake + Stage 1 (%) 11.3 8.4b 11.5 11.3 11.2 10.3 11.7 11.2 e
Stage 2 (%) 55.4 63.9b 56.9 58.4 55.7 58.9 55.7 57.1
Stages 3+4 (%) 7.6 4.9 8.3 6.3 6.6 6.6 6.2 6.8
REM (%) 25.5 22.8 23.4 24.1 26.5 23.8 26.4 24.9
Table 4 Effect of melatonin and temazepam upon various measures of nocturnal sleep
(means for 7 subjects)
+Sleep efficiency index: total sleep time/ time in bed 
ap<0.05; bp<0.01 compared with placebo 
ep<0.01 compared with temazepam
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Measure Placebo Temazepam Melatonin Mean of 
melatonin 
doses20mg O.lmg 0.5mg Img 5mg lOmg
Total sleep time (min) 332.8 332.3 335.9 331.9 336.1 331.7 333.6 333.8
Sleep efficiency 
index+ 0.92 0.92 0.93 0.92 0.93 0.92 0.93 0.93
REM/non-REM ratio 0.28 0.21 0.23 0.23 0.30 0.28 0.30 0.27
Number of REM 
periods 
Number of 
awakenings 
Number of stage 
shifts
3.2
11.1
93.6
2.9
9.9
91.6
3.0
11.3
103.1
3.1
11.9
86.0
3.1
12.1
97.4
2.9
10.4
96.1
3.3
9.7
97.9
3.1
11.1
96.1
Awake (min) 9.1 7.4 oo bo 10.6 9.0 8.2 10.2 9.4
Stage 1 (min) 23.5 16.6 25.9 27.9 24.9 24.6 26,4 25.9
Stage 2 (min) 202.9 236.8" 208.6 216.0 204.3 206.9 206.1 208.4
Stages 3 + 4 (min) 34.3 22.7 38.8 29.1 31.0 29.7 28.6 31.4
REM (min) 72.8 56.6 63.5 60.7 76.9 69.9 75.0 69.2
Awake (%) 2.7 2.2 2.6 3.1 2.6 2.4 3.0 2.7
Stage 1 (%) 6.9 4.9 7.5 8.1 7.2 7.3 7.6 7.5
Stage 2 (%) 59.0 69.6" 60.4 62.8 59.1 60.6 59.5 60.5
Stages 3+4 (%) 10.0 6.7 11.2 8.4 8.9 8.7 8.2 9.1
REM (%) 21.2 16.7 18.4 17.6 22.2 20.6 21.6 20.1
Table 5 Effect of melatonin and temazepam upon various measures of the first 6 hours of
nocturnal sleep (means for 7 subjects).
+Sleep efficiency index: total sleep time/ time in bed 
ap<0.05; bp<0.01 compared with placebo
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Measure Placebo Temazepam Melatonin Mean of 
melatonin 
doses20mg 0.5mg Img 5 mg lOmg
Total sleep time (min) 163.8 287.5" 294.7" 273.1" 273.3" 284.5" 281.4"
Sleep efficiency 
index"1" 0.46 0.80" 0.82" 0.76" 0.77" 0.80" 0.79"
Sleep onset latency 
(min) 19.5 22.1 19.0 24.4 25.4 27.0 24.0
REM/non-REM ratio 0.16 0.14 0.17 0.16 0.17 0.16 0.17
Latency (min) to slow 
wave sleep 
Latency (min) to 
REM sleep 
Number of REM 
periods 
Number of 
awakenings 
Number of stage 
shifts
72.3
104.6
1.5
8.7
56.5
19.0 
99.3
2.0 
8.7
84.7"
16.3
82.4 
2.5" 
12.0 
81.0"
21.8
79.8
2.7b
9.7
77.3
34.1 
79.7 
2.8b
12.2 
79.0
34.8
87.1
2.7b
11.8 
85.0b
26.8
82.3 
2.7"
11.4 
80.6"
Awake (min) 33.9 6.3" 15.9 13.6 13.3 14.6 14.3
Stage 1 (min) 16.1 18.5 26.3" 21.2 24.5 21.4 23.3
Stage 2 (min) 94.4 178.8" 185.4" 179.3" 161.0" 190.5" 179.1"
Stages 3 + 4  (min) 28.1 5 i .r 41.0 38.5 47.1 34.6 40.3
REM (min) 26.8 39.9 44.5 36.1 42.8 39.3 40.7
Awake (%) 13.9 2.2" 5.1" 4.8" 4.7" 5.0" 4.9"
Stage 1 (%) 6.9 7.5 8.5 7.8 7.6 7.1 7.7
Stage 2 (%) 44.6 63.0" 59.9b 61.6b 58.2" 62.9" 60.7b
Stages 3+4 (%) 17.1 15.4 13.1 13.0 14.8 12.1 13.3
REM (%) 10.9 11.9 13.4 12.8 13.2 12.9 13.1
Table 6 Effect of melatonin and temazepam upon various measures of early evening sleep
(means for 6 subjects).
+Sleep efficiency index: total sleep time/ time in bed 
ap<0.05; bp<0.01; ep<0.001 compared with placebo
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Sleep Stage Interval Placebo Temazepam Melatonin Mean of 
melatonin 
doses(min) 20mg O.Smg Img 5mg lOmg
Awake 0-100 4.6 1.2 5.6 3.7 5.6
rnod 5.8
100-200 6.5 2.0 5.3 3.8 4.1 3.8 4.3
200-300 15.1 2.3 3.9 6.0 3.8 1.8 3.9
Stage 1 0-100 6.3 7.2 7.7 5.7 9.3 8.4 7.8
100-200 3.3 5.2 8.4' 7.0 5.8 6.9 7.0
200-300 3.2 5.2 7.5 7.1 7.4 4.6 6.7
Stage 2 0-100 47.5 53.0 51.8 64.5 50.9 50.8 54.5
100-200 25.0 42.4 57.2b 53.3' 42.8 62.7= 54.0b
200-300 13.3 60.4C 59.2" 46.2b 55.0" 60.6= 55.2b
Stages 3 + 4 0-100 21.2 28.3 28.0 21.9 20.1 21.1 22.8
100-200 6.8 20.3 11.5 12.7 19.4 8.5 13.0
200-300 0.0 2.3 0.3 3.0 5.1 4.3 3.2
REM 0-100 11.3 9.3 6.9 4.3 9.6 11.4 8.0
100-200 11.1 13.4 14.4 12.8 12.9 13.4 13.4
200-300 3.2 13.2 12.4 15.4' 13.4 12.0 13.3
Table 7 Effect of melatonin and temazepam upon sleep during 100 min intervals from the 
onset of early evening sleep (means for 6 subjects).
ap<0.05; bp<0.01,cp<0.001 compared with placebo 
ep<0.01 compared with temazepam
ap<0.05; bp<0.01, cp<0.001 compared with placebo 
ep<0.01 compared with temazepam
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3.4 DISCUSSION
In the present study on healthy volunteers using electroencephalography a consistent effect of 
melatonin on nocturnal sleep across the dose range 0.1 to 10.0 mg was not established. The only 
change observed was that 5 mg led to a reduction in stage 3 in the first 100 min of sleep. A 
reduction in stage 3 and 4 sleep with 5 mg melatonin has been reported previously in studies on a 
simulated 9h phase advance (Stone et al. 1996), but it is considered that this minimal effect 
observed in the present study has little, if  any, clinical significance. It is possible that it would be 
difficult to improve the sleep o f these subjects who had a sleep efficiency of (0.92) when taking 
placebo. It is possible that poorer sleepers may derive some benefit from takinf melatonin at night. 
Small changes are unlikely to alter performance. In contrast, the active control, temazepam (20 mg), 
had beneficial effects on various sleep parameters including reduced wakefulness and drowsy (stage 
1) sleep and increased stage 2 sleep.
On the other hand an unequivocal effect of melatonin on early evening sleep across the dose range 
0.5 to 10.0 mg was established. The effect was fully developed with the 0.5 mg dose, with no 
additional effect observed above this dose. The increase in the number of REM periods observed 
during the early evening sleep was most likely due to an increase in total sleep time, as there was no 
change in the REM/non-REM ratio. Overall, the effect of melatonin during evening sleep was 
similar to that of 20 mg temazepam.
These studies suggest that melatonin is unlikely to possess useful hypnotic activity in healthy 
individuals when administered around the normal time of sleep, though the effect of melatonin on 
early evening, as opposed to nocturnal sleep, is comparable with that of a low dose of a 
benzodiazepine. Clearly, time o f administration would appear to be a crucial factor in the 
appearance of the hypnotic activity of melatonin. In humans melatonin secretion occurs in the late 
evening (Tzischinsky 1993)), as was observed in the present experiment on nocturnal sleep. It is, 
therefore, possible that in healthy young adults the limited hypnotic activity of melatonin is fully 
developed with the normal nocturnal endogenous secretion and that raising the plasma level of
melatonin, at that time, by ingesting melatonin, may have little, if  any, further effect. On the other 
hand, daytime doses, which raise plasma melatonin levels to within or beyond the normal nocturnal 
range, improve sleep (Dollins et al. 1994, Nave et al. 1996, Reid et al. 1996 Hughes et al. 1997 
Zhadanova et al. 1995 Nave et al. 1995). This time-of-day dependent response, together with the 
absence of a dose response over the range 0.5 to 10.0 mg, suggests that the effect of melatonin is 
fully developed at the natural endogenous plasma level.
The hypnotic activity of melatonin observed after administration in the early evening was not 
accompanied by a change in core temperature, and this would accord with the study on diurnal sleep 
by Matsumoto (1999). In this way our results support the view of Nave et al. (1995) and 
Tzischinsky and Lavie (1994) that the activity of melatonin is likely to be due to a direct effect on 
sleep rather than to any secondary effect of a fall in temperature. It is also possible that any effet on 
temperature was swamped by the evening circadian temperature rise. However, though other 
authors have reported changes in core temperature, (Reid et al. 1996 Hughes et al 1997 Lushington et 
al. 1997) Nave et al (1998) have suggested that any hypothermic effect o f melatonin occurs after the 
onset of hypnotic activity.
The present study has demonstrated that the hypnotic effect of melatonin is time-of-day dependent, 
and this, together with evidence that the ingestion o f melatonin in certain circumstances may lead to 
sleep disruption (Middleton et al. 1996), suggests that melatonin is only likely to be useful as a 
hypnotic at certain times of the circadian cycle which have yet to be delineated. This raises the issue 
of a ‘window of effect’ but it is unlikely that any individual coping with shift work would possess 
sufficient information on their circadian rhythm of melatonin secretion to ensure ingestion of the 
compound at times to avoid sleep disruption and to ensure some beneficial effect on sleep. On the 
other hand, whether individuals coping with time zone changes can use melatonin for entrainment 
remains controversial, and the present study does not provide any input for the debate on the phase 
shifting properties of melatonin.
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CHAPTER FOUR
ALTITUDE INDUCED INSOMNIA AND HYPNOTICS
This chapter consists of three studies, two in the field and one in the laboratory. The field sudies 
examined the practical situation experienced at two altitudes by climbers and wintersportsmen when 
they ascend suddenly to altitude. The laboratory study was designed to examine the effect of 
hypnotics on repiration in a controlled environment.
4.1 ALPINE FIELD STUDY
4.1.1 Introduction
In the first field study the sleep at 3500m during an Alpine expedition has been measured and the 
usefulness of a hypnotic has been tested at a lower altitude than studied previously. It is also 
possible at this altitude to study the activity temazepam without the complication of the 
Acetazolamide used at higher altitudes. A higher dose of temazepam (20mg) than used in the 
previous study (lOmg) (Nicholson et al. 1988) was given since that study had shown that the lower 
dose had limited activity and was, in any case, free of untoward respiratory changes (Greenwood 
and Bradshaw 1983). The awake ventilatory response to hypoxia of all the subjects was also 
measured. It has been suggested (Schoene 1982) that individuals with a brisk ventilatory response to 
hypoxia are likely to perform well at high altitude, and that brisk responders are more likely to 
exhibit periodic breathing Lahiri et al. (1984).
4.1.2 Methods
Fourteen male volunteers aged between 20 and 49 (mean 34.8) yrs and weighing between 62 and 
109 (mean 80) kg took part in the study. They all normally resided below 200m and none was 
acclimatised to altitude immediately before the expedition. Control recordings of sleep and 
respiration were made at sea level a month before the expedition. Sleep and respiration were 
recorded over one night at a simulated altitude o f 3500m in a hypobaric chamber to assess the 
individual’s response to acute hypoxia. These recordings were made between two and four weeks
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before the expedition. Prior to decompression the subject’s ventilatory response to isocapnic 
hypoxia was assessed.
The subjects flew to Geneva and travelled by coach and cable car to the Testa Grigia hut which is 
situated at 3480m in the Italian Alps. Subjects slept in individual bunks, three to a bedroom and 
were required to refrain from napping, to avoid alcohol ingestion after lunchtime, and to avoid 
caffeinated beverages after 1700h on the days studied. During the day the subjects skied or walked 
and at no time did any subject descend below 2050m. They returned to 3480m before 1700h each 
day, and recordings o f sleep and respiration were made on each of the seven nights of the 
expedition.
4.1.2.1 Sleep Recordings
Three channels o f electroencephalography, bilateral electro-oculograms and a submental 
electromyogram were recorded from the two central and one occipital channels.
Respiratory movements were monitored using a chest impedance method (Oxford Medical Systems 
IMP-i). Arterial oxygen saturation was measured continuously on the control night and on alternate 
nights at altitude using a pulse oximeter (Ohmeda-Box III) attached to the subject’s index finger. A 
portable physiological data recording system (Oxford Medical Systems Medilog 9000) was used 
throughout the study and sleep recordings were scored manually in 30s epochs according to 
conventional criteria (Rechtshaffen & Kales 1968). Respiratory disturbances were scored for the 
presence of apnoeas greater than or equal to 5s in duration (Berssenbrugge et al. 1983). This 
duration is shorter than that usually scored for the prescence of sleep apnoeas.Where an apnoea was 
present its duration, the sleep stage in which it started and whether any arousal was associated with 
it was noted.
Subjective assessments of sleep and well being were also measured using visual analogue scales. 
Half an hour after awakening each subject completed four assessments. The assessments and 
extremes of the 100mm analogue scales were -  A I slept, Very poorly - Very well; B: Now I feel,
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Very sleepy - Very wide awake; C:I fell asleep, Never - Immediately; D: After I fell asleep I slept, 
Very badly - Very well. In each case a favourable response tended toward the 100 extreme of the 
scale. Each morning and evening the subjects also completed an Environmental Systems 
Questionnaire (ESQ; Sampson and Kobrick 1979). This questionnaire was devised to improve the 
assessment of symptoms occurring during exposure to high altitude as well as to heat and cold. The 
sort of symptoms evoked by such a questionnaire include loss o f sleep, blueness of the lips, 
vomiting, frequent urination, headache, dizziness, loss of appetite, shortness of breath etc. The 
questionnaire is shown in Table 8 .
4.1.2.2 Ventilatory Response to Isocapnic Hypoxia
The ventilatory response to isocapnic hypoxia was measured in the 14 subjects details of the 
methodology used are given in Chapter 2
4.1.2.3 Medication
Previous studies have shown that the amount o f periodic breathing at high altitude varies widely 
between individuals and this variability tended to obscure any changes due to hypoxia (Nicholson et 
al 1988). Similarly any changes in slow wave sleep tended to be obscured by variations between 
individuals and the effects of age. For these reasons the subjects were divided into two groups of 
seven balanced for age and their response to acute hypoxia during the night in the decompression 
chamber at a simulated altitude of 3500m (number of apnoeas and amount of slow wave sleep).
This recording was taken at least two weeks prior to departure. One group of subjects received 
temazepam, 20mg on retiring, throughout the 7 day stay at high altitude (mean barometric pressure 
485 torr) and the other parallel group received matching placebo. All drugs were presented double­
blind.
4.1.2.4 Statistics
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The data were analysed by analysis of variance (ANOVA). Appropriate transformations were 
applied to the data prior to analysis where it was necessary to reduce heterogeneity. Sleep measures 
were calculated as a mean over the first three nights, and over the last three nights at altitude. To 
examine the effect of altitude the altitude means were tested against control sleep at sea level, and to 
examine the effect of acclimatisation the means of the first three nights were tested against the 
means of the last three nights. The effect of temazepam was tested between groups over the first 
three nights and over the last three nights at altitude.
The maximum, minimum and mean oxygen saturations, the number of apnoeas, total duration of 
apnoeas and number of arousals due to apnoeas were measured in one hour blocks from sleep onset. 
These were transformed (log (x+ 1)) and the data were analysed with an unbalanced analysis of 
variance. Comparisons were made between the night in the decompression chamber, the first three 
nights at high altitude and the last three nights at high altitude.
The Environmental Symptoms Questionnaires were analysed using principal component analysis 
with the aim to reduce the number of variables which required detailed analysis. Subsequently the 
data were analysed by analysis of variance. Correlation coefficients between ESQ scores, apnoeas 
and sleep stages were also calculated.
4.1.3 Results
On the second night at altitude one of the subjects developed high altitude pulmonary oedema that 
necessitated emergency evacuation to a lower altitude. His data were excluded from the analysis, 
and proved to be within the placebo group. The means of various sleep measures and durations of 
sleep stages are given in Tables 9 and 10 respectively. Sleep at sea level in all subjects was normal 
and there were no differences between the two groups of subjects.
At altitude (3480m) the group o f subjects taking placebo had reduced sleep efficiency (defined as 
the total sleep time divided by the time spent in bed) over the first three nights compared with sea
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level, and this reduction persisted through the last three nights (p < 0.01). The fall in sleep 
efficiency was due to a small decrease in total sleep time, as well as to increases in sleep onset 
latency, wakefulness and drowsy (stage 1) sleep. The amount of wakefulness in the last three nights 
was more than that at sea level (p < 0.01). The duration of rapid eye movement (REM) sleep during 
the last three nights at high altitude was longer in the placebo group compared with their first three 
nights (p < 0.00 1) and this increase was reflected in a greater REM/NREM ratio (p < 0.05).
An effect of temazepam over the first three, the last three or even over all seven nights at altitude 
could not be established. The reduction in sleep efficiency observed in the placebo subjects over 
both the first and last three nights at altitude was also present in those taking temazepam (p < 0 .0 1 ). 
With temazepam the amount o f stage 2 sleep over the last three nights was more than with placebo 
(p < 0.05). Compared with sea level recordings the temazepam subjects had more stage 2 sleep 
during the first three (p <0.05) and last three (p < 0.01) nights at high altitude. They had less REM 
sleep over the first three nights (p <0.05), and less slow wave sleep over the last three nights (p 
<0.01) at altitude. They also had less slow wave sleep over the last three nights compared with the 
first three nights at altitude (p < 0 .0 0 1 ).
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NAME...
AMS SYMPTOMS QUESTIONNAIRE 
DATE... TIME.
Circle the number that best describes how you have felt since you last filled in a questionnaire. Other symptoms 
may be added (Q20 etc).
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I have...
1 Felt ill 0 2 3 4 5
2 Felt weak 0 2 3 4 5
3 Felt tired 0 2 3 4 5
4 Been irritable 0 2 3 4 5
5 Been forgetful 0 2 3 4 5
6 Been slow in reacting 0 2 3 4 5
7 Difficulty in concentrating 0 2 3 4 5
8 Been disinterested 0 2 3 4 5
9 Slept badly 0 2 3 4 5
10 Headache on waking 0 2 3 4 5
11 Headache at other times 0 2 3 4 5
12 Been unsteady on my feet 0 2 3 4 5
13 Lost my appetite 0 2 3 4 5
14 Felt sick 0 2 3 4 5
15 Vomited 0 2 3 4 5
16 Stomach ache 0 2 3 4 5
17 Been short o f breath at rest 0 2 3 4 5
18 Been short o f breath on slight exertion 0 2 3 4 5
19 Noticed periodic breathing 0 2 3 4 5
20 Other... 0 2 3 4 5
21 Other... 0 2 3 4 5
22 Other... 0 2 3 4 5
Drugs taken since last questionnaire...
Table 8 Environmental symptoms questionnaire
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It was not possible to demonstrate any amelioration in the sleep disturbance with temazepam in the 
subjects as a group compared with placebo as there was a considerable variation in the individual 
subjects’ response to sleeping at this altitude. However, Figure 27 shows hypnograms at sea level 
and at 3480m for a 22-year-old subject who took placebo throughout the study.
ALPS
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A w a k e
S t a g e  1/REM -
S t a g e  2
Slow w a v e  
s l e e p
S e a  l e v e l
8  Time (h)
S le e p  S t a g e
A w ake
S t a g e  1/REM II
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8 Time (h)
Figure 27 Sleep at sea level and at 3480 m in a 22-year-old subject.
Few signs of disturbed sleep at altitude were apparent, with wakefulness increased slightly from 
1.4% at sea level to 2.4% at 3480m, otherwise sleep was little changed from sea level. On the other 
hand, in an older subject, aged 49, sleep on the third night at altitude was markedly disturbed, with
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wakefulness increased from a sea level value o f 4.6% to 10.6%. A frequency distribution of the total 
amount of wakefulness and drowsy sleep in the early part of the night for all sleeps at altitude 
showed that there were seven occasions, involving four subjects, in the placebo group, when this 
measure exceeded 80 minutes. These four subjects were the older subjects in the placebo group, 
being aged between 38 and 48 years. Such wakefulness however, did not occur on any occasion in 
the group o f subjects taking temazepam. The two groups were of comparable age.
Respiration during sleep at altitude was characterised by periodic breathing. One subject, an 
experienced mountaineer and Alpine guide (aged 50), exhibited periodic breathing at sea level. The 
subjects, as a group, had more respiratory disturbances at altitude, as indicated by an increase in the 
number of apnoeas, compared with sea level. It was not possible to establish a difference between 
the group of subjects taking temazepam and those taking placebo (Table 11). There was wide 
variation in subjects’ responses during sleep at this altitude and the number of apnoeas each night 
ranged from zero to more than 800. Except for one subject the number of apnoeas in the 
decompression chamber was greater than any of the nights at altitude.
Analysis of apnoeas in hourly blocks throughout the night showed no evidence of an effect of 
temazepam on the number or duration of apnoeas, nor on the arousals associated with apnoeas. For 
all three variables the events at sea level were lower than the mean of six nights of those at altitude 
(p < 0.01) (Table 12). There were more apnoeas in the middle of the night (quadratic pattern p 
<0.05) and there was also a linear increase in the number of apnoeas per night through the week (p 
< 0.01). More apnoeas were associated with Stage 1 and Stage 2 sleep (p < 0.01) compared with 
stages 3 and REM. The changes in the number of apnoeas were reflected in similar alterations in the 
total duration of apnoeas. There were more arousals due to apnoeas in the middle of the night and 
there was also a linear increase in this measure through the week (p < 0.05). The number of 
apnoeas, total duration of apnoeas and the number of arousals due to apnoeas were all greater 
during the night in the decompression chamber compared with on the mountain (p < 0 .0 1 ).
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Oxygen saturations during sleep at sea level varied between 92 and 99% (mean 97%) (Table 13).
The minimum value of 92% was recorded in the subject who showed periodic breathing at sea level. 
These values fell at altitude to a minimum of 80 -  84% during the first three nights at altitude.
There were no differences in oxygen saturation between the temazepam and placebo groups. There 
were no differences between the first and the last three nights, but all measurements were less in the 
decompression chamber than on the mountain (p <0.01). Oxygen saturations showed no systematic 
alterations over the course of a night.
The hypoxic ventilatory response measurements showed a linear relationship between ventilation 
and oxygen saturation in all cases, but it was not possible to establish a correlation between the 
ventilatory response to hypoxia and the respiratory parameters measured during sleep. The subject 
who developed high altitude pulmonary oedema had a noticeably blunted ventilatory response to 
hypoxia compared with the other subjects.
There were no differences in the subjective assessments o f sleep. The five factors which resulted 
from the principal component analysis of the environmental symptoms questionnaire may be 
interpreted as general malaise, nausea, heart irregularity, muscle ache and coldness. Factor 1 
(malaise) declined with length of stay up the mountain. However, there was no difference between 
the placebo and the temazepam group. Factor 2 (nausea) was greater on the first morning than for 
the remaining five days (p <0.01). There were no differences between the temazepam and placebo 
groups. Factor 3 (heart irregularity), Factor 4 (muscle ache) and Factor 5 (coldness) did not change 
with time at altitude or show any differences between the placebo and temazepam groups. 
Furthermore, there was no correlation between environmental symptoms and the hypoxic 
ventilatory response.
4.1.4 Discussion
In our previous study we observed little evidence during the ascent around 3000m of sleep 
disturbance, but on reaching 4000m the climbers slept poorly and experienced difficulties in falling
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asleep and in sustaining their sleep. Over 4000m the low dose o f an hypnotic (temazepam lOmg) 
proved useful in helping the climbers both to fall asleep and stay asleep and there was no obvious 
effect on respiratory patterns (Nicholson et al. 1988).
In the present study sleep disturbance at 3000 m was limited to reductions in sleep efficiency and 
increases in awake activity, but even so factors other than altitude, such as shared rooms and 
environmental noise, may have contributed to these changes. As far as the structure o f sleep was 
concerned there was a reduction in REM sleep in the first half of the night but this was almost 
certainly due to temazepam which induces a delay in the onset o f REM sleep (Nicholson and Stone 
1976). In this context the increase in REM sleep and in the REM/NREM ratio during the last three 
nights could well have been related to a rebound from the initial reduction in these measures rather 
than any acclimatisation process. Similarly, the reduction in slow wave sleep may well have been 
due to the repeated ingestion of temazepam (Mitler et al. 1979).
Although sleep was impaired around 3500m it was not possible to demonstrate any overall 
beneficial effects from temazepam. There is, therefore, no evidence from the present study to 
recommend the routine use of temazepam at such an altitude, although an hypnotic may be 
beneficial for particular individuals who may respond unfavourably to adverse sleeping conditions. 
This could be especially true of older subjects who usually have, in any case, less restful sleep and 
would be more likely to experience increased nocturnal wakefulness at altitude.
The symptoms of mountain sickness declined with length of stay on the mountain but there was no 
evidence of acclimatisation of the changes observed in respiration during sleep. Indeed, there was a 
linear increase in periodic breathing during the week at altitude. This lack of acclimatisation in 
periodic breathing has been observed at the higher altitude of 6300m (West et al. 1986). The higher 
dose o f temazepam used in this study did not appear to lead to any respiratory depression.
Hypnotics may cause respiratory depression (Mendellson and Cirignotti 1988) but it would appear 
that temazepam in doses of 20mg are free of such effects at altitude (Greenwood and Bradshaw 
1983 Dorwood 1983 Pleuvry 1980).
The incidence of periodic breathing at altitude varied between subjects and, unlike Lahiri et al 1984 
with subjects at 5400m, we were unable to establish a relationship between the amount of periodic 
breathing and hypoxic ventilatory response. Nevertheless we were able to confirm our previous 
finding (Nicholson and Stone 1988) that although more apnoeas appear in drowsy and stage 2 sleep 
they are not exclusive to NREM sleep. This observation differs from that o f Reite (1975) and Weil 
(1978), who reported that periodic breathing ceased with the onset o f REM sleep. Further, the 
increased frequency and duration of periodic breathing in the decompression chamber and increased 
arousals are probably related to an acute onset of hypoxia immediately before sleep. This is in 
contrast with the nights spent in the Alps when the subjects rested at 3480m from 1700h and the 
preceding parts of the day had been spent above 2050m.
The subject who developed pulmonary oedema had a blunted hypoxic ventilatory response (HVR) 
and had experienced a similar episode on a previous occasion. Lakshiminarayan and Pierson 1975 
and Hu et al. 1982 have raised a possible relationship between the appearance of pulmonary 
oedema, poor climbers, and blunted responses to hypoxia. However, high altitude residents with 
blunted HVRs tend to be less sensitive to acute mountain sickness than lowlanders (Severinghaus 
1966). Further, no correlation between HVR and symptoms scores for acute mountain sickness has 
been found in lowland climbers during the first few days after arrival at 430Gm and 5300m 
(Milledge 1988).
We were unable to show any correlation at 3500m. It may well be that a poor outcome at altitudes 
as low as 3500m might be expected in subjects with blunted responses, while no correlation exists 
between briskness o f the response and subsequent performance at altitude in subjects with normal 
responses to hypoxia. It is of interest that the subject who developed pulmonary oedema did not 
have periodic breathing at altitude and that there were only short apnoeas in the decompression 
chamber, but he had a poor ventilatory response to hypoxia and a reduction in respiratory rates.
In summary, the sleep disturbance which occurs around 3500m may be more marked in older 
subjects. Although no case can be made for the routine use of an hypnotic as a prophylactic useful
for ameliorating sleep disturbance, a drug such as temazepam in the dose of 2 0 mg may be 
appropriate for those over 40 years of age. Further, though the symptoms of acute mountain 
sickness may recede over a period of seven days it is unlikely that there will be any significant 
improvement in sleep. Further, that subjects who suffer serious symptoms of mountain sickness 
may have blunted or even absent hypoxic ventilatory responses.
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Measure Drug Sea Level Control
High Altitude 
(3480m) 
First 3 Nights
High Altitude 
(3480m) 
Last 3 nights
Sleep Onset Latency Placebo 15.9 17.8 20.7Temazepam 10 17.6 19.3
Total sleep time (min) Placebo 430.0 393.0 385.0Temazepam 408.0 399.0 385.0
Number of awakenings
Placebo 8 .8 11.4 14.2
Temazepam 8.4 13.2 14.5a
REM/NREM ratio
Placebo 0.32 0.26^ 0.34
Temazepam 0.29 0 . 2 2 0.27
Latency to REM (min) Placebo 79.4 94.4 92.7Temazepam 100.4 140.3 117.2
Sleep Efficiency Index
Placebo 0.92 0.85b 0.83b
Temazepam 0.94 0 .8 8 b 0.85b
Table 9 Effects of altitude (3480m) and temazepam (20mg on retiring) on various sleep
measure
ap <0.05; bp <0.01; compared with sea level
°p <0.05;. first 3 nights at altitude compared with last 3 nights at altitude
124
Measure Drug Sea Level Control
High Altitude 
(3480m) 
First 3 Nights
High Altitude 
(3480m) 
Last 3 nights
Awake
Placebo 5.6 15.8 19.7*
Temazepam 8 .6 13.2 17.1
Drowsy Sleep stage 1
Placebo 18.1 217 213
Temazepam 17.9 24.4 219
Stage 2
Placebo 194.3 180.8 166.7
Temazepam 168.6 212.5* 216.7 t,b
Slow wave
Placebo 56.6 53.7 49.3
Temazepam 74.4 34.5® 2 0 .2 b
REM Sleep
Placebo 79.5 53.4d 74.7
Temazepam 73.2 47.3® 59.6
Table 10 Effects of altitude (3480m) and temazepam (20mg on retiring) on duration of
sleep stages in the first 6h of sleep
n = 6  for placebo group, n = 7 for temazepam group 
P  <0.05; p <0.01; compared with sea level
Cp <0.05; p <0.01; ep <0.001;. first 3 nights at altitude compared with last 3 nights at altitude 
P  <0.05; temazepam compared with placebo
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ALPINE STUDY -  NUMBER OF APNOEAS
PLACEBO
AGE SEALEVEL DC A1 A2 A3 A4 AS A6 A7
2 2 1 70 38 6 3 3 3 0 1
2 2 2 941 - 262 245 426 0 0 -
2 2 3 27 1 5 26 12 75 0
38 1 2 0 0 - - - - -
42 0 744 163 25 7 12 101 236 187
50 0 76 5 1 28 2 0 41 19 -
50 118 843 235 295 146 810 809 789 528
TEMAZEPAM
AGE SEALEVEL DC A1 A2 A3 A4 AS A6 A7
2 2 0 23 0 1 10 10 - 0 -
23 0 440 4 0 24 44 2 2 2 -
38 19 831 229 71 56 149 135 573 273
40 0 851 343 218 385 817 770 544 -
40 0 56 5 3 12 4 5 4 -
40 2 816 78 44 56 3 1 0 389 171
49 7 73 0 0 5 0 0 2 2
Table 11 Number of apnoeas at sea level, at 3480m (A1 -A7) and In the decompression
chamber (DC) in individual subjects
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Night 1 2 3+4 REM
P T P T P T P T
Sea Level 0 .1 1 0 . 2 0 0 .1 1 0.06 0.06 0.04 0.08 0.08
3480m -1 0.60 0.31 0.45 0.36 0.14 0.15 0.18 0.09
2 0.26 0 . 2 2 0.30 0 . 2 2 0.06 0.13 0.13 0 . 1 2
3 0.30 0.36 0.24 0.27 0.07 0.14 0 . 2 0 0 .1?
4 0.29 0.35 0.40 0.28 0.28 0 . 2 0 0.17 0 .2 ?
5 0.57 0.43 0.55 0.25 0 . 2 2 0.16 0.31 0 .0 ?
6 0.55 0.47 0.58 0.54 0.24 0.16 0.24 0 .2 ?
7 0.39 0.99 0.79 0.78 0.45 0 .2 1 0.26 0 .1?
Decompression 
chamber (3500m) 1.70 2.32 0.91 1 .21 0.69 0.59 0.51 0.39
Table 12 Number of apnoeas (per min) by sleep stage (n=7) for temazepam group, (n=6)
for placebo group
P = placebo, T = temazepam (20mg on retiring)
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Night Number of apnoeas Total duration (s) Number of arousals
Sea Level 2.7 36.2 0 . 8
3480m - 1 18.3 170.2 13.2
2 14.6 128.2 14.3
3 15.2 127.0 13.4
4 29.8 293.2 7.2
5 29.3 290. 74.4
6 53.5 579.1 91.8
7 48.2 508.5 91.6
Decompression 
chamber (3500m)
65.4" 608.9" 131.8"
Table 13 Number and duration of apnoeas and arousals associated with apnoeas (per
hour) (n =13)
a p < 0.01 Decompression Chamber> 3480m
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OXYGEN SATURATION %
Night Minimum Maximum Mean
Sea Level 92.0 99.0 97.0
3480m (1-3) 79.9 84.5 82.2
3480m (4) 81.8 86.7 84.3
3480m (5-7) 82.6 8 8 . 0 85.3
Decompression 
Chamber (3500m)
73.6* 79.3» 76.4»
Table 14: Oxygen Saturations at sea level, at 3480m and in the decompression chamber
(DC) (n=13
ap < 0.01 Decompression Chamber> 3480m
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The second study of sleep at altitude was carried out in the laboratory in a decompression chamber.
4.2 DECOMPRESSION CHAMBER EXPERIMENT
4.2.1 Introduction
During altitude experiments in the field there are serious limitations to the experimental protocols 
adopted. In particular, it is unlikely that within subject comparisons are possible and it is necessary 
to make between group comparisons. For the same reasons dose response studies and comparison 
between different drugs is not possible. The ability to repeat an expedition to altitude with the same 
subjects is extremely unlikely and even should this prove possible it is impossible to control for 
many factors such as time of year, weather conditions which serve to produce variation in the data. 
In addition although it is possible to gather some measures of respiration in the field, it is not 
possible to carry out the detailed measurement required to be sure that there were no adverse effects 
of the drugs on respiration. For these reasons a study was carried out in an altitude chamber at a 
simulated altitude of 3810m and the effect at altitude of three doses o f temazepam were compared 
with diazepam (lOmg), with placebo and with sleep at sea level. Sleep was also recorde at sea level 
in a sleep laboratory in order that the effect of sleeping in the chamber per se could be determined.
4.2.2 Methods
The subjects were six healthy male volunteers aged between 19 and 23 (mean 20.9) years and 
weighing between 57 and 95 (mean 74) kg. They were all familiar with the recording techniques 
used and had given their informed consent.
The study involved ten experimental nights for each subject separated by an interval o f at least one 
week. The ten nights began with an adaptation night recorded in the sleep laboratory, and a baseline 
night recorded in a hypobaric chamber with a simulated altitude maintained at 122m (749 torr). Six 
nights were then recorded in the hypobaric chamber at a simulated altitude o f 3810m (473.8 torr)
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during which temazepam ( 1 0 , 2 0 , 30mg), diazepam (lOmg) or matching placebo (on two nights) 
was ingested by each subject in a double blind, 6 x 6  Latin square design. Another night in the 
chamber at 122m and a final night in the sleep laboratory were then recorded. Subjects were 
required to refrain from napping and to avoid drinking alcohol and caffeinated beverages after 
lunchtime on each experimental day. The factors in the ANOVA were drug and altitude. More 
details o f the analysis, are ginen in Chapter two. Dunnet’s procedure was uswed for the multiple 
comparisons.
Two channels of electroencephalography (EEG) (C3 -  A2 and O2 -  Aj), bilateral electro-oculograms 
(EOG) and a submental electromyograms (EMG) were recorded onto a Grass 8 - 1 0  EEG machine 
situated in an adjoining room (during the nights in the sleep laboratory) or outside the hypobaric 
chamber on the other nights. Respiratory movements were monitored using circoabdominal 
mercury filled capillary strain gauges and the electrocardiogram (ECG) was also recorded. 
Respiratory mass spectrometry (VA Micromass or Centronics 007) was measured continuously 
during the nights in the hypobaric chamber using a probe taped into a naso-buccal face mask (RAF 
PQ oxygen mask). The mask was kept in place by a cloth helmet, which had been modified to allow 
the EEG electrodes to be worn normally. Arterial oxygen saturation (SaCy was measured 
continuously using a Biox III Pulse Oximeter, a finger probe being used because o f the difficulty in 
using an ear probe with the cloth helmet. These data were recorded onto paper together with a real 
time code signal to allow accurate comparison with the sleep recordings during the analysis.
During each experimental night two subjects and a safety man slept in the hypobaric chamber and a 
medical officer was in attendance throughout the night. The hypobaric chamber was decompressed 
at a rate of 1219m per minute. The chamber was light shielded and the operating noise o f the 
chamber was kept at its lowest practicable level. The mass spectrometers were calibrated at the 
start, in the middle and at the end of the night. Calibration necessitated the removal and subsequent 
replacement, by the safety man, of the mass spectrometry probe from the facemask. This procedure 
unavoidably led to some disturbance of the subject’s sleep.
Sleep records were scored into 30-second epochs independently by two analysts using conventional 
criteria (Rechtschaffen and Kales, 1968). End tidal PCO2 and PO2 were averaged over one minute 
epochs, the maximum and minimum SaC>2 was measured in 4 minute epochs and respiratory 
frequency (one minute epochs) was measured for the whole night. Respiratory disturbances were 
scored for the presence of apnoeas greater than or equal to 5 seconds in duration. Where an apnoea 
was present its duration, the sleep stage in which it started and whether any arousal was associated 
with it were noted. Results are given in Tables 15 to 18.
The awake ventilatory response to isocapnic hypoxia was measured in each subject by the 
rebreathing method of Rebuck and Campbell (1974). For this assessment the subjects rebreathed 
from a 5-litre bag, which initially contained a mixture of 25% oxygen in nitrogen. Rebreathing was 
used to create progressive hypoxia whilst end tidal PCO2 was held at ‘mixed venous’ level by a 
variable CO2 scrubbing circuit. The subject continued rebreathing until end-tidal PO2 fell to 35mm 
Hg. Oxygen saturation was measured continuously by ear oximetry (Hewlett Packard) and 
regression lines of ventilation on oxygen saturation were fitted by the least squares method. 
Subjective assessments of sleep and well being were completed before and after each overnight 
sleep period. Assessments included the Stanford Sleepiness Scale, visual analogue scales related to 
sleep quality and quantity and estimations of sleep onset latency and sleep duration.
4.2.3 Results
There were no consistent changes in total sleep time, sleep onset latency or latency to the various 
sleep stages associated with sleeping in the chamber at sea level or by ascent to a simulated altitude 
of 3500m. The hypnotic effects of diazepam (lOmg) and temazepam (20mg and 30mg) at altitude 
were apparent in the increased sleep efficiency seen compared with placebo at altitude. There were 
several changes in specific sleep stages associated with ascent to altitude and with the ingestion of 
diazepam and temazepam.
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In particular the reduction in REM sleep on sudden ascent to altitude was seen in a reduced 
REM/NREM ratio (p<0.05) and in the number of minutes o f REM sleep (pO.OOl). There were no 
effects of the two hypnotics at altitude in REM sleep when compared with placebo. Sleeping in the 
decompression chamber (p <0.05) increased the amount o f wake activity. Both diazepam (p<0.05) 
and temazepam 20mg (p<0.05) and 30mg (pO.Ol) ameliorated this alerting effect of altitude. 
Drowsy sleep was also increased in the placebo condition (p<0.05) but there were no effects of any 
of the drugs in this measure.
Stage three sleep was also reduced by the ascent to altitude from around 37 minutes at sea level to 
around 20 minutes with placebo at altitude. Temazepam and diazepam restored slow wave sleep, 
although the effects with temazepam did not show a dose response, the low and high doses were 
effective and restored slow wave sleep to sea-level values whereas 2 0 mg showed a more variable 
response which did not reach significance.
In the analysis o f data from the first 6  hours of sleep (Table 17), similar results were observed to the 
whole night values for the effect of diazepam and temazepam. There were some additional effects 
of sleeping in the chamber at sea level and improvements between the 1st and 2 nd night spent at sea 
level in the chamber. There was also some evidence of improvements in sleep between the first and 
second nights at altitude on placebo.
As far as the respiratory changes associated with sleeping at a simulated altitude o f 3500m, results 
are given in table 18. Data were not taken in the sleep lab and comparisons are with sea-level 2 
values.
There were considerable drops in maximum, minimum and mean oxygen saturation associated with 
an ascent to 3500m. For example, maximum arterial oxygen saturation fell from 98.2% to 80.6% on 
placebo altitude (pO.OOl). Similarly end tidal PaCOz and PaOz fell from sea level (p,0.001). The 
decrease in end tidal PaCCb was restored to sea-level values by diazepam (lOmg). In addition 
breaths per minute were increased from both sea-level and placebo values by diazepam lOmg 
(p<0.01) and temazepam 30 mg (pO.Ol).
LAB SL1 SL2 Pi
CHAMBER
Pz Dio Tio t 20 t 30
Total sleep time (min) 460.3 385.0 436.4 364.5 407.8 481.9 377.0 392.8 418.9
Sleep onset latency (min) 22.1 37.2 9.9 18.0 11.6 12.3 14.4 15.3 11.5
Latency to Stage 3 sleep 
(min)
13.5 14.1 13.8 10.9 15.0 14.5 17.4 12.3 14.8
Latency to REM sleep 
(min)
90.3 181.0 119.1 120.9 122.3 146.2 139.1 163.8 175.9
Sleep efficiency index 
(total sleep time / time in 
bed)
0.87 0.87 0.92 0.88 0.89 0.91" 0.88 0.93" 0.91"
REM/NREM ratio 0.29 0.21 0.25b 0.14 0.12 0.13 0.12 0.14 0.12
Table 15 Effects of a simulated altitude of 3810m on various sleep measures (mean of six
subjects)
ap <0.05 compared with placebo at altitude sea level 
bp <0.05 compared with all altitude conditions
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LAB SL1 SL2 Pi
CHAMBER
?2 Dio Tio T 2o T30
Awake (min) 19.5C 24.7 21.4d 30.0 25.4 21.3" 26.5 10.6" 16.2b
Stage 1 (min) 38.5 42.6 35.9d 65.0 58.1 44.9 59.8 36.8 39.9
Stage 2 (min) 192.7 230.1 228.9 251.5 264.7 257.8 254.0 266.8 257.5
Stage 3 (min) 41.2 28.5 36.7d 19.9 19.7 30.6* 34.4* 29.1 38.2b
Stage 4 (min) 35.3 45.3 24.6 27.6 28.8 23.5 19.2 27.7 22.5
Stage REM (min) 93.5" 69.3 82.6* 50.4 44.0 46.9 46.7 49.4 51.6
Table 16 Effects of a simulated altitude of 3810m on various sleep measures (mean of six
subjects)
ap <0.05, bp <0.01 compared with placebo at altitude sea level
°p <0.05 lab sleep compared with sleeping in the decompression chamber at sea level
dp <0.05, ep <0.001 second sea level night in the chamber compared with the first placebo night at
altitude
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LAB SL1 SL2 Pi
CHAMBER
Pz Dio Tio T 2o T 3o
Awake (min) 5.8" 29.4 13.8 41.7 20.3 15.5" 33.1 12.5b 13.0b
Stage 1 (min) 21.8"
**
36.9 25.1 51.7 43.8 31.6 43.7 27.1 23.8*
Stage 2 (min) 186.2 186.5 202.5 192.4 223.8 224.5 199.3 227.8 228.3k
Stage 3 (min) 38.6d 27.3 32.1e 18.8 18.5 29.8 a 33.2 b 28.8 37.0 b
Stage 4 (min) 33.1 42.3 24.6 27.4 28.4 23.5 19.1 27.7 22.5
Stage REM (min) 67.8 d 37.9 6i y 26.5 25.3 26.9 27.0 32.6 35.2
Table 17 Effects of a simulated altitude of 3810m on various sleep measures in first six
hours of sleep (means for six subjects)
ap <0.05, bp <0.01 compared with placebo
cp <0 .0 1 , dp <0 . 0 0 1  lab sleep compared with sleeping in the decompression chamber at sea level 
ep <0 .0 1 , p <0 . 0 0 1  second sea level night in the chamber compared with first placebo night at 
altitude
SL2 Pi P2
CHAMBER
Dio Tio t 20 T3o
End tidal PaC 02 (MM 
Hg2)
42.7" 39.2 37.2 43.7* 38.6 39.5 38.1
End tidal Pa0 2 (MM Hg2) 101.2* 52.2 50.9 52.2 50.9 50.2 51.7
Breaths per minute 15.5 15.1 16.4 18.l b 17.0 16.9 18.0 a
Max arterial oxygen 
saturation (%)
98.2e 80.6 80.1 78.0 80.9 79.4 78.9
Mean arterial oxygen 
saturation (%)
97.7c 78.4 78.1 76.1 79.0 77.5 77.0
Min arterial oxygen 
saturation (%)
97.2e 76.3 76.0 74.1 77.1 75.6 75.1
Table 18 Effect of drugs on various measures of respiration (means for 6 subjects) 
ap <0.05, bp <0.01 cp <0.001 compared with placebo mean
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4.2.4 Discussion
In this controlled laboratory study there was no evidence of any respiratory depressant effect of 
temazepam at doses as high as 3Omg. Indeed both temazepam (30mg) and diazepam (lOmg) slightly 
increased the repiratory rate compared with placebo. An increase in end tidal PCO2 was observed 
with diazepam but not with temazepam. The amount of sleep disturbance observed after this sudden 
ascent to altitude was similar to the values recorded in the alpine study. There was evidence of 
habituation/acclimatisation as there were improvements between the first and second placebo 
condition at altitude. However, there were also improvements between the first and second sea level 
conditions. The improvements are more likely to be due to habituation to sleeping in the chamber 
with the awakenings for repiratory measurements etc.
The respiratory depressant or otherwise activity o f hypnotic drugs at altitude is still a subject of 
controversy. Dubowitz (1998) reported that benzodiazepines do not have a depressant effect. On the 
other hand, Rôggla and co-workers (2000) have reported that at 3000m subjects with temazepam 
(lOmg). had lower arterial oxygen concentrations and increased arterial carbon dioxide 
concentrations at altitude than when taking placebo. These results relied on blood gas analysis one 
hour after ingestion of temazepam or placebo. The study in the decompression chamber does not 
support the findings of Rôggla. Indeed even at 3 Omg there was no evidence o f respiratory 
depression in a series of readings taken throughout the night.
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4.3 KARAKORUM STUDY
4.3.1 Introduction
As detailed previously, disturbed sleep is a common complaint of mountain climbers. Many 
individuals are unable to sleep well at altitude and may awake many times each night. Periodic 
breathing with spells of apnoea also occur when sleeping at altitude and arousals from sleep may be 
associated with these apnoeas. However they do not seem to be the only cause of arousals since 
abolition of these with oxygen administration does not necessarily improve sleep.
During a previous expedition to 4000m it was shown that the ingestion of Acetazolamide (500mg) 
daily improved sleep. The addition of a low dose of benzodiazepine such as temazepam (lOmg) 
improved sleep efficiency close to that seen at sea level.
The usefulness of Acetazolamide at higher altitudes is unknown, as is the effectiveness of hypnotic 
drugs. Changes in sleep or in respiration due to acclimatisation were also studied. Further studies 
on the sleep or climbers up to an altitude of 5400m were carried out.
4.3.2 Methods
6000
5000
4000
3000
2000
1000
days
Figure 28 Ascent profile for Karakorum expedition
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The subjects were eight healthy male volunteers, aged between 24 and 45 (mean 35.3) years old 
who normally resided below 2 0 0 m and were not acclimatised to altitude immediately prior to the 
expedition. At least two weeks before the expedition, a sea level recording o f sleep was made in the 
sleep laboratory at Famborough. The subjects were divided into two groups o f four balanced for age 
for the amount of respiratory disturbance observed during one night in a decompression chamber at 
a simulated altitude of 3810m. They flew to Skardu (2300m) Pakistan via Rawalapindi, were then 
driven (9 hours) to Hushe (3300m) where they rested for four nights. During the following four 
days they climbed to 4815m where they remained for three nights. The subjects then climbed, in a 
day, to 5400m where a camp was established for six nights. They then descended rapidly to Hushe 
and returned to Rawalapindi. The participants slept on lilo’s in tents. They were enclosed in 
sleeping bags suitable for the extreme cold
From Day One of the expedition all of the subjects took Acetazolamide (500mg) in sustained 
release form, daily. The subjects in one group ingested temazepam (lOmg) on retiring on three of 
the experimental nights:- the second, fifth and sixth nights at 5400m; on the other experimental 
nights they received a matching placebo. The other group received a placebo on all experimental 
nights. All drugs were presented double-blind.
Three channels of EEG (C2-O2, C3-A2, C4-A 1), bilateral EOGs and submental EMG were recorded. 
The subjects slept on air filled beds and retired shortly after darkness. Respiratory movements were 
monitored using a chest impedance method and, in four subjects, arterial oxygen saturation was 
measured continuously by a pulse oximeter (Ohmeda Biox III) using a non invasive probe attached 
to the subject’s index finger. These data were recorded onto a portable physiological data recording 
system (Oxford Medical Systems’ Medilog 9000). Subjects were required to refrain from napping
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and alcohol ingestion throughout the study and to avoid caffeinated beverages after 1700h before 
sleep recording.
The sleep recordings were scored manually in 30s epochs according to the conventional criteria. 
Respiratory disturbances were scored for the presence of apnoeas of > or equal to 5s in duration. 
Where an apnoea was present its duration, the sleep stage in which it started and the presence of 
associated arousals was noted.
The sleep and respiratory data were analysed by analysis o f variance. The factors anaysed were 
drug, altitude and time.
4.3.3 Results
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The technique of principle components was used to summarise the symptoms experienced by 
constructing fewer variables that account for most of the variation in the original data.
Analysis was initially confined to those questionnaires answered by subjects whose sleep was 
recorded only on those nights (that is evening preceding and morning following) when recording 
took place. Analysis of variance (ANOVA) was used to analyse the principle components (with 
transforms as necessary) with the following as factors:
Factor Levels Description
T 2 Morning or evening
D 8 Day on which answers were given
G 2 Placebo or Temazepam taken on drug nights
S 8
A random subject effect nested under G and 
crossed with other factors
Table 21 ANOVA factors for principle component analysis of subjective data
The factor D was split into contrasts to compare low with other altitudes, medium with high 
altitude, linear change with number of days spent at high altitude, drug with non-drug nights and 
nights after drug with other non-drug nights (carry-over). T-tests were used to investigate the 
differences between the first night at high altitude and the nights at low and medium altitude, and 
further investigation of altitude effects was made for those variables where a drug by G interaction 
was present, by conducting a second ANOVA treating as missing values from drug nights for 
subjects taking Temazepam (the missing values were then estimated using standard least squares 
methods).
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It was found that the data were best described by four principle components. Broadly speaking these 
correspond to (i) illness; (ii) tiredness; (iii) difficulty in breathing; and (iv) difficulty in sleeping.
In order to satisfy the assumptions of the analysis the variables were transformed: (i) log(3-x); (ii) 
log(2-x); (iii) 1 / /  (4-x); and (iv) 1 / /  (4+x).
For variable (i) there was a drug by G interaction (p<0.05). T-tests indicated no differences due to 
altitude or differences between the two groups on the nights when drugs were taken (with the nights 
considered both separately and meaned as a group). The ANOVA with the Temazepam nights 
treated as missing indicated a T effect (p<0.05) but no other effects. Mean values for the 
transformed variable are given below (higher values correspond to feeling more ill etc.)
For variable (ii) there was a difference indicated between low altitude and the other values and an 
interaction indicating that this difference was not the same for the two groups (both p<0.05). There 
was also a D effect not accounted for by any of the contrasts (p<0.05). T-tests revealed that there 
was a difference between low and medium altitudes (p<0.05 for mean of subjects) but not between 
the first night at high altitude and medium or low altitude. The difference between low and medium 
altitude was due entirely to those subjects who were to take Temazepam (pO.Ol for these subjects). 
Mean values for the transformed variable are given below in Table 22 (higher values correspond to 
feeling more tired etc).
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MEANS FOR TRANSFORMED VARIABLE (ii)
Low altitude 0.59718
Medium altitude 0.49309
High altitude night 1 0.57542
High altitude night 2 0.40802
High altitude night 3 0.50755
High altitude night 4 0.41142
High altitude night 5 0.42444
High altitude night 6 0.41495
Table 22 ESQ changes with altitude- tiredness factor
For variable (iii) no significant effects were indicated. T-tests revealed a difference between low 
altitude and the first night at high altitude (p<0.01). It was also noted that the last night at high 
altitude was not significantly different from the night at low altitude. Mean values for the 
transformed variable are given in Table 23 (higher values correspond to feeling less short of breath 
etc).
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MEANS FOR TRANSFORMED VARIABLE (iii)
Low altitude 0.52577
Medium altitude 0.50366
High altitude night 1 0.49095
High altitude night 2 0.48882
High altitude night 3 0.50317
High altitude night 4 0.50504
High altitude night 5 0.50459
High altitude night 6 0.51834
Table 23 ESQ changes with altitude- difficulty in breathing factor
For variable (iv), difficulty in sleeping there was a difference between medium and high altitudes 
and a linear change with the number of days spent at high altitude. T-tests indicated that the first 
night at high altitude was significantly different to both that at low and that at medium altitude. The 
change over the days spent at high altitude was such that the last night at high altitude was not 
significantly different from the night at low altitude, Mean values for the transformed variable are 
given in Table 24 (higher values correspond to sleeping less badly etc.
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MEANS FOR TRANSFORMED VARIABLE (iv)
Low altitude 0.52093
Medium altitude 0.51035
High altitude night 1 0.47643
High altitude night 2 0.48054
High altitude night 3 0.49706
High altitude night 4 0.50736
High altitude night 5 0.50862
High altitude night 6 0.51186
Table 24 ESQ changes with altitude- difficulty in sleeping factor
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HYPOXIC VENTILATORY RESPONSE -  KARAKORUM STUDY
Subject Age Percentage change in ventilation
Percentage change in O2 
saturation
5 39 +126% -9%
6 48 +4% -23%
8 24 +22% -12%
9 25 +56% -18%
10 36 +50% -18%
11 45 +54% -15%
13 39 +114% -19%
14 49 +87% -13%
Table 25 Relationship between hypoxic ventilatory responses at sea level and oxygen
saturation
Altitude, level and drug were the factors used in theANOVA.
During the ascent total sleep time increased linearly (p < 0.01) (Table 19), however at the same time 
there was a linear reduction in the sleep efficiency index (p < 0.001). This reduction in sleep quality 
was also evident in a linear increase with altitude o f the number of awakenings and increased awake 
and stage 1 sleep (all p < 0.001) (table 20). Stage 4 sleep also reduced linearly with altitude (p < 
0.01) and this was reflected in an increase in Stage 2 sleep (p < 0.001). There was also a reduction 
in the percentage of REM sleep at altitude.
At 5400m there were linear reductions in total sleep time and increases in sleep onset latency (both 
p < 0.001) and sleep efficiency continued to fall (p < 0.01) reach a mean value of 0.69 on the final 
night at altitude. Stage 4 sleep also decreased linearly during the six nights at 5400m. There were 
some reductions in the number of awakenings during the stay at altitude (p < 0.001).
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In those subjects taking temazepam (lOmg) the amount o f stage 2 and the percentage of stage 3 
sleep were increased on the nights when the drug was ingested compared with the placebo group (p 
< 0.05).
Apnoeas were more frequent during stage 1 and 2 sleep than in stage 3 or 4 and also occurred in 
REM sleep and were spread throughout the night.
The number of apnoeas increased linearly with altitude. However, there was a large difference 
between subjects in the pattern of their respiration during sleep at altitude. The number of 
respiratory pauses at 5400m greater than 5 sec ranged from 700 in one subject to less than 20 in 
another.
The number of apnoeas did not reduce during the stay at 5400m.
There was no difference between temazepam and placebo in the number of apnoeas. However, the 
apnoeas in the middle of the night were reduced with temazepam (p < 0.05).
The hypoxic ventilatory response at sea level (Table 25) was very variable and did not predict the 
incidence of subjective or objective changes at altitude.
4.3.4 Discussion
Sleep was very disturbed on arrival at 5400m in spite o f prophylactic treatment with Acetazolamide 
(500 mg) throughout the ascent. Apart from a reduction in the number o f awakenings there was no 
evidence of any improvement in sleep due to acclimatisation. Indeed, sleep continued to worsen 
throughout the stay at top camp. Furthermore, although Acetazolamide has been reported to reduce 
periodic breathing it was very frequent in some subjects who ingested Acetazolamide. It is possible 
that sleep would have been even more disturbed without Acetazolamide and that periodic breathing 
would have been more prevalent. Alternatively, it is possible that natural acclimatisation is 
somehow impaired by Acetazolamide.
149
The beneficial effects of temazepam on sleep seen at 4850m were not as evident at this increased 
altitude. However, there appeared to be no adverse effects of temazepam on respiration during sleep 
This is in agreement with recent studies by Dubowitz (1998) who studied the effect of temazepam 
10 mg on the oxygen saturations of climbers at 5300m. They reported that there were fewer changes 
in oxygen saturation when the climbers took temazepam. In this study subjective improvements 
were reported although this was not analysed statistically. It is possible that the acetazolamide had 
already improved sleep to a level that could only be marginally improved by this low dose of 
temazepam.
The lack of correlation between hypoxic ventilatory response and mountain sickness symptoms is in 
agreement with the study by Milledge et al., 1988, who studied 32 members of two mountaineering 
expeditions and also was unable to correlate the response to hypoxia at sea level with the mountain 
sickness symptoms.
4.4 CONCLUSIONS
These studies suggest that even with the prophylactic use of Acetazolamide at 5400m sleep is 
extremely disturbed with reductions in slow wave sleep and increases in awake and stage 1 sleep. 
Periodic breathing with frequent apnoeas is seen in some subjects, although others show little of this 
activity. Six days at 5400m was insufficient for any acclimatisation in sleep or respiration during 
sleep to take place. The use of a benzodiazepine hypnotic did not appear to be indicated at this 
altitude, although if they are used they seem unlikely to depress respiration.
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CHAPTER FIVE
NOISE AND LIGHT, EFFECTS ON SLEEP
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5.1 LIGHT STUDY
5.1.1 Introduction
For aircrew and shift-workers attempting to sleep during the day, factors such as light may disturb 
sleep and account for high levels of fatigue during subsequent duty periods. The effects of these 
factors on daytime sleep have been investigated here. The effects of the light levels likely to be 
present during the day in the summer when curtains are inadequate on daytime sleep were studied. 
Sleep on the preceding night was shortened in order to simulate the conditions experienced by 
aircrew.
5.1.2 Methods
Subjects who participated in the current study were in the age range 35-51 years (middle-aged), 
chosen to represent the pilot population. Investigations of the relationship between age and sleep 
quality have shown that with ageing, individuals report earlier sleep times, shorter sleep periods and 
more awakenings (Williams et al. 1974 Reyner and Home 1995 Hume et al. 1998). Middle-aged 
individuals also have more problems adjusting to shiftwork compared to younger individuals 
(Âkerstedt 1990 Monk and Tepas 1985 Harma et al. 1992), and adapt more slowly to simulated 
time zone changes (Moline et al. 1992). In addition, middle-aged subjects may be less sensitive to 
the alerting effects of light than younger individuals (Campbell 1995).
Minor effects of light on the latency to SWS across a range of ages have been reported previously 
(Giedke and Spohn 1994). However, there appear to be no studies on the effect o f light during the 
day on the sleep of humans.
The lowest light intensity investigated in the light trial was based on that o f moderate interior 
lighting (300 lux). Other levels used in the study were 300, 600, 1200, and 2400 lux.
5.1.2.1 Subjects
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Six healthy, male volunteers took part in the study. The subjects were aged between 35 and 51 
(mean 45.5) years and were all staff at DERA CHS. Prior to the study, subjects completed 
questionnaires to ensure that they were free from significant medical complaints and sleep 
disorders, and did not take regular medication. In addition, they were already familiarised with the 
recording procedures before the study began. Subjects gave informed consent to take part in the 
experiment which had been approved by the local Ethics Committee.
Subjects were requested to refrain from consuming alcohol or caffeinated beverages from 18:00 
during the evening preceding the daytime recordings and to refrain from smoking one hour prior to 
each sleep period.
5.1.2.2 Schedule
The study was carried out in the Sleep and Performance laboratory at Famborough and involved six 
test sessions, each separated by at least one week. On the day prior to the sleep recording, subjects 
were asked to retire to bed at 00:00 in their own home and to attempt to sleep until 04:00, at which 
time they were asked to get up and remain awake until 10:00. Subjects reported to the laboratory at 
09:00 to have electroencephalogram (EEC), electroocculogram (EOG) and electromyogram (EMC) 
electrodes applied and were then asked to attempt to sleep between 10:00 and 15:00. This timetable 
was an attempt to smulate the coditions experienced by aircrew following a n overnight flight This 
was checked with the output from the actiwatches.
A Latin square design (6 subjects x 6 conditions) was used to determine the order in which the 
subjects were exposed to the different light levels during sleep. Moderate interior lighting is 
equivalent to approximately 300 lux (Le Grand 1957). The light levels used in the current study 
were chosen as a doubling dose based on this figure. Levels of 2400 lux are equivalent to natural 
interior light levels on a sunny day with the curtains open. The light levels used for the six test 
sessions were as follows:
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• darkness -  light-proof bedroom with no interior lighting (twice)
• 300 lux - moderate interior lighting
• 600 lux
• 1 2 0 0  lux
• 2400 lux - a sunny day with no interior lighting and the curtains open
Illumination was provided by overhead banks of full spectrum lights (Osram Biolux emitting 400- 
700 nm) supplied by Siemens Lighting Limited to give uniform light levels in each bedroom. Light 
levels were measured using a Minolta Illuminance T-1H hand held lux meter. The bedrooms of the 
sleep laboratory were sound attenuated, light-proofed and temperature controlled (18 ± 2°C).
5.1.2.3 Objective measures 
Sleep electroencephalography
Four channels of electroencephalographic (EEG) activity from the C3-A2 , C4-A 1, O1-A2 and O2-A 1 
electrode connections, the submental electromyogram (EMG) and bilateral electro-oculograms 
(EOG) were monitored using silver-silver chloride electrodes. Electrodes were applied to the scalp 
using collodion, and adhesive discs were used to secure the facial electrodes. The cup of each 
electrode was filled with conductive jelly and the skin abraded lightly with a blunt needle to reduce 
impedance to less than 10 KOhms.
Sleep data were recorded on a Nicolet Biomedical Ultrasom (digital EEG system) and were 
manually scored from the screen. The records, which corresponded to a recording speed of 10 
mm/s, were scored into 30 second epochs according to the criteria of Rechtschaffen and Kales 
(1968). Various sleep measures were derived for statistical analysis.
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5.1.2.4 Subjective measures
Subjects completed questionnaires 30 minutes before going to bed and 30 minutes after rising. The 
pre-sleep questionnaire covered physical well-being, consumption of caffeine and medication, the 
Stanford Sleepiness Scale (Hoddes et al. 1973) (1 = wide awake to 7 = very sleepy) and two 100 
mm visual analogue scales [During the day, I felt Tired (0) - fresh (100); Now I feel, very tired (0) - 
wide awake (100)].
The post-sleep assessments included the Stanford Sleepiness Scale (SSS) and five subjective sleep 
scales. The extremes of the 100mm sleep scales were:
I slept, very poorly (0) - very well (100)
Now I feel, very sleepy (0) - wide-awake (100)
I fell asleep, never (0) - immediately (100)
After I fell asleep, I slept, very badly (0) - very well (100)
Did you want to sleep more (0) - less (100) than you did?
Subjects were also asked to make subjective assessments of mood using a series o f twelve 100-mm 
visual analogue scales (Nicholson et al. 1984) at hourly intervals between 07:00 - 10:00 and 15:00 - 
18:00. In each case, a favourable response tended towards the 100-mm extreme o f the scale. 
Subjects wore wrist-mounted activity monitors (Actigraph Z80-32k VI, Gaehwiler Electronic, 
Hombrechtikon, Switzerland) from 18:00 on the evening prior to the daytime recordings until the 
end of the sleep period in the laboratory. The data were then downloaded and checked to ensure 
subjects were attempting to sleep and were awake at the times requested.
5.1.2.4 Statistical analysis
As there were no significant differences between the data for the two darkness conditions these 
values were averaged. The subjective and objective measures o f sleep, together with the subjective 
assessments of mood, were analysed by analysis of variance (ANOVA). The total sleep time (TST)
155
was divided into three one hundred minute blocks and the time spent in each sleep stage in each of 
the blocks was analysed.
Data for TST and sleep efficiency index (SEI) were transformed for the purposes of ANOVA. TST 
was analysed as V(300 - TST) and the SEI as V(1 - SEI). The data presented in the tables are the raw 
means. Where appropriate, given means were back-transformed. In all cases, a prior hypothesis that 
darkness had a significantly different effect from the light conditions was tested using Dunnett’s test 
(Dunnet, 1964). Where a main effect in the ANOVA was significant, more general post hoc tests 
were performed.
Subjective sleep assessment: Order (week) was considered as a linear covariate for all variables and 
was included in the analysis of the pre-sleep assessments of daytime fatigue, post sleep Stanford 
Sleepiness Scale (SSS) and the assessment of the quality of sleep after waking. Analysis of the pre­
sleep SSS showed a significant difference between conditions. Therefore, the pre-sleep SSS was 
also considered as a covariate for the post-sleep measures.
Subjective mood assessment: The 12 subjective mood assessments were reduced to two main factors 
by a principal components analysis. These two factors were anxiety (higher values representing 
higher anxiety) and fatigue (lower values represent higher levels of fatigue).
5.1.3 Results
5.1.3.1 Objective measures
Data from the activity monitors indicated that subjects were following the study protocol.
The effects of different light levels on sleep (means for 6 subjects) are given in Table 26. There 
were more awakenings in the light at 1200 lux (p<0.05) than the dark. There were no differences in 
TST, sleep onset latency, stages 1, 2, slow wave sleep (SWS) and Rapid Eye Movement (REM) 
sleep.
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SLEEP VARIABLE
LIGHT LEVEL (lux)
No light 300 600 1200 2400
Total Sleep Time (min) 211.20 233.25 206.83 211.75 206.00
Sleep onset latency (min) 15.04 11.17 13.67 15.42 14.17
Sleep Efficiency Index 
(SEI)+
0.71 0.79 0.69 0.72 0.71
Awake (min) 12.75 18.75 23.42 26.58 19.75
Stage 1 (min) 24.79 26.75 26.92 31.58 30.17
Stage 2 (min) 114.04 133.17 124.17 117.92 115.25
SWS (min) 12.83 15.08 10.33 7.67 6.58
Rapid Eye Movement sleep 
(min)
62.04 60.08 50.67 59.50 59.00
No. of awakenings 8.08 8.83 8.33 11.50a 10.00
Table 26 Various sleep measures effects of light (means for 6 subjects)
ap<0.05; compared with darkness 
+ SEI = Total sleep time/time in bed
When the data were analysed in three 100 minute blocks it was found that a number o f subjects 
were awake for approximately 85 minutes of the final 100 minute period. Therefore, data for this 
period are not presented.
During the first 100 minutes there was less SWS under the brightest light condition (2400 lux) than 
under conditions of darkness (p<0.05), 300 lux (pO.Ol), and 600 lux (p<0.05). In the second 100 
minutes sleep was more disturbed in the light with more time spent awake at 600 and 2400 lux than 
in the dark (p<0.05) (table 27).
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SLEEP VARIABLE LIGHT LEVEL (lux)
Total time during first 100 
min
No light 300 600 1200 2400
Awake (min) 5.54 7.42 5.53 9.50 9.75
Stage 1 (min) 10.29 11.92 11.25 15.50 12.42
Stage 2 (min) 50.13 56.67 53.50 49.08 56.67
SWS (min) 6.91 13.37 6.50 2.38
0.79 a,b,c
REM (min) 27.38 13.75 17.83 23.92 20.67
Sleep stage duration 
during second 100 min
Awake (min) 2.76 4.70 5.18* 5.01
5.68a
Stage 1 (min) 9.35 10.45 7.44 10.30 11.80
Stage 2 (min) 43.92 40.67 42.58 45.17 40.58
SWS (min) 9.16 2.55 8.05 6.34 10.52
REM (min) 20.75 35.58 24.42 25.42 23.42
Table 27 Total sleep time broken down into two 100-minute blocks: duration of sleep
stages (means for 6 subjects)
ap<0.05; compared with dark 
bp<0.05; compared with 600 lux 
cp<0.01; compared with 300 lux
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5.1.3.2 Subjective measures
Pre-sleep assessments: The SSS scores showed individuals felt more sleepy before retiring under a 
light level of 1200 lux than 300 lux. In addition, individuals were more tired during the day prior to 
sleeping under a light level of 600 lux than 300 lux (Table 28).
ASSESSMENT
LIGHT LEVEL (lux)
No light 300 600 1200 2400
Stanford Sleepiness Scale (1 
= wide awake, 7 = very 
sleepy)
2.50 2.00 2.83 3.33b 2.67
During the day I felt: tired (0) 
- fresh (100)
71.67 79.00 57.08* 61.00 64.83
Now I feel: very tired (0) - 
wide awake (100)
63.42 55.00 52.25 53.33 49.17
Table 28 Pre-sleep assessments (means for 6 subjects) before light treatment 
ap<0.05; bp<0.01; compared with 300 lux
Post-sleep assessments: Compared to all other conditions, individuals rated their sleep as being 
worse under 2400 lux (pO.Ol). Subjects felt most sleepy after sleeping in the brightest light 
condition (p<0.05). In addition, after falling asleep they felt that they had slept poorly in the bright 
light compared to the dark condition (p<0.05) (Table 29).
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SLEEP ASSESSMENT
LIGHT LEVEL (lux)
No light 300 600 1200 2400
Stanford Sleepiness Scale (1 
= wide awake, 7 = very 
sleepy)
2.85 3.06 3.07 2.77 3.33
I slept poorly (0) - well (100) 70.41 68.46 63.76 62.71 36.00b
Now I feel sleepy (0) - wide 
awake (100)
66.00 63.50 67.17 70.67 51.33a
I fell asleep never (0) - 
immediately (100)
70.75 70.0 73.83 75.83 59.33
After I fell asleep I slept very 
badly (0) - very well (100)
69.52 67.23 64.73 68.10 41.17°
I wanted to sleep more (0) - 
less (100)
51.35 46.73 50.57 49.11 38.33
Table 29 Post-sleep assessments (means for 6 subjects)
ap<0.05; bp<0.01; compared with darkness and all other light levels 
cp<0.05; compared with darkness
Pre-sleep Mood Assessments: There were no significant differences in anxiety prior to the recorded 
sleep period. Mean ratings of fatigue were greater at 07:00 than at 08:00 (p<0.05) and were also 
greater before sleep at 600 lux than before sleep in the dark (table 30).
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Time of 
assessment
LIGHT LEVEL (lux)
No light 300 600 1200 2400 Mean
07:00 0.28 -0.36 -0.92 -0.23 -0.68
-0.38*
08:00 0.73 0.19 -0.05 0.27 0.18 0.26
09:00 0.49 0.73 -0.30 0.06 -0.11 0.17
10:00 0.06 0.32 -0.28 -0.74 -0.26 -0.18
Mean 0.39 0.22 -0.39 -0.16 -0.21 -0.03
Table 30 Pre-sleep fatigue assessments - means for 6 subjects
ap<0.05; compared with 08.00 
bp<0.05; compared with darkness
Lower (i.e. negative) values indicate higher levels of fatigue
Post-sleep mood assessments: There were no differences in anxiety or fatigue after the daytime 
sleep period (Table 31).
161
Time of 
assessment
LIGHT LEVEL (lux)
No light 300 600 1200 2400 Mean
15:00 -0.22 -0.66 -0.19 0.40 -0.39 -0.21
16:00 0.10 0.03 -0.24 0.39 -0.22 0.01
17:00 0.45 -0.09 0.17 0.16 0.06 0.15
18:00 0.35 -0.06 -0.21 0.24 -0.002 0.07
Mean 0.17 -0.19 -0.12 0.30 -0.14 0.004
Table 31 Post-sleep mood assessments (fatigue) - means for 6 subjects 
Lower (i.e. negative) values indicate higher levels of fatigue
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Figure 29 Changes in SWS with light during the 1st 100 minutes of sleep (mean data for 6
subjects)
Comparisons with 2400 lux condition where *p<0.05; **p<0.01
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5.2 NOISE STUDY
5.2.1 Introduction
The effects of noise on sleep during the day after a shortened period o f sleep on the preceding night 
were studied. This design was chosen in order to simulate conditions experienced by aircrew who 
may be required to sleep during the day in hotel rooms which may not be adequately screened from 
noise. The noises chosen were those likely to be present in the hotel environment. The parameters 
for the noise trial were based on information from the literature, and used intermittent noise events 
of up to 8 per hour. A pilot trial was used to identify the level likely to cause disruption (from 
45dB(A), 55dB(A) and 65dB(A)) and from this study a level of 55dB(A) was selected for the main 
trial. To put this in context, noise levels of 35dB(A) are approximately equivalent to that heard in a 
library, 65dB(A) to office noise and 125dB(A) to a jet aircraft taking off.
5.2.2 Methods
5.2.2.1 Subjects
Six healthy, male volunteers took part in the study. The subjects were aged between 31 and 52 
(mean 42.2) and all were staff at DERA CHS. Prior to the study, subjects completed questionnaires 
to ensure that they were free from significant medical complaints and sleep disorders, and did not 
take regular medication. In addition, they were familiar with the recording procedures before the 
study began. Volunteers gave informed consent to take part in the experiment, which had been 
approved by the local Ethics Committee.
Subjects were requested to refrain from consuming alcohol or caffeinated beverages from 18:00 
during the evening preceding the daytime recordings and refrain from smoking Ih prior to each 
sleep period. They completed the Weinstein questionnaire (Weinstein, 1978). 
to assess their sensitivity to noise. Each subject also completed an audiometric assessment where a 
criterion of H2 or above was acceptable (the sum o f low frequency loss is not more than 84dB and 
high frequency loss is not more than 123dB).
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5.2.2.2 Schedule
The study was carried out in the Sleep and Performance Laboratory at Famborough and involved 
six test sessions each separated by at least one week. On the day prior to the sleep recording, 
subjects were required to retire to bed at 00:00 in their own home and attempt to sleep until 03:00 at 
which time they were requested to get up and remain awake until 10:00. They reported to the 
laboratory at 09:00 to have their EEG, EOG and EMG electrodes applied and were then asked to 
attempt to sleep between 10:00 and 14:00.
The noise levels used in the main trial were based on the findings from a pilot trial. During this trial, 
subjects were exposed to three noise conditions, with maximum levels o f 45dB, 55dB and 65dB. 
Sound stimuli were transmitted over loudspeakers into the bedrooms. Individuals retired to bed and, 
after sleep onset or a maximum of 5 minutes asleep, pre-recorded noises were played. The noise 
stimuli were randomly presented via a computer with a maximum of eight events per hour. The 
maximum duration of an individual noise event was 10 seconds. Individuals were asked to attempt 
to sleep for a total of 4 hours and noise was transmitted for 4 minutes (8 events o f 10 seconds 
duration per hour, for 3 hours) during each condition. The results from the pilot trial indicated that 
55dB (16dB above the background noise level) showed significant effects on sleep compared to that 
of 45dB. There were no significant differences between 55dB and 65dB and therefore 55dB was 
chosen for the main trial.
For the main trial a Latin square (6 subjects x 6 conditions) was used to determine the order in 
which the subjects were exposed to the different noise levels. The noise conditions were:
• No sound stimuli (control)
• Sound stimuli commencing at ‘lights out’.
• Sound stimuli commencing at the first occurrence of stage 2 sleep or within 5 minutes o f 
sleep onset.
• Sound stimuli commencing one hour after the first occurrence o f stage 2 sleep.
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• Sound stimuli commencing two hours after the first occurrence o f stage 2 sleep.
• Sound stimuli commencing after the first occurrence of stage 2 sleep for 1 hour, off for 1 
hour, then on for 2  hours.
Each noise condition had a pseudo-random presentation of 8  noises played 3 times during a 3-hour 
period. No noise was played more than once consecutively and the less strident/alerting sounds 
were used as the first noise in each condition. The noises used were doors closing/slamming, phone 
ringing, hair dryer, vacuum cleaner, jet aircraft, police sirens and car alarms. These sounds were 
considered to be representative of the noises likely to be heard by someone sleep ing during the day.
5.2.2.3 Measures of Sleep
Four channels of electroencephalographic (EEG) activity from the C3-A2 , C4-A 1, O1-A2 and O2-A 1 
electrode connections, the submental electromyogram (EMG) and bilateral electro-oculograms 
(EOG) were monitored using silver-silver chloride electrodes. Electrodes were applied to the scalp 
using collodion, and adhesive discs were used to secure the facial electrodes. The cup of each 
electrode was filled with conductive jelly and the skin abraded lightly with a blunt needle to reduce 
impedance to less than 10 KOhms.
Sleep data were recorded on a Nicolet Biomedical Ultrasom (digital EEG system) and were 
manually scored from the screen. The records, which corresponded to a recording speed of 10 
mm/s, were scored into 30s epochs according to the criteria o f Rechtschaffen and Kales (1968) 
Various sleep measures were derived for statistical analysis.
Before each sleep period, subjects completed questionnaires 30 minutes before going to bed and 30 
minutes after rising. The pre-sleep questionnaire covered physical well-being, consumption of 
caffeine and medication and the Stanford Sleepiness Scale and both questionnaires included 100 
mm analogue assessments of sleep and alertness. In each case, a favourable response tended toward 
the 1 0 0  mm extreme of the scale.
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Subjects were asked to wear lightweight wrist-mounted activity monitors (Cambridge 
Neurotechnology AW4-32K) from 18:00 on the evening prior to the daytime recordings until the 
end o f the sleep period in the laboratory. An accelerometer within the watch recorded the 
occurrence and degree of motion and integrated this information to produce activity counts. The 
accelerometers were sensitive to movements of 0. Ig in all directions. Data were recorded at 2- 
minute intervals. The monitors were then downloaded and checked by the recordist to ensure 
subjects were attempting to sleep and wake at the times requested.
5.2.2.4 Performance tests
Between 04:00 and 10:00, and also between 15:00 and 18:00, participants were asked to complete a 
10-minute battery of performance tests at hourly intervals on a hand-held Psion computer. They 
completed two tasks as described below.
Testax: This task has previously been used in a number of laboratory studies at DERA CHS and a 
number o f field studies. It has been shown to be sensitive to the effects o f fatigue (Borland et al. 
1986 Rogers et al. 1989 Spencer and Robertson 1999). It was adapted from a task designed by 
Rosvold (1956) to measure sustained attention.
A random sequence of letters was presented one at a time on the Psion screen at a rate o f one per 
second. Two letters (the critical stimulus) were displayed continuously at the top left-hand comer of 
the screen. Subjects were required to press the space bar whenever the letters o f the critical stimulus 
were presented consecutively during the random sequence. Response times and the nature o f the 
responses (correct or incorrect) were recorded.
Serial choice reaction time (CRT) task: An asterisk appeared in one o f four positions on the display. 
As soon as the asterisk appeared the subject was required to cancel it as quickly as possible by 
pressing one of four keys. The four response keys were ‘A ’ top left position, ‘Z’ bottom left, 
top right, *?’ bottom right. Subjects were asked to respond as quickly and as accurately as possible. 
A total of 160 responses were completed during the task (Totterdell and Folkard 1992).
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Subjects were also asked to complete a sleepiness questionnaire and the Samn-Perelli Checklist 
(Samn and Perelli 1982) to assess levels of subjective fatigue. The fatigue rating has been validated 
in air operations and has been used in previous studies of aircrew fatigue. Subjects were asked to 
choose a number from 1-7, which most closely related to their current fatigue level:
• Fully alert, wide awake
• Very lively, responsive, but not at peak
• Okay, somewhat fresh
• A little tired, less than fresh
• Moderately tired, let down
• Extremely tired, very difficult to concentrate
• Completely exhausted, unable to function effectively.
The sleepiness questionnaire was completed after the fatigue rating. Subjects selected one of the 
following statements:
• Wide awake throughout
• Occasionally felt a little sleepy
• Sometimes felt rather sleepy
• Sometimes struggling to stay awake
• Often struggling to stay awake
5.2.2.S Statistical analysis
The subjective and objective measures of sleep were analysed by analysis of variance (ANOVA). 
Order (week) was considered as a linear covariate for all variables and was included in the analysis 
of total sleep time, REM/non-REM ratio, total stage 2, total stage 3, total stages 3+4, percentage 
stage 3 and percentage stages 3+4.
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Total sleep time (250-TST), sleep efficiency index (l-(TST/time in bed)), total stage 0, percentage 
stage 0, total stage 4, percentage stage 4, latency to stage 3 and duration o f third REM period 
required log transforms. Three of the subjects did not achieve stage 4 and so were not included in 
the analyses of total stage 4, percentage stage 4 and in the analysis of time in stage 4 in first 100 
minutes. Times in stage 4 for the second and third 100 minutes epochs have not been analysed as 
only one subject achieved this stage.
Where transforms have been applied, given means are back-transformed. In all cases, a prior 
hypothesis of no noise versus noise has been tested using Dunnett’s test. Where the ANOVA was 
significant, more general Newman-Keuls tests have also been applied.
Subjective assessments: Assessments were analysed separately for pre (seven times) and post (four 
times) sleep and a further comparison of the means before and after the sleeps was performed. The 
sleepiness questionnaire required a square root transform. Order of exposure (week) was considered 
as a covariate, but was not significant. No data were available for one subject.
Performance measures: Analysis of variance was used to test for significant differences between 
the different conditions. All data were tested for the requirement for transforms and, where this was 
found necessary, the transformed data have been analysed but the back transformed data have been 
used to construct the table of means. Due to technical problems with the Psion computers, data from 
2 subjects have not been included in the analysis. Order of exposure (week) was tested as a 
covariate but was found not to be significant. Analyses of the two performance tests investigated 
error rates and correct response times.
5.2.3 Results
5.2.3.1 Performance
Psion tasks Two different types of Psion computer were used (3a and 3c) in the study. Technical 
problems with the 3 a computers meant that only data from the 3c computers were included in the 
analysis (4 subjects).
168
Noise did not affect the number of errors subjects made on either the Choice Reaction Time (CRT) 
or Testax task. There were no differences between conditions or with time. Time of day influenced 
response times, although there were no differences between noise conditions.
Testax When reaction times were averaged across all conditions there was an effect of time of day 
(pO.OOl). Reaction times were slowest at 04:00, 05:00 and 06:00 than at any other time from 08:00 
onwards (Table 32).
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Time No noise Lights
out
Sleep
onset
Ihr
after
sleep
onset
2h after
sleep
onset
Sleep 
onset Ih 
on/lh  
off/on
Time
mean
04:00 0.608 0.619 0.604 0.536 0.616 0.617 0.600
05:00 0.581 0.608 0.586 0.596 0.564 0.589 0.587
06:00 0.625 0.624 0.595 0.632 0.549 0.603 0.605
07:00 0.577 0.580 0.606 0.557 0.549 0.581 0.575
08:00 0.593 0.549 0.549 0.589 0.525 0.584 0.564 * t
09:00 0.552 0.561 0.558 0.560 0.535 0.565 0.555 *
f t
10:00 0.556 0.584 0.575 0.551 0.537 0.571 0.562 * t
15:00 0.555 0.537 0.513 0.549 0.564 0.557 0.546 **
t t t  t
16:00 0.558 0.548 0.549 0.590 0.534 0.620 0.567 * f
17:00 0.552 0.528 0.573 0.538 0.500 0.535
0.538
ÎÎ
18:00 0.559 0.549 0.609 0.575 0.564 0.552 0.568* f
Noise
mean 0.574 0.571 0.574 0.570 0.549 0.580 0.570 ‘
Compared with 04:00 where *p<0.05; **p<0.01; ***p<0.001 
Compared with 05:00 where / p<0.05; / / p<0.01 
Compared with 06:00 where fp<0.05; f fp<0. 01;  f f f  p<0.001
Table 32 Effects of noise on reaction times for Testax (mean for 4 subjects)
Serial Choice reaction time task: When response times were meaned across all conditions, they 
were slower in the early morning (05:00, 06:00, 07:00) that in the late afternoon (16:00) p<0.05 
(Table 33).
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Time No
noise
Lights
out
Sleep
onset
Ihr
after
sleep
onset
2h after
sleep
onset
Sleep 
onset Ih 
on/lh  
off/on
Time
mean
04:00 0.579 0.585 0.589 0.606 0.606 0.579 0.591
05:00 0.620 0.602 0.633 0.587 0.569 0.599 0.602
06:00 0.581 0.597 0.590 0.613 0.599 0.605 0.598
07:00 0.607 0.597 0.587 0.582 0.610 0.590 0.596
08:00 0.559 0.570 0.561 0.570 0.548 0.531 0.557*$
t
09:00 0.581 0.551 0.564 0.564 0.610 0.568 0.573
10:00 0.572 0.580 0.579 0.572 0.569 0.569 0.574
15:00 0.600 0.615 0.536 0.555 0.547 0.568 0.570
16:00 0.548 0.558 0.580 0.576 0.551 0.526 0.556* $
t
17:00 0.568 0.596 0.573 0.562 0.567 0.529 0.566
18:00 0.553 0.570 0.549 0.590 0.564 0.572 0.563*
Noise
mean 0.579 0.584 0.576 0.577 0.576 0.567 0.577
Table 33 Effects of noise on reaction times for the Choice Reaction task (mean for 4
subjects)
Compared with 05:00 where * p<0.05;
Compared with 06:00 where J p<0.05;
Compared with 07:00 where f  p<0.05;
5.2.3.2 Subjective measures
Samn-Perelli (only 3 subjects): No data were available for one subject and after studying the data it 
was concluded that two other individuals had misinterpreted the scale. Therefore the data presented 
below are based on three subjects. Due to the small amount of data available only one analysis 
including all time points has been performed. Fatigue ratings at 04:00, 06:00 and 07:00 were greater 
than those at 15:00 and 18:00 (p<0.05)(Table 34)
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Time No
noise
Lights
out
Sleep
onset
Ihr
after
sleep
onset
2h after
sleep
onset
Sleep 
onset Ih 
on/lh  
off/on
Time
mean
04:00 5.33 5.33 5.17 5.33 5.67 5.67 5.42
05:00 5.33 4.67 5.50 5.00 5.00 5.00 5.08
06:00 5.33 5.33 5.39 5.51 5.67 5.89 5.52
07:00 5.67 5.33 4.92 5.67 5.00 5.42 5.33
08:00 4.33 4.33 4.71 4.67 4.00 4.21 4.38
09:00 4.33 3.67 3.75 4.33 3.67 3.75 3.92
10:00 4.67 4.00 4.92 4.67 3.33 4.42 4.33
15:00 4.00 3.33 3.72 4.11 2.94 3.72 3.63* $
t
16:00 4.67 3.33 3.69 4.52 3.00 3.69 3.81
17:00 4.00 3.33 4.19 4.82 3.33 3.69 3.89
18:00 4.67 2.15 3.19 4.08 3.41 3.19 3.45* i  
t
Noise
mean 4.76 4.07 4.47 4.79 4.09 4.42
Table 34 Effects of noise on Samn-Perelli assessment (mean for 3 subjects)
Compared with 04:00 where * p<0.05 
Compared with 06:00 where f  p<0.05 
Compared with 07:00 where f  p<0.05
Sleepiness Questionnaire (3 subjects): This showed an effect of time of day (pO.Ol) with 
individuals feeling more sleepy in the early morning than in the early evening (Table 35).
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Time No noise Lights
out
Sleep
onset
Ihr after
sleep
onset
2hrs
after
sleep
onset
Sleep 
onset Ih 
on/lh  
off/on
Time
Mean
04:00 4.02 3.61 3.52 3.61 3.71 4.14 3.77*
05:00 3.61 3.67 3.68 3.28 4.02 4.15 3.73*
06:00 4.02 4.02 4.08 3.53 3.61 4.08 3.89*
07:00 3.71 3.67 3.22 4.02 4.02 4.18 3.80*
08:00 3.06 2.71 2.47 2.65 3.00 2.32 2.70
09:00 2.71 2.06 2.47 2.71 2.37 2.47 2.46
10:00 4.06 1.99 3.18 3.00 2.06 2.64 2.78
15:00 2.71 1.97 2.40 1.99 1.89 2.40 2.22
16:00 2.37 1.69 2.17 2.42 1.69 2.17 2.08
17:00 2.37 1.97 2.07 2.71 2.06 2.07 2.20
18:00 2.96 1.30 1.48 2.87 1.44 1.48 1.86
Noise
Mean
3.20 2.52 2.74 2.95 2.63 2.84
Table 35 Effects of noise on the Sleepiness questionnaire (mean for 3 subjects)
Compared with value at 18:00 where * p<0.05
P re-s leep  assessments: There were no differences in the pre-sleep questionnaires (completed 
before sleeping in the laboratory).
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CONDITION
No noise Lights out Sleep
onset
Ih after
sleep
onset
2h after
sleep
onset
Sleep 
onset Ih 
on/lh  
off/on
Total Sleep Time 
(min) 217.17 220.22 211.89 213.97 219.47 199.09
Efficiency Index 0.91 0.93 0.88 0.90 0.92 017
Sleep Onset Latency 
(min) 7.67 5.17 5.92 818 4.00 713
REM/non-REM
Ratio 0.32 0.45 0.42 013 0.30 0.36
Total Stage 0 (min) 7.23 8.47 8.71 9.14 9.42 11.61
Total Stage 1 (min) 19.75 21.00 2125 2108 22.50 19.08
Total Stage 2 (min) 114.33 120.75 112.42 130.25 121.67 108.75
Total Stage 3 (min) 24.58 13.17**
f t
16.17* f 19.42 2175 13.42* f t
Total Stage 4 (min) 12.90 0.82 0.53 7.85 312 0.31
Total Stage REM 
(min) 50.58 68.50 6013 40.17 51.33 5113
Total Stage 3 & 4 
(min) 28.17 13.42** f 16.50* f 23.00 2918 13.50** t
Latency to Stage 3 
(min) 25.81 47.37 44.90 19.68f 21.54
34.70
Number of 
Awakenings 5.33 6.33 613 6.50 810
613
Number of Stage 
Shifts 54.50 56.17 62.00 64.00 64.50
50.00
Latency to 1st REM 
Period (min) 58.92 59.75 40.50 50.42 52.50 4213
Duration of 1st 
REM Period (min) 24.83 38.00 13.83 13.67 13.42
21.58
Latency to 2n 
REM Period (min) 148.08 172.17 116.00 126.50
120.75 113.00
Duration of 2nd 
REM Period (min) 25.75 33.92 30.67 2108
32.42 19.42
Latency to 3 rd 
REM Period (min) 210.87 211.08 168.92 189.14 138.11
195.67
Duration of 3rd 
REM Period (min) 6.45 130
12.94 11.40 7.58 18.80
Number of REM 
Periods 2.67 2.17 2.67
217 213 2.50
Time in stage 2 1st 
100 minutes (min)
46.58 59.92 51.92 56.67 50.17 5218
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Time in stage 2 2n 
100 minutes (min) 51.42 5683 50.25 52.83 45.42 47.42
Time in stage 2 in 
3 rd 100 minutes 
(min)
16.33 11.0 10.25 20.75 26.08 8.75f
Time in stage 3 1st 
100 minutes (min) 16.33 5 .42ft * 8.50f 13.75 20.67 5.83ft *
Time in stage 4 1st 
100 minutes (min) 11.79 0.74 0.42 7.17 3.31 0.11*
Time in REM 1st 
100 minutes (min) 21.58 27.17 21.67 13.00 16.25 2358
Time in REM 2ntl 
100 minutes (min) 24.25 25.17 31.83 26.33 34.00 19.42
Time in REM 3rd 
100 minutes (min) 5.42 17.46 5.99 1.53 1.62 7.09
Table 36 Effects on noise on various measures o f sleep (means for 6 subjects)
Compared with no noise: * p<0.05, ** p<0.01
Compared with underlined value in row: f  p<0.05, f t  p<0.01
5.2.3.3 Objective measures
The majority of the sleep parameters were unaffected by noise (Table 36). Variables that may have 
been expected to vary such as total sleep time, the number of awakenings and stage transitions did 
not differ between conditions. However, total time in stage 3 was, in general, reduced with noise. 
The greatest amount of stage 3 sleep was observed in the no noise and two hours after sleep onset 
conditions. When the noise commenced at lights out, stage 3 sleep was approximately half that of 
the control value. Total stage 3 and 4 (i.e. SWS) was similarly affected by noise.
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Figure 30 Total stage 3 in the first 100 minutes of the sleep period with noise (mean for 6 
subjects
Compared with no noise: * p<0.05 
Compared with 2h: + p<0.05, ++ pO.Ol
The change in stage 3 was confined to the first 100 minutes of the sleep period (figure 30), which is 
approximately equivalent to the first sleep cycle. Indeed, when subjects were allowed to sleep 
undisturbed for the first hour after sleep onset there was no impact on stage 3.
When the sound stimuli commenced at LO there was an increased latency to stage 3 sleep compared 
to Ih after sleep onset (p<0.05). Latency to stage 3 was also high for the SO condition, although this 
was not significant.
The reduction in stage 3 was not associated with any compensatory increase in other stages or sleep 
parameters. However, some of this loss of stage 3 sleep may be counteracted by changes in REM 
sleep variables (total REM, latency to first REM period, REM in the 1st, 2nd, and 3rd 100 minute 
blocks of sleep).
Post-sleep assessments: There were no differences in the subjective ratings o f sleep between the 
various conditions.
5.3 DISCUSSION
The two studies reported here have identified the extent to which environmental stressors, such as 
noise and light, can affect the quality of daytime sleep. The nature of the disturbance depends on the 
characteristics of the stressor such as intensity, timing and frequency. With respect to noise, there 
are other factors that may affect an individual’s response. These include the complexity of the 
sound, the duration (continuous or intermittent) and the meaningful content of the noise.
As far as the effects of light were concerned, the principal changes in sleep were limited to the 
brightest condition (2400 lux). However, this is unlikely to be a serious consideration for aircrew. In 
practice this intensity of light is unlikely to be experienced by individuals sleeping in hotel rooms, 
unless they have fallen asleep on a bright sunny day with the curtains open. For those who choose to 
close the curtains and sleep with the lights on there is likely to be little impact on the quality of 
sleep.
Noise, on the other hand, is more likely to disturb the sleep of aircrew, especially those trying to 
sleep during the day in a hotel room. In the worst case, noise reduced the amount of SWS by 50% 
and this reduction could have serious implications for levels o f alertness following sleep. Indeed, 
this effect alone could account for the high levels o f fatigue reported during the Seychelles study, 
that could not be explained by the Alertness Model.
5.3.1 The structure of sleep
Previous studies of daytime sleep have shown that total sleep times (TST), sleep efficiency and 
slow wave sleep (SWS) are reduced compared to nocturnal sleep (Âkerstedt and Kecklund, 1991, 
Dahlgren, 1981, Arendt, 1989). The amount of SWS obtained by middle aged individuals at night is 
reduced compared to younger individuals and relatively small amounts o f SWS are not unusual in 
middle aged subjects (e.g. 23% SWS in 19 year old males: 8.5% SWS in 40-49 year old males) 
(Williams et al., 1974). It is possible that the longer nightime sleep may have provided greater 
potential for impairment.
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In the current study the total amount of SWS obtained across the whole sleep period was unaffected 
by exposure to light. The changes in SWS were confined to the first 100 minutes o f sleep and it 
would appear that the main effects of light are likely to occur during the early part of the sleep 
period. This could have implications for individuals taking short anticipatory naps where the loss of 
SWS would mean that sleep is less recuperative.
In the second 100 minute block, more time was spent awake at 600 and 2400 lux than in the dark. 
However, there were no other effects on the duration of sleep stages during this period. This 
increase in time spent awake may be related in part to the time at which individuals are trying to 
sleep. There is an increased propensity to wake up around noon whilst individuals are least likely to 
wake between midnight and the early morning. It has been suggested that there is a barrier to sleep 
around noon (Âkerstedt and Gillberg, 1981). In this study the second 100 minute period started 
around mid-day. Therefore, the combination of increased chance of waking and light may have 
resulted in more time spent awake in the light. Indeed, one explanation for subjects not being able to 
sleep for more than 3.5 o f the 5 hours available is that they were attempting to sleep across this 
‘barrier’.
In general, there was little evidence from this study that light impairs the quantity o f daytime sleep. 
Individuals were able to fall asleep quickly (within 14 minutes) and slept on average for 3.5 of the 5 
hours available. Although there were more awakenings in the brighter conditions this did not affect 
the overall quantity of sleep and sleep stages.
Individuals felt that they slept poorly in the bright light and were tired on waking. The subjects may 
have anticipated that they would sleep poorly in the light, especially as the study could not be 
completed ‘blind’ and this may have influenced the subjective ratings. Mood assessments were 
completed for a further 3 hours after rising but there was no evidence of increased fatigue beyond 
that observed immediately after sleeping in the light.
The minimal effects observed are in keeping with the only other identified study investigating the 
effect of light on sleep (Giedke and Spohn, 1994). In this study of nocturnal sleep, subjects were
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exposed to a room illumination of 300-400 lux. Only two effects were observed; with exposure to 
light ratings of sleep quality were reduced and there was an increase in latency to stage 4 sleep. 
Although higher light levels were used in the current study light still had little impact on sleep 
quality and quantity.
It might be expected that nocturnal sleep would be more sensitive to light disturbance than daytime 
sleep. This possibility may relate to effects of light on melatonin. This hormone is secreted at night, 
is suppressed by light (Arendt, 1989) and thought to have hypnotic effects (Walderhauser et al., 
1990, Dollins et al., 1993) which are maximal around nocturnal bedtime (Tzischinsky and Lavie,
1994). For total suppression of melatonin, light levels of approximately 2500 lux (Lewy et al.,
1980) are required, although most individuals will show some disturbance to sleep at around 300 
lux (Bojkowshi et al., 1987). Therefore, during the study of nocturnal sleep, melatonin may have 
been suppressed or partially suppressed, and this may have contributed to the disturbed sleep.
The sleep data collected during this study were analysed using conventional techniques 
(Rechtschaffen and Kales, 1968). However, the use of spectral analysis techniques may have 
detected an overall decrease of power in the delta frequency that is indicative o f changes in SWS. A 
closer analysis of the spectral power of the EEG may have indicated whether other more subtle 
changes in the EEG, such as microarousals and changes in other frequencies, occurred.
Light is considered to disturb sleep and recommendations are often made to shift-workers and other 
groups who may be attempting to sleep during daylight hours to ensure that the room is adequately 
darkened (Novak and Auvil-Novak, 1996). The effect of partial sleep deprivation would be to 
increase the pressure for daytime sleep and it may be sufficient to overcome any alerting/disturbing 
effect o f light. This may explain why sleep was relatively unaffected by light. In addition, middle- 
aged individuals are not as sensitive to the alerting effects of light as young subjects (Campbell,
1995) and equally may not be as sensitive to the disturbing effects of light as younger individuals. 
Light, unlike some other environmental factors (e.g. noise), can be avoided by using bed clothes to 
obstruct the light. Although subjects were asked not to avoid the light, this was difficult to enforce
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as they were not observed to establish whether they employed light-avoiding strategies. However, 
as the illumination was not directional, but was generated from overhead lighting and was uniform 
in distribution it was therefore more difficult to avoid the light by turning away from the source, 
than would be the case with a single point (or points) light source.
Overall, the observed changes in sleep and alertness were minimal and insufficient to suggest that 
the low levels of alertness during the Seychelles trip were due solely to the effects of light on 
daytime sleep.
Although many of the changes in sleep associated with the environmental factors investigated were 
relatively small, this did not apply to the effect of noise on SWS. However, it is SWS, rather than 
the other stages of sleep, which recovers first after sleep loss or following SWS suppression 
(Gillberg and Âkerstedt, 1994, Dijk and Beersma, 1989) and it is considered to be an important 
aspect of the recovery process. The 50% reduction observed in SWS is therefore of considerable 
significance and these changes are likely to affect subsequent levels of alertness.
The timing of the noise during sleep has implications for its quality and structure. With the level 
and type of noise considered in this study, there was no increase in the time taken to initiate sleep; 
however, the noises that persisted after sleep onset delayed the start of SWS. Overall, the main 
effect o f noise was to reduce the amount of SWS during the first part of the sleep period, and it is 
during this time that the requirement and propensity for SWS will normally be highest. Thus, when 
the exposure to noise coincides with the early part of sleep, the individual may be unaware of any 
sleep disturbance. However, the structure of sleep may change and the overall level of sleep may be 
much lighter than in the absence of noise.
This study has also demonstrated that noise can have a greater effect on short periods of daytime 
sleep than on normal nocturnal sleep. The important consideration is the timing of the noise within 
the sleep period. If the noise occurs after the first 2 or 3 hours of daytime sleep, when the main part 
of the requirement for SWS has been satisfied, then it is likely to have only a small impact on the 
quality o f sleep. However, when it occurs during the first few hours of sleep, it is unlikely that the
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loss of SWS will be recovered. This contrasts with normal overnight sleep, when there is greater 
opportunity to recoup the lost SWS, albeit during the latter part of the night.
5.3.2 Effects on performance
Although a reduction in SWS would normally be associated with impairments in performance, it 
was not possible to demonstrate this relationship in the current study where performance was 
unaffected by the exposure to noise during sleep. This may be partly explained by the small sample 
size and the problems arising from the loss of some data.
In addition, this investigation only monitored performance over a 4-hour period after rising, and it is 
possible that the impact of the sleep impairment generated by noise may only become apparent 
later.
5.3.3 The type of noise
As well as the timing of the noise events, the nature of the noise is a major factor in determining the 
extent of any sleep disturbance. The evidence suggests that intermittent events rather than 
continuous noise have a more significant impact on the quality of sleep. This is precisely the type of 
noise to which aircrew are most likely to be exposed in hotel rooms during the day and suggests that 
it was this form of disturbance that was the most likely origin of the problems on the Seychelles 
route.
Traffic noise is unlikely to have been a disturbing factor, as most studies o f the effects o f high- 
density traffic noise on sleep have shown increases in the amount o f SWS (Thiessen and Lapoint 
1983 Wilkinson and Campbell 1984) and reductions in REM sleep. In one study o f shift-workers 
sleeping during the day, levels of SWS increased compared to nocturnal sleep (Studies around 
airports indicate that, once they have fallen asleep, very few people are at risk of disturbance later at 
night, even at high noise levels (Ollerhead et al., 1992)
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5.3.4 Countermeasures
It follows from the previous discussion that an important requirement is to ensure that the 
accommodation that crews use for resting during a layover affords adequate protection against 
intermittent noises that may disturb sleep. Bedrooms should have adequate sound attenuation and, 
in addition, crews should consider the use of foam earplugs. In general, such devices provide 
between 20 - 30dB protection, depending on the characteristics of the sound.
During short layovers, where the only opportunity to sleep may be during the day, the use of 
earplugs may be insufficient to maintain sleep in a noisy environment. In extreme cases, a possible 
approach would be to use an ultra short-acting hypnotic, such as zaleplon. This has been shown to 
be effective in restoring sleep and to have no residual effects when taken up to 2 hours before rising 
(Danjou et al. 1999) At present, however, it does not have a product licence in the UK.
5.3.5 Other factors
This investigation has been concerned with the individual effects o f noise and light on sleep, rather 
than their combined effects. While it is possible that the combined effects may be more severe, this 
has not been studied in this series of experiments.
Another environmental factor that may disturb sleep is temperature. Slow-wave sleep is disrupted 
when the environmental temperature is high (Bradley, 1994), and it has been shown that sleep is 
more disturbed by a temperature of 35 C that by traffic noise o f 71dB(A) (Libert, 1991). When 
sleeping in hot conditions overnight, total sleep time decreased while the duration of wakefulness, 
number of sleep stage changes, and drowsy sleep episodes increased.
5.3.6 Conclusions
Exposure to light of 1200-2400 lux has only minor effects on daytime sleep. These effects include 
an increase in the number of awakenings and a reduction in SWS with bright light. However, 
individuals do report that they sleep poorly in bright light and are more tired on waking.
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Disturbances of daytime sleep caused by light are likely to occur during the early part of the sleep 
period and to involve a loss of SWS. Although aircrew are likely to experience disturbance of 
daytime sleep it does not appear likely that light is a major cause of these disturbances. Where high 
levels of fatigue are observed during subsequent duties, other factors such as noise, may be 
involved.
Intermittent noise disturbs daytime sleep. The greatest disruption occurs when the noise occurs 
within the first hour o f attempted sleep. Noise during this period can halve the amount of SWS 
individuals obtain. Noise occurring 2 hours after retiring is unlikely to have much effect on short 
periods of sleep.
Continuous traffic noise is unlikely to disrupt sleep. In some situations it may increase the amount 
of SWS and reduce the amount of REM sleep.
Noise-induced sleep disturbance is influenced not only by the intensity, duration and frequency of 
the noise but also by other factors such as noise-sensitivity.
The noise generated during the normal activities undertaken within a hotel and the surrounding 
environment can lead to sleep disturbances with potentially serious consequences for levels of 
alertness on the flight deck. Noise-induced sleep disturbance could explain the high levels of fatigue 
experienced by crews operating the Seychelles route and it is likely that similar disturbances will be 
experienced at other locations. Light is unlikely to have been a contributory factor.
5.3.7 Recommendations
To avoid sleep disturbance, intermittent noise should be kept to a minimum. Steps should be taken 
to ensure that the levels o f intermittent noise in hotel bedrooms are kept to a minimum when 
aircrew are attempting to sleep during the day.
In situations where the only opportunity to sleep is during the day and noise is likely to disturb 
sleep, crews should consider the use of ear-plugs to minimise the effects of noise. In noise-sensitive 
individuals, an ultra-short acting hypnotic such as zaleplon may, in the future, provide a method of
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ensuring that crews obtain adequate sleep during the day. However, at present this drug does not 
have a commercial licence.
Light levels are less likely to be a major cause of disturbance. Normal precautions (closing curtains) 
should be sufficient to avoid sleep disruption. If necessary, the use of eyeshades should be 
Considered.
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CHAPTER SIX
USEFULNESS OF ZALEPLON IN NOISE INDUCED 
INSOMNIA
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6.1 INTRODUCTION
Noise is a problem for those attempting to sleep in noisy hotel rooms and in this chapter the 
usefulness of a hypnotic in the return to sleep after a middle of the night awakening is studied.
The pharmacokinetic profile of a hypnotic is a key factor in understanding its clinical usefulness. 
The rate of absorption determines a hypnotic's effectiveness in initiating sleep, while its duration of 
action depends upon the kinetics o f absorption, distribution, and elimination. Indeed, the residual 
effects of a hypnotic upon next-day performance is an important aspect of its clinical profile, 
particularly in those individuals involved in skilled activity. Thus, the development of rapidly 
eliminated hypnotics that are free from residual effects and o f accumulation upon repeated nightly 
ingestion is an area of continuing interest. The most rapidly eliminated hypnotic recently introduced 
into clinical practice is zaleplon, a pyrazolopyrimidine compound that binds selectively to the y- 
aminobutyric acid (GABA)a receptor complex (Beer 1997 Damgen et al. 1999) It is rapidly 
absorbed, with peak plasma concentrations at around Ih, and rapidly eliminated with a plasma 
elimination half-life of approximately Ih (Beer et al. 1994 Hurst et al. 1999)
The pharmacokinetic properties o f zaleplon indicate its potential usefulness for shortening sleep 
onset when there is difficulty falling asleep. Studies have shown a reduction in the latency to 
persistent sleep when zaleplon was given at bedtime to patients with sleep onset insomnia (Elie et 
al. 1999 Walsh et al. 1998). It is also effective when administered after an awakening in the middle 
of the night to patients with sleep maintenance insomnia (Walsh et al. 2000). The swift elimination 
of zaleplon means that it is unlikely to be followed by impairments in next-day performance after 
middle-of-the-night administration, and studies have reported freedom from residual effects when 
given 2 h before awakening (Danjou et al. 1999). Only one previous study has investigated both the 
hypnotic and residual effects of zaleplon, and so the present study was conducted to replicate these 
findings.
6.2 METHODS
6.2.1 Subjects
Thirteen healthy volunteers (6 females, 7 males) aged 20 to 30 (mean 22.2, standard deviation 3.1) 
years were enrolled in the study. Their weight (range 49.8 to 85.5 Kg; mean 69.0 Kg, standard 
deviation 11.0) was within 20% of the normal range for their height as determined by a nomograph. 
The subjects were non-smokers who consumed no more than five caffeinated beverages per day. 
They were not taking any medication except paracetamol and oral contraceptives (females only). 
Prior to the study, they underwent a physical examination, a medical history was taken and clinical 
laboratory tests were carried out, including a urinary drug screen (for opiates, barbiturates, 
benzodiazepines, cannabinoids, cocaine, amphetamine), a breath ethanol test, and audiometry. The 
inclusion and exclusion criteria ensured that only those subjects who were in good health took part 
in the study. A urinary drug screen and breath ethanol test were also carried out during the study on 
each night the subjects slept in the laboratory, except for the adaptation night. At the end of the 
study, the clinical laboratory tests were repeated. The subjects gave written informed consent to 
take part in the study, which was approved by the local Ethics Committee.
6.2.2 Procedures
The subjects were healthy volunteers with situational middle-of-the-night insomnia, rather than 
patients with sleep maintenance insomnia, as in the previous study, which can be inconsistent in an 
experimental context (Walsh et al. 2000a). The situational insomnia induced in the present study 
was achieved using a sound stimulus. This method that has been used previously to investigate the 
hypnotic properties o f benzodiazepines and the hormone melatonin (Saletu et al. 1985 Saletu. et al 
1987 Waldhauser et al. 1990 Gieschke et al. 1994 Cluydts et al. 1995 Terzano et al. 1995 Parrino et 
al. 1997). Since the sound stimulus used in these previous studies (traffic noise or continuous white 
noise) disturbed sleep, but did not prolong sleep latency per se, a pure tone pulse was used in the 
present study, as this has been shown to increase sleep latency (Nakagawa 1987).
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Zopiclone was used as an active control to indicate the sensitivity of the experimental procedures. It 
is an established hypnotic with an elimination half-life of around 5 h, and would be expected to 
have residual effects on performance 4 h after administration (Nicholson 1998).
The subjects were instructed to retire to bed no later than 23:00 on the night at home preceding a 
night in the sleep laboratory and to refrain from drinking caffeinated beverages and alcohol for 24h 
prior to attendance at the laboratory. Before the double-blind phase of the study, an adaptation night 
(from 23:00 to 07:00) in a single room was undertaken to familiarise each subject with the 
recording procedures and to establish whether their sleep patterns were normal. Only those subjects 
with normal sleep patterns were included in the next phase of the screening procedure. At least four 
days after the adaptation night, these subjects reported to the laboratory on two occasions separated 
by at least one night to determine whether they were sensitive to the sleep-disrupting effects of 
noise. On both of these occasions, after a 5 h sleep period (22:45-03:45) in a quiet environment, the 
subjects got up and completed a 4-min test of performance (the digit symbol substitution task).
They returned to bed at 04:00 and, after ingestion of placebo (administered single blind), they were 
asked to fall asleep. On the first single-blind placebo night, there was no sound stimulus (the mean 
background noise level in the bedrooms was 36.8 dB(A)), while on the second single-blind placebo 
night the subjects were exposed to a pure tone pulse (described below). The sound stimulus was 
started at 04:00 and a recordist monitored the electroencephalogram and determined the latency to 
persistent sleep (10 min of stage 2, 3, 4, or rapid eye movement (REM) sleep; methods described 
below). The sound stimulus was stopped either after persistent sleep had been reached, or after 2 h 
if  the subject did not fall asleep. At 08:00, 4 h after drug ingestion, the subjects were awoken, if 
necessary, and they completed a battery o f performance tasks and assessments of well being 
(described below).
Only those subjects who had an increase of at least 10 min in the latency to persistent sleep (EPS) 
from the night without noise to the night with noise were included in the double-blind phase of the 
study. They subsequently reported to the laboratory on four occasions separated by a period of at
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least four nights. The experimental procedure was identical to the second single-blind placebo night, 
except that at 04:00, each subject was administered placebo, zaleplon 10 mg, zaleplon 20 mg, or 
zopiclone 7.5 mg, double-blind, on separate occasions according to a four-period randomised cross­
over design.
6.2.3 Sound stimulus
The sound stimulus was an 80 dB(A) 1kHz pure tone pulse with an inter-tone interval of 1 s, rise- 
decay times of 2.5 ms, and a duration of 50 ms. The sound stimulus was recorded onto a computer 
and replayed simultaneously into each bedroom via loudspeakers positioned 1 m behind the 
subject’s head. Before each test night, a sound level meter was positioned at the subject's pillow in 
each bedroom and used to ensure that intended noise levels were replayed and that noise doses did 
not exceed those permitted by UK Health and Safety legislation.
6.2.4 Psychomotor performance and memory tests
Subjects were trained to plateau performance on all tests before the study began and were observed 
during the tasks by means of closed circuit television. The tests were presented in the following 
order: digit symbol substitution, immediate word recall, critical flicker fusion, choice reaction time 
and delayed word recall.
Digit symbol substitution: Subjects were presented with one of a series of 30 sheets with 200 
randomised digits (0-9) arranged in 10 rows on each side of the sheet (Wechler 1981). In the space 
below each digit they were required to insert the appropriate symbol indicated by a code at the top 
of the page. Subjects were given 90 s to complete as many substitutions as possible, and the number 
of correct substitutions was recorded.
Critical flicker fusion: Subjects observed four red light-emitting diodes held in foveal fixation at 1 
m and were required to discriminate flicker from fusion as the frequency of the flickering diodes 
alternately increased or decreased. Individual fusion thresholds were determined using the mean of
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four ascending and four descending presentations on a Leeds Psychomotor Tester (Sherwood and 
Kerr 1993).
Choice reaction time: Subjects were required to press a key corresponding to one of six equidistant red 
light-emitting diodes illuminated in a random sequence of 50 presentations, from a central starting 
position (Sherwood and Kerr 1993). Recognition reaction time, motor reaction time and total reaction 
time were recorded using a Leeds Psychomotor Tester.
Immediate and delayed memory recall: Subjects were given 2 min to memorise a list of 20 nouns. The 
number of correct words recalled in any order during a 2-min period immediately after presentation of 
the list (immediate free recall) and 30 min later (delayed free recall) were recorded.
6.2.5 Subjective assessments
Subjects completed the Leeds Analogue Rating Scale immediately upon waking (Hindmarch 1980). 
Of eleven 100-mm visual analogue scales, three related to assessments o f sedation and eight were 
dummy scales. The subjects were instructed to consider the midpoint of each scale as their normal 
state.
6.2.6 Electroencephalography
The subjects slept in single light-proofed, sound-attenuated, and air-conditioned rooms. Silver-silver 
chloride electrodes were used to record electroencephalograph (EEG) activity from the O1-A2 and 
C4-A1 positions, together with bilateral electro-oculograms (EOG) and the submental 
electromyogram (EMG), on a Nicolet Biomedical Ultrasom (digital EEG) system via three Nihon- 
Koden 4300 series EEG machines. A simulated paper speed of 10 mm/sec was used and each 
recording from the second period of sleep (04:00 to 08:00) was scored manually upon completion of 
the study into 30s epochs according to the criteria of Rechtschaffen and Kales (1968). Various 
measures were derived from the data for subsequent statistical analysis.
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6.2.7 Statistical methods
Estimates of variance from a previous study with a similar experimental design (Danjou et al. 1999) 
were used to calculate the required sample size. The power calculation indicated that 12 subjects 
would be required to detect a difference in the digit symbol substitution task of 6.1 symbols with 
80% power at the 5% significance level.
The data from 12 subjects who completed all four treatments were analysed by an analysis of 
variance (ANOVA) with subjects, period, treatment, and first order carry-over as factors in the 
model. First order carry-over was not significant, and was therefore removed from the ANOVAs 
and least squares means calculated. If the overall treatment effect in the ANOVA was significant, 
then linear pairwise comparisons were made which included the data from a 13th subject who 
completed three of the four treatments (described in the results). The primary pairwise comparisons 
were between each of the three drug treatments and placebo. A Bonferroni adjustment was made for 
the three active treatments compared with placebo. The 5%, 1% and 0.1% significance levels 
adjusted for multiple comparisons were: p<0.0167 (0.05/3); p<0.0033 (0.01/3); and p <0.0003 
(0.001/3), respectively. Means and standard deviations of raw data are given in the tables of results, 
though this may occasionally lead to apparent inconsistencies with the results of the analysis, which 
is based on within subject comparisons.
6.3 RESULTS
Twelve of the 13 subjects enrolled in the study completed all four treatments. One subject was 
withdrawn from the study after the third drug treatment because drug treatments two and three had 
been administered in reverse order and therefore the order of treatment did not meet that specified 
by the randomisation.
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At 08:00, 4h after drug ingestion, 11 of the 13 subjects required awakening after all drug treatments. 
One subject required awakening following all treatments except 10 mg zaleplon, while another 
subject was awoken on one occasion only, after 7.5 mg zopiclone.
No residual effects of zaleplon (10 and 20 mg) were found on psychomotor performance, memory, 
or subjectively assessed sedation. The active control, zopiclone (7.5 mg), impaired performance 4 h 
after ingestion on the digit symbol substitution task (p=O.OO4) and choice reaction time task 
(p=0.001), and reduced the number of words recalled on the delayed memory recall task (p=0.001), 
compared with placebo (Table 36). However, the subjects as a group did not report any change in 
sedation 4 h after zopiclone ingestion, compared with placebo.
The latency to persistent sleep was reduced by both doses of zaleplon (10 mg, p=0.001; 20 mg, 
p=0.014) and the duration of stage 1 (drowsy) sleep was reduced by the 20 mg dose (p=0.012), 
compared with placebo (Table 37). Zopiclone reduced stage 1 sleep (p=0.001), increased stage 3 
sleep (p=0.0001) and increased total sleep time (p=0.003), compared with placebo.
No serious adverse events or discontinuations due to adverse events were reported during the study. 
The only treatment-emergent adverse event that was reported by more than one subject was a bitter 
after-taste with zopiclone (n=5 subjects, 38%).
6.4 DISCUSSION
This study has confirmed previous findings that the therapeutic dose of zaleplon (10 mg), taken in 
the middle of the night, does not impair psychomotor performance the following day (Walsh et al. 
2000 Danjou et al. 1999). Although one study has reported an impairment of memory (delayed free 
recall) following administration of zaleplon 3 h before awakening (Vermeeren et al. 1998), the 
present study found no residual effects of zaleplon on memory 4 h after ingestion. Other 
investigators have reported that zaleplon is free from adverse effects on memory 2, 3, 4, and 5 h 
after nocturnal administration (Danjou et al. 2000). In the present study, the test measures were
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sufficiently sensitive to detect residual effects of the active control, zopiclone, upon psychomotor 
performance and memory, although the subjects as a group did not report sedation with zopiclone. 
Zaleplon (10 and 20 mg) was effective in reducing the latency to persistent sleep using a model of 
sleep maintenance insomnia in healthy volunteers. This model would appear to be a useful method 
of assessing the sleep-promoting properties of hypnotics following an early morning awakening. 
Although the model required the selection of noise-sensitive subjects, which increased the overall 
pre-study screening failure rate to approximately 50%, the use of a sound stimulus appears to be a 
more consistent method of delaying sleep onset than using patients with sleep maintenance 
insomnia (Walsh et al. 2000). The sleep-promoting properties of zaleplon were similar to those 
reported previously in patients with insomnia (Elie et al. 1999 Walsh et al. 1998 Walsh et al. 2000). 
The present study found no change in the various stages of sleep with zaleplon, except for a 
reduction in drowsy (stage 1) sleep with the 20 mg dose, a finding that accords with the limited 
published data on effects of zaleplon on sleep architecture (Walsh et al. 1998). Zopiclone also 
reduced stage 1 sleep, in addition to increasing slow wave sleep (stage 3), an effect which has been 
reported previously in healthy subjects (Nicholson and Stone 1983 Wright et al. 1986 Nakajima et 
al. 2000). An increase in slow wave sleep has also been observed with zolpidem (Nakajima et al. 
2000 Nicholson and Pascoe 1988 Guieu et al, 1996), which has a selectivity similar to zaleplon for 
the benzodiazepine type 1 receptor on the GABAa receptor complex (Damgen et al. 1999, 
Nicholson and Pascoe 1988). Whether the reported differential effect o f zaleplon and zolpidem on 
slow wave sleep is related to a greater intrinsic activity of zolpidem is unknown. Further studies, 
which include a delta frequency analysis of the EEG, would be required to confirm any difference. 
Zaleplon appears to be a useful hypnotic for individuals who experience difficulty in falling asleep 
either at bedtime or in the middle of the night, as it is free from residual effects 4h after ingestion. 
Such sleep problems may be common as a sleep survey in the United States found that 56% of 
respondents reported difficulty in falling asleep and 67% reported awakening in the middle of the 
night (Ancoli-Israel et al. 1999). Many currently available hypnotics will sustain sleep and reduce
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the incidence of early morning awakenings if taken at bedtime. Given that the severity of an 
individual’s sleep problem is likely to vary from night to night, a potential benefit of zaleplon may 
be a reduction in the requirement for nightly prophylactic use o f hypnotic medication. This may 
avoid the phenomenon of rebound insomnia after cessation of prolonged treatment. Clearly, 
assessment of the nature of the insomnia would be essential and patients would need to be given 
guidelines on the use o f such a short-acting hypnotic in order to avoid ingestion of unnecessarily 
large prophylactic doses in an attempt to sustain sleep.
Little information is currently available on the effectiveness of zaleplon in healthy volunteers with 
transient insomnia arising from transmeridian travel or shiftwork. The present study suggests that 
the drug may be useful following a westward time zone change when individuals may experience an 
early morning awakening and are unable to return to sleep. Zaleplon may also be effective if used 
occasionally to promote sleep in those who have to rest at unusual times of the day, for example, in 
. the early evening before a night shift, because it is shrt acting. However, further work would be 
required to establish whether zaleplon is useful in the management of this type o f transient insomnia 
in healthy individuals involved in skilled activity when residual effects are to be avoided.
In conclusion, the present study has shown that zaleplon (10 mg and 20 mg) is free from residual 
effects 4h after ingestion in the middle of the night, and possesses hypnotic properties in a noise- 
induced sleep maintenance insomnia model in healthy subjects.
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Measure Placebo
(n=13)
Zopiclone 
7.5 mg 
(n=13)
Zaleplon 
10 mg 
(n=13)
20 mg 
(n=12)
Digit symbol substitution 
(Number of substitutions) 
95% Cl
59.3 ± 8.9 52.8 ±9.8» 
-10.5, -2.1
58.3 ± 12.0 
-4.9, 3.5
55.6 ±12.5 
-7.7, 0.9
Choice reaction time (ms)
Recognition reaction time 
95% Cl
344.3 ±38.6 375.0 ± 47.3b 
11.9, 48.2
339.6 ±35.2 
-22.6, 13.7
347.8 ±41.2 
-20.0, 17.1
Motor reaction time 
95% Cl
260.3 ± 64.3 292.8±87.3»
10.1,51.0
257.0 ± 74.8 
-24.9, 16
268.6 ±77.1 
-7.1,34.8
Total reaction time 
95% Cl
604.6 ± 68.9 667.8 ± 86.7 b 
29.9,91.3
596.6 ±78.7 
-39.5,21.8
616.6 ± 98.0 
-19.1,43.8
Immediate word recall 
(Number correctly recalled) 
95% Cl
14.8 ±4.1 11.9 ±4.2 
-5.0, -0.7
13.3 ±4.1 
-3.6, 0.7
13.4 ±4.5 
-4.1, 0.4
Delayed word recall 
(Number correctly recalled) 
95% Cl
13.2 ±4.8 7.9 ± 4.6b 
-7.6, -2.5
11.0 ±4.8 
-4.5, 0.6
10.6 ± 5.6 
-5.5, -0.3
Critical flicker fusion (Hz) 
95% Cl
29.9 ±2.9 28.7 ±2.0 
-2.2,-0.1
30.0 ±2.7 
-0.9, 1.1
29.9 ±3.3 
-1.1, 1.1
Subjective assessment of sedation 
(LARS+)
95% Cl
61.9 ± 11.6 62.8 ± 12.0 
-6.1, 7.9
64.4 ± 12.9 
-4.3, 9.7
63.0 ± 15.0 
-6.0, 8.4
Table 37 Residual effects of zaleplon and zopiclone (4h after ingestion) on performance, 
memory, and subjective sedation (means ±standard deviation).
ap<0.0167,b p<0.0033 (the 5% and 1% significance levels, respectively, adjusted for multiple 
comparisons) compared with placebo.
+ LARS: Leeds Analogue Rating Scale.
‘95% Cl: Confidence interval of individual differences between placebo and each drug treatment.
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Measure Placebo 
_ (n=13)
Zopiclone 
7.5 mg 
(n=13)
Zaleplon
10 mg 
(n=13)
20 mg 
(n=12)
Latency to persistent sleep (min) 42.4 ±21.1 33.5 ±8.5 28.6 ± 13.2b 33.0 ± 12.8 a
95% Cl -16.1, rl.3 -21.2,-6.4 -17.2, -2.1
Latency to REM+ (min) 39.6+11.3 52.8±16.9 44.5±13.7 46.6±18.0
95% Cl 0.1,26.9 -8.2, 18.5 -5.9,21.6
Total sleep time 189.2 ±31.7 204.9 ±8.6b 199.2 ± 14.9 200.2 ±14.7
95% Cl 5.6, 24.7 0.3, 19.4 1.6,21.2
Number of awakenings 7.0±3.0 5.0±3.0 7.0±4.0 7.0±3.0
95% Cl -3.7, 0.1 -1.6, 2.2 -1.6, 2.2
Awake (min) 8.7±9.4 4.0±4.1 6.3±5.2 6.0±5.6
95% Cl -8.1,-1.1 -5.8, 1.2 -6.4, 0.8
Stage 1 (min) 20.8±8.5 13.4±6.1b 16.5±6.4 16.5±6.6a
95% Cl -10.8, -3.8 -7.8,-0.8 -8.3,-1.1
Stage 2 (min) 98.8±20.7 110.5±19.3 100.4±20.8 97.5±14.6
95% Cl -1.6, 24.3 -11.2, 14.6 -13.9, 12.6
Stage 3 (min) 7.8±7.1 22.1±13.6b 13.6±8.7 17.5±8.4
95%CI 6.6,21.9 -1.9, 13.3 1.6, 17.2
Stage 4 (min) 0.4±1.4 4.5±8.1 5.5±10.1 7.3±7.6
95% Cl -1.9, 9.8 -1.1, 10.6 1.5, 13.5
REM+ (min) 62.4±18.6 54.4±16.0 64.3±14.7 61.5±12.3
95% Cl -18.6,2.3 -8.5, 12.3 -11.9, 9.5
Stage 1 (%) 11.0±5.0 6.0±3.0 8.0±3.0 8.0±3.0
95% Cl -6.2, -2.2 -4.6, -0.6
ooo
Stage 2 (%) 49.0±7.0 53.0±8.0 49.0±9.0 47.0±6.0
95% Cl -2.3, 9 -6.4, 4.9 -7.9, 3.8
Stage 3 (%) 4.0±4.0 11.0±7.0 7.0±4.0 9.0±4.0
95% Cl 2.6, 10.3 -1.4, 6.3 0.3, 8.1
Stage 4 (%) 0.0±1.0 2.0±4.0 3.0±5.0 4.0±4.0
95% Cl -0.8,4.9 -0.4, 5.3 0.8, 6.7
REM+ (%) 31.0 ±8.0 26.0 ±8.0 31.0 ±7.0 30.0±5.0
95% Cl -9.7, 0.3 -4.6, 5.4 -6.4, 3.9
Table 38 Effect of zaleplon and zopiclone (ingested at 04:00) on various measures of 
sleep during exposure to a sound stimulus from the start of a second period (04:00-08:00)
of nocturnal sleep (means ±standard deviation
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ap<0.0167,b p<0.0033 (the 5% and 1% significance levels, respectively, adjusted for multiple 
comparisons) compared with placebo.
+ REM: Rapid eye movement sleep.
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CHAPTER SEVEN
OVERALL CONCLUSIONS AND RECOMMENDATIONS 
FOR FURTHER WORK
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The sleep disturbance associated with environmental disturbances of sleep show large differences 
between the disturbing factors and between the susceptibility of the individual subjects to the 
disturbance. The effect of noise for example is more disturbing than that of light.
With some environments it is possible to avoid the stimulus, for example by the use of an eye mask 
or by earplugs. For altitude only the provision of oxygen at altitude would restore conditions near to 
sea level values.
The drug investigated for the treatment of shift work and jet lag was melatonin. Melatonin has been 
advocated for the treatment o f such conditions. The usefulness of melatonin depends on its ability to 
be effective at all times in the circadian cycle. Melatonin had little effect on nocturnal sleep. 
Hypnotic activity of melatonin (0.5 to 10 mg) in the evening was similar to 20 mg temazepam. As 
far as pharmacological intervention is concerned, Melatonin is useful when attempting to sleep in 
the evening before the natural Melatonin is present. It is unlikely to be of any use when attempting 
to sleep at night with environmental disturbance. Field studies on the effect of melatonin on sleep in 
conditions such as shift work and jet lag are lacking and should be conducted.
Sleep is disturbed in those who ascend to altitude with periodic breathing and many awakenings; 
this may lead to daytime drowsiness and impaired performance. Sleep disturbance at two altitudes, 
3500m, in the Italian Alps, and 5400m, in the Karakorum mountains in Pakistan, were studied. The 
effects of 20mg temazepam at the lower altitude and the effects of lOmg temazepam together with 
500mg acetazolamide daily were studied at the higher altitude in two groups of climbers. In 
addition a dose response study o f the effects of temazepam (10 to 30 mg) and diazepam lOmg on 
sleep at ‘altitude’ was carried out in a decompression chamber at a simulated altitude of 3810m.
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Sleep during the alpine expedition was limited to reductions in sleep efficiency and increases in 
awake activity. Delays and reductions in rapid eye movement sleep were seen at the beginning of 
the stay at altitude. No overall benefit of temazepam was seen at this lower altitude although 
hypnotic treatment showed some benefit in older subjects who had more disturbed sleep. Now 
relationships between hypoxic ventilatory responses and behaviour at altitude were established.
In the Karakorum expedition sleep at around 5,400m was very disturbed in spite of prophylactic 
treatment with acetazolamide. Total sleep time shortened and sleep onset lengthened linearly during 
the six nights at 5,400m. Similar reductions in sleep efficiency and stage 4 sleep were also 
observed. The number of respiratory pauses greater than 5 seconds at 5,400 ranged for 700 per night 
in one subject to less than 20 in another. There was no effect of temazepam on the number of these 
events. The beneficial effects of temazepam (lOmg) on sleep seen previously at around 4900m were 
not evident at this increased altitude.
The detailed analysis of the respiratory data in the decompression chamber study showed no 
evidence of respiratory depression with up to 30 mg temazepam. Although there was an increase in 
end tidal PCO2 with diazepam (lOmg). Both 20 and 30 mg temazepam improved sleep at the 
simulated altitude without any evidence of respiratory depression.
Temazepam was still useful for sleeping at altitude and it did not accentuate sleep disordered 
breathing. It does however have certain problems -  it is drug of addiction chosen by some addicts 
and therefore subject to strict controls. It is possible that zaleplon may be useful for altitude induced 
insomnia.
Two separate experiments were carried out, one of which investigated the effect of light, the other 
the effect of noise on sleep during the day after a reduced night of sleep at home.. The levels o f light
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were chosen based on 300 lux, which is roughly equivalent to moderate interior lighting. The 
brightest condition was 2400 lux, which is approximately equivalent to interior light levels on a 
sunny day. The conditions investigated were dark, 300, 600, 1200, and 2400 lux.
Prior to the second experiment, a pilot study was used to identify the noise level most likely to 
cause sleep disturbance. Based on this study, sounds at approximately 55dB(A) were presented to 
subjects via loudspeakers whilst they were in bed. To put this in perspective, noise levels o f 35 
dB(A) are approximately equivalent to that heard in a library, 65dB(A) to office noise and 
125dB(A) to a jet aircraft taking off.
Light had only a small effect on the quality of daytime sleep. The main disturbance occurred when 
sleeping in the brightest condition (24001ux). Slow wave sleep (SWS), was reduced. In addition, 
total sleep time was reduced during the second 100-minute period, and individuals reported that 
their sleep had been disturbed. Some changes were also seen at lower light levels: at 1200 lux more 
awakenings occurred compared with sleeping in the dark, and at 600 lux there was a reduction in 
total sleep time during the second 100-minute period.
Noise commencing at or soon after falling asleep reduced the amount of SWS by approximately 
50%. This reduction was associated both with the overall sleep period and with the first 100 minutes 
of sleep, which is roughly equivalent to the first sleep cycle. The time taken to enter SWS after 
sleep onset also increased when the noise began at lights out. There was no evidence that 
performance during the 4 hours after rising was affected by exposure to noise, and subjects did not 
report any differences in the quality of their sleep under the different noise conditions.
The final experiment studied the effect of a novel hypnotic, zaleplon on sleep in a noisy 
environment. The effectiveness and residual effects o f zaleplon, 10 and 20mg, zopiclone 7.5 mg in 
promoting sleep after middle o f the night administration were compared with placebo. The residual 
effects 4hours after administration were also compared.
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Zaleplon 10 and 20 mg reduced the time taken to return to sleep after awakening in the middle o f 
the night an d was free of effects on psychomotor performance the next morning. The control drug, 
zopiclone , impaired performance in the morning. Zaleplon is a useful hypnotic for those who have 
difficulty initiating sleep or returning to sleep after waking in the night.
In summary, the diverse environmental factors considered here are all associated with some degree 
of sleep disturbance and potentially impaired performance. Pharmacological interventions are useful 
in some instances. Further studies of zaleplon in other environments are proposed. Zaleplon appears 
to be potentially useful for all the conditions studied, and has the advantage that it can be used late 
in the night when a disturbance may not be present at the beginning o f the night
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